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Kurzzusammenfassung 
In der Vergangenheit wurden zahlreiche 18F-markierte aromatische Aminosäuren 
überwiegend als Radiopharmaka für die Tumordiagnostik mittels Positronen-Emissions-
Tomographie entwickelt. Tryptophan erweckte kürzlich große Aufmerksamkeit, da einige 
Tumorarten im Verdacht stehen, es in erhöhtem Maße aufzunehmen. Diese Aminosäure 
konnte bisher jedoch nur in unbefriedigender Weise markiert werden. In der Arbeit hier 
wurde daher eine einfachere nukleophile, dreistufige Radiosynthese zur Darstellung von L-4-
[18F]Fluortryptophan entwickelt. Hierzu wurde ein entsprechender carbonyl-aktivierter 
Markierungsvorläufer mittels Isotopenaustausch radiofluoriert, die aktivierende Carbonyl-
gruppe durch reduktive Decarbonylierung entfernt und anschließend durch eine saure 
Hydrolyse der Schutzgruppen in L-4-[18F]Fluortryptophan überführt. 
Zunächst wurde der Einfluss der Positionen des Fluors und der Formylgruppe auf den 
Isotopenaustausch an diversen Fluor-1H-indolcarbaldehyden getestet, welche mit 
verschiedenen Schutzgruppen am Stickstoff geschützt waren. Weiterhin wurde die 
Decarbonylierungsreaktion mit Rh(PPh3)3 an diesen Molekülen untersucht und optimiert. Die 
besten Ergebnisse zeigte hierbei das 1-Benzyl-4-fluor-1H-indol-5-carbaldehyd. 
Basierend auf diesen Ergebnissen wurden weiterhin Synthesekonzepte entsprechender 
Markierungsvorläufer für L-6-[18F]Fluortryptophan und L-4-[18F]Fluortryptophan entwickelt. 
Damit konnten die Verbindungen Benzyl (2S,5S)-2-tert-butyl-5-[(1-benzyl-4-fluor-5-formyl-
1H-indol-3-yl)methyl]-3-methyl-4-oxoimidazolidine-1-carboxylat und Benzyl (2S,5S)-2-tert-
butyl-5-[(1-Boc-4-fluor-5-formyl-1H-indol-3-yl)methyl]-3-methyl-4-oxoimida-zol-idine-1-
carboxylat in 11-stufigen linearen Synthesen in Ausbeuten von etwa 8 % erhalten werden. 
Beide wiesen eine hohe Diastereomerenreinheit von > 99 % auf. 
Während die Radiosynthese von L-6-[18F]Fluortryptophan aufgrund der nicht erfolgreichen 
Hydrolyse der Benzylgruppe scheiterte, konnte L-4-[18F]Fluortryptophan in der dreistufigen 
Synthese, bestehend aus Isotopenaustausch, reduktiver Decarbonylierung mit Rh(PPh3)3 und 
Hydrolyse mit HCl, in einer Enantiomerenreinheit von > 99 % isoliert werden. Nach 
Optimierung der Radiosynthese gelang die Isolierung des Radiotracers mit einer gesamten 
radiochemischen Ausbeute von ca. 13 % und einer molaren Aktivität von >70 MBq/mmol bei 
einer Synthesedauer von etwa 115 min. Somit konnte eine effizientere nukleophile 
Radiosynthese von L-4-[18F]Fluortryptophan entwickelt werden, welches nun präklinisch 
evaluiert werden kann. 
 
  
Abstract 
In the past a variety of 18F-labeled aromatic amino acids have been developed, primarily for 
tumor diagnostics with positron-emission-tomography. Recently tryptophan got high 
attention, since evidence came up that some tumors exhibit an elevated consumption of it. So 
far, this amino acid could only be radiofluorinated by unsatisfactory approaches. In the work 
here, a simpler, 3-step method for a nucleophilic radiosynthesis of L-4-[18F]fluorotryptophan 
was developed. For this a carbonyl activated precursor was radiofluorinated by isotopic 
exchange, followed by removal of the activating formyl group by reductive decarbonylation 
and subsequent hydrolysis of the protecting groups under acidic conditions. 
First, the influence of positions of fluorine and of the formyl group on the isotopic exchange 
was examined in several fluoro-1H-indolecarbaldehydes where different protecting groups 
were attached to the indole nitrogen. Further, a decarbonylation reaction with Rh(PPh3)3 on 
those molecules was carried out and optimized. The best results regarding radiochemical yield 
and chemical stability were obtained with 1-benzyl-4-fluoro-1H-indole-5-carbaldehyde. 
Based on these results a concept for the synthesis of precursors for L-6-[18F]fluorotryptophan 
and L-4-[18F]fluorotryptophan was developed. Hereby the compounds benzyl (2S,5S)-2-tert-
butyl-5-[(1-benzyl-4-fluoro-5-formyl-1H–indol–3-yl)methyl]–3–methyl–4–oxoimidazolidine-
1-carboxylate and benzyl (2S,5S)–2–tert–butyl–5-[(1–Boc–4–fluoro–5–formyl-1H–indol–3 
yl) methyl]-3-methyl-4-oxoimidazolidine-1-carboxylate were prepared following 11-step 
linear synthetic pathways with overall yields of about 8 % and an enantiomeric purity of  
> 99 %. 
While the radiosynthesis of L-6-[18F]fluorotryptophan was not successful due to the failing 
hydrolysis of the benzyl group, L-4-[18F]fluorotryptophan was prepared by the three step 
radiosynthesis, consisting of an isotopic exchange, a reductive decarbonylation with 
Rh(PPh3)3 and the hydrolysis of the protecting groups with HCl, yielding an enantiomeric 
purity of > 99 %. After optimization of this procedure L-4-[18F]fluorotryptophan was isolated 
in a radiochemical yield of ca. 13 % and a molar activity of > 70 MBq/mmol within about 115 
min. Hence, a new and more efficient nucleophilic radiosynthesis of L-4-[18F]fluoro-
tryptophan was developed which is now available for preclinical evaluation. 
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 1  Introduction 
1.  Introduction 
In recent years, the field of radiopharmacy and radiochemistry gained an increased impact. 
This was possible through the findings of Röntgen and Becquerel who discovered 
radioactivity at the end of the 19th century by the observation of x-rays and -radiation, 
respectively.  
First medicinal trials with radiation were made with skin disorders, tuberculosis or epilepsy.[1] 
A few years after the discovery of radiation it was already used for the treatment of tumors 
with promising results. Irradiation itself was usually carried out by implantation of 
radiumbromide capsules since this made the removal after treatment easy.[2] 
In 1898, the harmful properties of radiation towards microorganisms were found after the 
successful treatment of Morbus Lupus by irradiation. Between 1918 and 1930 radioactivity 
attained an enormous popularity. At this time it was believed that radiation has rejuvenating 
and curing effects. Therefore, a variety of radium containing products such as water or 
chocolate were commercially available to everyone.[2] 
The first application of radioactivity as a tracer began with de Hevesy and Paneth who used 
radioactive nuclides for isotopic exchange reactions, diffusion studies and also first in life 
sciences for the determination of the uptake of lead in different types of plants.[3] 
They are usually called the inventors of the “tracer-concept”. This concept is based on small 
amounts of a radiolabeled substance which is then used as a “mass substitute”. By application 
into an organism, the pathway and distribution of this substance can be measured due to the 
low threshold of radioactivity. The very low amounts of tracer, that are used for this purpose 
do normally not have any impact on physiology and can be neglected in most cases. De 
Hevesy was awarded with the Nobel prize in chemistry in 1933 for the application of this 
principle in vivo.  
The requirement for a widespread application of this principle was the development of 
artificial radioactivity. This was done in 1929 by Lawrence who built the first cyclotron at the 
University of California, Berkeley. The development of this new technique was delayed 
through the Second World War, especially in Germany. 
However, the evolution of radiopharmacy as an independent research field began after the 
world war. The first radionuclides for medicinal applications were developed in 1945 at Oak 
Ridge (Tennessee) and the first radiopharmaceutical products such as Na131I were available in 
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1955. In the middle of the 70s the Section on Nuclear Pharmacy was founded by the 
American Pharmaceutical Association.[2] Since then, uncountable developments have been 
achieved in this field and their number is still growing. Nowadays, radiotracers are mainly 
used for diagnosis and therapy in nuclear medicine, but also for a broad variety of research 
purposes. 
 
1.1  Principle of positron emission tomography (PET) 
Positron Emission Tomography (PET) is an analytical imaging technology in nuclear 
medicine using labeled compounds as molecular probes to measure biochemical processes in 
vivo.[4] It is mainly applied for diagnosis in nuclear medicine but also for research purposes in 
the fields of oncology[5],[6],[7],[8], neurology[9],[10],[11], cardiology[12],[13],[14] and psychiatry[15]. 
Other imaging techniques such as magnetic resonance imaging (MRI), x-rays or ultrasound, 
that are commonly used for anatomical or structural imaging, give limited or no information 
on biochemical and molecular processes. Therefore, these imaging techniques are limited to 
the in vivo measurement of diseases associated with structural changes whereas PET and 
SPECT (single photon emission tomography), a technique related to PET but relying on the 
detection of a single photon, are great options for the in vivo measurement of malfunctions 
related to metabolic events.  
PET is based on the simultaneous detection of two 511 keV photons resulting from the vice 
versa annihilation of a positron and an electron. Positron emitters are unstable isotopes 
bearing an excess of protons in their nucleus. The nucleus of a positron emitter stabilizes by 
emission of a positron (β+) and a neutrino (Scheme 1) which is formally the conversion of a 
proton into a neutron. The emitted positron thermalizes through collisions with other atoms 
and molecules in its surrounding.  
 
XN →  YN +  β1
0 + + veZ−1
A
Z
A  
Scheme 1 Decay of a radionuclide by positron emission. 
 
After thermalization a para-positronium, a hydrogen like particle consisting of an electron 
and a positron is formed in its singulet state (S = 0). The positron and the electron are anti-
particles that eventually annihilate and emit two 511 keV γ-rays (annihilation radiation) in an 
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angel of almost 180°. Compared to the mainly occurring para-positronium the ortho-
positronium with parallel spins (S = 1) is relatively rare.[16] In contrast to the β+-particles the 
emitted γ-radiation is body penetrating and can be detected by special szintillation crystals 
outside the body. Common materials for those detectors are high density crystals with a good 
ability to absorb the emitted γ-radiation such as bismut-germanate (BGO)[17] and Ce3+ doped 
lutetium-yttrium-oxide-ortho-oxosilicate (LSO)[18]. If two γ-photons with an energy of  
511 keV are detected in two detectors with an 180° angle within a certain time window of 
generally less than ten nano seconds, the signal is registered as valid (see Figure 1). The 
position of the annihilation can then be assigned along the connecting line in between the two 
events. This is a major advantage of PET over SPECT because the noise signal of other 
occurring events is diminished. The high spatial resolution of PET results from the fact that it 
is only dependent on the distance travelled by the positron and defined by the kinetic energy 
of this particle, which usually reaches from hundreds of keV up to a few MeV and results in a 
travelling distance of up to a few millimeters in human tissue.[19] 
 
 
Figure 1  Schematic representation of the principle of PET showing positron decay and  
 γ-annihilation which produces two γ-photons of 511 keV.[20] 
 
In order to obtain reconstructed images that are linearly correlated to the measured activity 
several corrections need to be done to avoid uncertainties caused by scattering, attenuation 
ring of photon  
detectors 
γ photon 
detection 
γ photon 
detection 
decay by 
positron 
emission 
annihilation 
γ γ 
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and the dead time of the detectors. For this purpose usually a transmission measurement is 
done before the radiotracer is injected. This is generally accomplished by use of the positron 
emitter 68Ga. Thereby one of the annihilation photons is used for the transmission information 
and the other one is needed to define the line of response. The application of this procedure 
allows the quantification of the radioactivity measured in the tissue which is the greatest 
advantage of PET.[21] In order to gain quantitative medical relevant information from the 
quantitative measurement of the distribution of the radioactivity in the body, the radioactivity 
is measured, which represents the distribution of the radiotracer in vivo. These data are then 
combined with a suitable bio-mathematical compartment model that describes the 
pharmacokinetic behavior of the radiopharmaceutical in the human body and thereby delivers 
quantitative information about the process under study.[22] In a typical PET study, a positron 
labeled probe is injected, and PET scans provide measures of the tissue concentration of the 
probe and its metabolites over time. These data are combined with a measurement of the 
plasma probe concentration over the course of time and, thus, representing its delivery to 
tissue. The obtained data are subsequently processed with the help of a suitable 
compartmental model and differential equations, which describe the transport and reaction 
processes the probe undergoes. Thus, an image of the physiological process of interest can be 
created. With the help of this image further analysis and rating of this process become 
possible.[4] Since PET probes are usually administered in the concentration ranges of pico- to 
femtomoles it is unlikely they have a pharmacodynamic influence on the biological process 
they are involved in. 
Some of the commonly used short lived radioisotopes for PET are identical with those found 
in biologically active substances. Hence it is possible to label these molecules without 
changing their original composition or structure. The widely used so called “organic” PET 
isotopes including their half-life, production route and decay product are listed in Table 1.[20] 
The isotopes shown in Table 1 all have relatively short half-lives which leads to one of the 
main challenges for radiochemists because the labeled probe needs to be synthesized, 
purified, analyzed, and formulated within a time scale of roughly two or three half-lives.[19] 
Therefore, the development of rapid synthetic strategies for the production of these radio-
labeled products is of high interest.[20] 
Nowadays PET measurements are usually combined with anatomical measurements by a CT 
(computed tomography) or MRI. Hereby both techniques are normally combined and 
integrated into one device. This allows matching of the functional data obtained by PET with 
the anatomical data recorded by CT or MRI and thereby supports diagnosis.  
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Table 1  Commonly used short-lived radionuclides in PET with their half-lifes, nuclear 
reactions, target and decay products.[12] 
Radionuclide T1/2 [min] 
Nuclear 
reaction 
Target 
material 
Product 
Decay 
product 
11C 20.4 14N(p,α)11C 
N2 (+O2) 
N2 (+H2) 
[11C]CO2 
[11C]CH4 
11B 
13N 9.97 16O(p,α)13N 
H2O 
H2O + EtOH 
[13N]NOx 
[13N]NH3 
13C 
15O 2.04 14N(d,n)15O N2 + O2 [
15O]O2 
15N 
18F 110 
20Ne(d,α)18F 
18O(p,n)18F 
Ne (+F2) 
H2[
18O]O 
[18F]F2 
[18F]F- 
18O 
 
 
1.2  Labeling of organic molecules with fluorine-18 
Fluorine-18 is the most widely used radionuclide for routine diagnosis in PET. It was first 
produced in 1936[23] and found its way into medical application during a few years. The 
intensive use of fluorine-18 can be dedicated to its almost perfect nuclear properties. It also 
can be produced in high yields even on low energy cyclotrons which guarantees its 
availability quite easily. The relatively long half-life of 109.7 min allows shipping of the 
desired products within a few hours to medical institutes that do not have a cyclotron on site. 
The low maximum kinetic energy of the positron emitted during the nuclear decay of 635 keV 
(mean energy of 250 keV) results in a maximum range in water of 2.4 mm (mean range of 0.7 
mm).[24] Thus, the low β+-energies enable high resolution PET images and relatively low 
radiation doses to the patients.   
Most of the established labeling methods with fluorine-18 follow general fluorination 
concepts applied in organic chemistry like electrophilic or nucleophilic substitution. But the 
short half-life and the sub-nanomolar amount of fluorine-18 used under no-carrier-added 
(n.c.a.) conditions cause difficulties in some reactions like the Balz-Schiemann reaction. 
Therefore, radiofluorination reactions do often require special methods and synthesis-
techniques that make use of non-standard leaving groups and reaction set-ups.  
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1.2.1 Electrophilic fluorination 
For electrophilic 18F-fluorination, [18F]F2 is essential which is nowadays generally produced 
by the 18O(p,n)18F nuclear reaction on a 18O-gas target. After irradiation a small amount of 
carrier F2 is added to the target to remove the produced radioactivity.
[25] The necessary 
addition of carrier and the fact that every molecule of [18F]F2 carries only one radioactive 
atom result in a maximum radiochemical yield of 50 % and a low specific activity. Hence 
radiotracers produced by electrophilic radiofluorination are limited to applications where a 
high specific activity is not required e.g. 18F-labeled amino acids or [18F]fluorosugars. 
Another major drawback of the electrophilic 18F-fluorination is the high reactivity of [18F]F2 
which results in a low selectivity, a broad variety of undesired side products and a need of 
extensive purification. In order to increase the regioselectivity in arenes, demetallation 
procedures were used (Scheme 2) with [18F]F2 and [
18F]CH3COOF as fluorination 
agents.[26],[27] 
 
M(CH3)3
X
F
18
X
[18F]CH3COOF
[18F]F2
CFCl3, -78 °C
 
Scheme 2  Regioselective 18F-labeling via electrophilic demetallation reactions  
(M = Sn, Ge, Si; X = OCH3, CH3, H, F, CF3, NO2).
[19] 
 
Experiments performed on a series of para-substituted trimethylaryltin, -germanium, -and 
silicon compounds gave the corresponding [18F]fluoroarenes in high regioselectivity showing 
a decrease in the radiochemical yield in the order Sn > Ge > Si including rings containing 
electron withdrawing groups. Only marginal differences could be observed between [18F]F2 
and the somewhat less reactive CH3COO[
18F]F.[24]  
Attempts were also made in order to increase the specific activity of [18F]F2 and to reduce the 
amount of carrier needed. Besides electrochemical attempts for this reason[28], 
methyl[18F]fluoride was prepared by no-carrier-added (n.c.a.) nucleophilic substitution of 
CH3I with n.c.a. [
18F]fluoride followed by an electric gaseous discharge (Scheme 3). This 
method allows the production of [18F]F2 with specific activities of up to 30 GBq/µmol, but has 
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a major drawback on the radiochemical yield. Further, the specific activity is still not high 
enough for, e.g. labeling of receptor-ligands. [29] 
CH3I CH3
18
F [
18
F]F2
[K 2.2.2] 18F-
MeCN
20 - 30 kV
140 nmol F2  
Scheme 3 Elemental [18F]fluorine generated by electric discharge of CH3[
18F]F.[29] 
 
 
1.2.2  Nucleophilic fluorination 
The most important method for labeling of organic molecules with fluorine-18 is the 
nucleophilic substitution with n.c.a. [18F]fluoride easily available with both, high activity and 
high specific activity via the 18O(p,n)18F nuclear reaction on H2[
18O]O enriched targets. The 
[18F]fluoride is received from the target in aqueous solution and, due to high hydration, is 
poorly reactive. Further treatment of the [18F]fluoride containing solution is necessary prior to 
any use in nucleophilic radiosyntheses. Although amply described[30],[31] it should be briefly 
summarized here: The first step herein is usually the separation of [18F]fluoride from the 
expensive 18O-enriched water. This generally takes place by adsorption of [18F]fluoride on an 
ion exchange resin, enabling the recovery of the 18O-enriched water, followed by the elution 
of the [18F]fluoride with a small amount of an aqueous solution of a weak base.[32],[33] The 
remaining water is removed by repeated azeotropic distillation with MeCN.[31] 
Alternatively, [18F]fluoride can be separated by use of an electrochemical cell. This method 
does not require thermal drying. After adsorption the electrode is rinsed with a dry organic 
solvent to remove the remaining water. Afterwards the [18F]fluoride is released into an aprotic 
polar solvent of choice by inversion of the voltage in the cell and eluted.[34]  
Because of the strong hydration of fluoride in water, labeling has to take place under aprotic 
conditions. Therefore, routine labeling via nucleophlic substitution is usually performed in 
dipolar aprotic solvents such as DMSO (dimethylsulfoxide), DMF (N,N-dimethylformamide) 
or MeCN (acetonitrile) using alkali salts with soft cations resulting in weak and easy to 
separate ion pairs and “naked” fluoride ions of high nucleophilicity. Additional anion 
activation can be achieved by the use of phase transfer catalysts (PTC) like 
tetraalkylammonium carbonates[32],[35] or aminopolyether like the mainly used 
Kryptofix®2.2.2 in combination with alkali carbonates or oxalates.[36],[37],[38] This is the 
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generally favored system in most n.c.a. radiofluorination reactions. Also wall loss of the 
[18F]fluoride plays a minor role if the solubility product of the cryptate complex is not 
exceeded.[39] However, there are a few cases where tetrabutylammonium carbonate shows 
advantages over the Kryptofix® system.[30],[33]  
Since direct aliphatic 18F-fluorinations are generally performed in dipolar aprotic solvents, 
they proceed according to an SN2-mechanism. Good leaving groups such as mesylates, 
triflates or other sulfonic esters are required for high radiochemical yields. The yields are also 
increasing from tertiary to primary carbon position. 
For aromatic nucleophilic radiofluorination (SNAr) the aromatic ring needs to be activated by 
an electron withdrawing group like an aldehyde, ketone or nitrile in ortho or para position to 
the leaving group. Commonly used leaving groups for this type of reaction are -F, -NO2 or  
-N(CH3)3
+. In general aromatic nucleophilic substitution reactions require higher temperatures 
than aliphatic ones. Hence solvents with higher boiling points such as DMF or DMSO are 
preferred here. The application of those labeling methods has been reviewed in detail by 
Ermert and Coenen.[40] 
Further, the requirement of electron withdrawing groups limits the scope of direct aromatic 
fluorination. Detailed information about this can be found in a review by Coenen and 
Ermert.[41] For the fluorination of an electron rich arene it is generally essential to generate an 
electrophilic center. Diaryliodonium salts offer a promising possibility for this type of 
reaction. It is well known that they react with a wide range of nucleophiles giving the 
corresponding arenes and iodoarenes.[42] The distribution of the resulting products after the 
nucleophilic attack is strongly dependent on the electronic and steric character of each arene 
ring (Scheme 4). The reaction itself proceeds also via a SNAr-mechanism and in asymmetric 
diaryliodonium salts the more electron deficient ring is of course preferred for the 
nucleophilic attack of the [18F]fluoride.  
 
I
+
R R'
X
-
n.c.a. [18F]fluoride
K 2.2.2
F
18
R
F
18
R'
+
 
Scheme 4  General principle of 18F-labeling via diaryliodonium salts (X = Cl, Br, TsO, ClO4, 
CF3SO3; R, or R’ = H, Cl, Br, I, NO2, CH3, OCH3.  
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Also symmetrical iodonium salts have been prepared in order to avoid 18F-labeled side 
products originating from 18F-fluorination of the undesired arene ring.[43],[44],[45] 
Due to their chemical properties the use of iodonium salts was limited mainly to small 
molecules or synthons in the past. Recently, aryliodonium ylides were found to be a 
promising alternative for direct n.c.a. radiofluorination of complex, even electron rich 
[18F]fluoroarenes. An example for this is the radiofluorination of the NET (norepinephrine 
transporter) and SERT (serotonin transporter) ligands 3- and 4-fluorophenoxy)phenyl-
methyl)piperidine (3- and 4- FPPMP) via the corresponding iodonium ylides giving the 
transporter ligands in a RCY of up to 45 % (Scheme 5). 
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Scheme 5 Radiosynthesis of 4[18F]FPPMP via the corresponding iodonium ylide.[46] 
 
However, when the radiosynthesis of 4-[18F]FPPMP was carried out, also the positional 
isomer 3-[18F]FPPMP was always detected with about 10 % RCY. This behavior was also 
observed with the small molecules 4-methoxyphenyl-(5-[2,2-dimethyl-1,3-dioxane-4,6-
dione])ylide and 4-benzyloxyphenyliodonium-(5-[2,2-dimethyl-1,3-dioxane-4,6-dione])ylide 
indicating rearrangement reactions during substitution.[46] 
As the incorporation of fluorine-18 by nucleophilic substitution into an organic compound at a 
carbon atom is usually carried out under rather harsh conditions like high temperature and 
basic conditions, the labelling of complex biomolecules (e.g. peptides or proteins) is often not 
possible due to their limited stability in this process. Recently, the high affinity of fluorine to 
silicone was used in order to accomplish 18F-fluorination under very mild conditions. With 
this principle basically two approaches were made for the introduction of fluorine-18. The 
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preparation of a synthon by an isotopic 18F-for-19F exchange[47] that is only applicable when 
high specific activities are not required, and a method where the silicone is directly attached 
to the desired molecule. In the second case the leaving group on the silicone is usually an 
alkoxy, hydroxy or hydride group.[48][49] Examples for the application of these methods are 
shown in Scheme 6. 
Si
N
O
N
O
H
peptide
tBu
tBuF
19 Si
N
O
N
O
H
peptide
tBu
tBuF
18
Si
R
RH
R'
Si
R
RF
18
R'
Si
N
O
peptide
tBu
tBuF
18
H
Si
N
O
peptide
tBu
tBuOH
H
18F-, K 2.2.2
18F-, K2.2.2
18F-, K2.2.2
Scheme 6  Examples for the radiofluorination of silicone precursors with fluorine-18 by 
 isotopic 18F-for-19F exchange, 18F-for-OH substitution and 18F-for-H-substitution. 
 
Another 18F-fluorination method for the radiolabeling of arenes that was recently introduced 
is based on boronic esters. One of the major advantages of this procedure is that the arenes do 
not require previous activation by an electron withdrawing group which is essential when 
radio-fluorination is carried out under standard SNAr conditions. Herein, a direct copper(II)-
mediated fluorination of aromatic boronic esters with n.c.a. [18F]fluoride has been 
accomplished using a commercially available copper(II)-catalyst (Scheme 7). The boronic 
esters herein are usually prepared by a transition metal catalyzed boron for halogen exchange. 
Using this procedure a broad variety of small arenes has been labeled in moderate to good 
RCY.[50] 
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Scheme 7  Aromatic Cu(II)-mediated 18F-fluorination of pinacol-derived boronic esters with 
 n.c.a. [18F]fluoride.[50] 
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An interesting method that has emerged in recent years is the radiofluorination of peptides by 
the chelation of Al18F. The best RCY and in vivo stability were obtained when pentadentate 
ligands were applied leaving one binding site of aluminum free for the coordination with 
[18F]fluoride. For this reason, a good ligand is 1,4,7-triazacyclononane-1,4,7-triacetic acid 
(NOTA), where one of the carboxylic acids is already linked to the peptide of interest. By the 
application of this labeling technique a RCY of up to 97 % and specific activities of up to 115 
GBq/µmol were obtained within a very short reaction time of about 115 min. Since then this 
method has been used for the radiofluorination of several proteins and peptides, especially 
RGD peptides.[51] 
 
1.2.3 Fluorination through secondary groups 
Radiofluorination is not always possible by a direct one-step labelling procedure with 
[18F]fluoride. This is especially true when electron rich arenes and macromolecules such as 
peptides or proteins are subject to labeling. Therefore, alternative procedures are required that 
allow nucleophilic radiofluorination of those molecules.  
This goal can be achieved using a secondary group that can be directly labeled through 
nucleophilic substitution with n.c.a. [18F]fluoride followed by coupling to the target molecule.  
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Scheme 8  Possibilities of conversion of [18F]fluorobenzaldehydes as examples of versatile 
 synthons.[52] 
 
Aromatic, so called radiofluorinated synthons are often derived from 2- or 4-[18F]fluorobenz-
aldehydes that are easily accessible by direct labeling with n.c.a. [18F]fluoride. The activating 
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aldehyde in those molecules can be converted to versatile functional groups, e.g. 
benzylhydroxides or –halides by reductive reactions. It is also possible to remove the 
aldehyde function completely by reductive decarbonylation. Conversion to phenols can be 
accomplished by the Baeyer-Villiger Oxidation. Some important aromatic synthons derived 
from [18F]fluorobenzaldehydes are shown in Scheme 8. More detailed information on this can 
be found in the review by Ermert and Coenen.[52],[30][30][30][30][30] 
Other important procedures for the introduction of [18F]fluoride are the 18F-fluoroalkylation, 
the 18F-fluoroacylation and the 18F-fluoroamidation (Scheme 9).[53],[54],[55] Applications for the 
prosthetic groups shown in Scheme 9 are widespread and reach from radiolabeling of 
macromolecules and peptides to 18F-fluorination of small molecules such as neurotransmitters 
or hormones. By far the most important of these procedures is the fluoroalkylation which was 
used extensively in the recent years to radiofluorinate molecules like tyrosine, L-DOPA or L-
5-hydroxytryptophan. The 18F-fluoroalkylation synthons are usually prepared by 18F-
fluorination of symmetrically 1,n-substituted precursors. The most commonly used of those 
18F-fluoroalkylation agents is probably [18F]fluoroethyltosylate which has been applied to a 
series of radiolabeled compounds.[56],[57],[58] 
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Scheme 9  Prosthetic groups for 18F-fluoroalkylation, 18F-fluoroacylation and 18F-fluoro- 
amidation (X, Y = Br, I, OTs, OTf; Z = N, O, S; R = alkyl, aryl).[53][54][55] 
 
A further important secondary group that is mainly used for protein or peptide labeling is  
N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB). This versatile compound can be prepared in 
a three step linear radiosynthesis in less than 60 min. The starting material is ethyl 4-
(trimethylammonium triflate)benzoate that is radiofluorinated in the first step followed by 
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hydrolysis of the ester and subsequent coupling with N,N,N’,N’-tetramethyl-O-(N-succini-
midyl)uronium hexafluorophosphate (HSTU) giving a RCY of about 44 %.[59] The synthesis 
is shown in Scheme 10. 
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Scheme 10  Synthetic route for the preparation of [18F]SFB in a three step linear pathway  in 
less than 60 min.[59] 
 
The radiosynthesis of [18F]SFB was later optimized using a microwave assisted setup. 
Thereby the synthesis time could be reduced to 20 min while increasing the RCY to about  
61 %.[60] Labeling with [18F]SFB is usually done at amine functions of amino acids and 
proteins.  
TsO
n
F
18
n
F
18
N N
N peptide
O
n
O
peptideN3
CuI, Na-ascorbate
DIEA
N3
TsO
n
O
peptide
CuI, Na-ascorbate
DIEA
N3
F
18
n
F
18
N N
N peptide
O
[K2.2.2]18F
MeCN
[K2.2.2]18F
MeCN
Scheme 11  The two alternative onsets for Huisgen´s 1,3-dipolar cycloaddition for 
  preparation of [18F]fluoropeptides. [61],[62] 
 
An additional concept that has become popular in the past few years is the 18F-fluorination via 
“click chemistry”. Most often, a Huisgen 1,3-bipolar cycloaddition of an alkyne and an azide 
is used for this purpose (Scheme 11). The reaction originally required the addition of CuI and 
proceeds under mild conditions in aqueous solution. In the past the addition of CuI was a 
problem when the radiotracer should be used for in vivo applications, but in recent years 
several optimizations for this type of reaction were made, that allow radiofluorination by this 
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method without the addition of CuI. Some examples for this can be found in the 
literature.[63][64] Further advantages are that generally there is no need for protection of 
functional groups and that the reaction is usually done within 30 min giving high RCY.[62][61] 
 
 
1.2.4 Transition metal catalyzed fluorination 
In recent years methods relying on transition metal catalyzed mechanisms came into focus of 
radiochemists. Since then a variety of approaches has been made in this direction. One of the 
first approaches in this direction was made by Lee et al.[65] who developed a Pd-catalyzed 
electrophilic late stage 18F-fluorination method starting from n.c.a. [18F]fluoride (see Scheme 
12). The major drawback of this method is the preparation of the palladium complex which is 
hard to facilitate and requires extremely anhydrous conditions.  
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Scheme 12  Electrophilic radiofluorination of palladium aryl complexes to afford aryl   
 fluorides. Top: With the electrophilic fluorination reagent F-TEDA.  
 Bottom: With the Pd(IV) fluoride complex, made from [18F]fluoride.[65] 
 
An improved modification of this method was developed relying on a Ni-mediated 18F-
fluorination with less sensitive complexes and a higher RCY (see Scheme 13). The 
fluorination is accomplished by combination of a corresponding Ni-complex with an oxidant 
and aqueous [18F]fluoride. This method avoids some of the limitations inherent to the 
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palladium chemistry shown in Scheme 12, especially the possibility of a one-step 
radiosynthesis. Furthermore, the Ni-complex is much more stable. The drawback of this 
procedure is the requirement of a special oxidant that is very sensitive to humidity and needs 
to be prepared and handled under extremely anhydrous conditions in glove-boxes.[66]  
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Scheme 13 Ni-mediated nucleophilic n.c.a. 18F-fluorination of simple aromatic  
  compounds.[66] 
 
Recently, a method was developed which describes a late stage benzylic 18F-for-H 
fluorination with n.c.a. [18F]fluoride based on Mn(salen)-complexes (see Scheme 14). It 
proved suitable for a large series of small arenes such as the pharmaceutical Ibuprofen.[67] 
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Scheme 14  Benzylic 18F-for-H fluorination with n.c.a.[18F]fluoride. [67] 
 
1.3 Indoles 
The indole motive is one of the most frequently occurring heterocyclic moieties in natural 
products.[68] It is, for example, part of the essential amino acid L-tryptophan, its metabolite 
skatol, the plant growth factor 3-indolylacetic acid (heteroauxin) and the neurotransmitter 
serotonin.[69] There is also a broad variety of plant alkaloids that contain indole, e.g. 
strychnine and ellipticin. Many of those plant alkaloids are highly toxic but may have 
properties that are highly valuable for special medicinal applications.[70] Indole was first found 
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by Baeyer and Knoop while studying the structure and properties of indigo.[71] In 1869 Baeyer 
and Emmerling proposed the structure that is still generally accepted (Figure 2).[72]  
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Figure 2  Chemical structure of indole with IUPAC numbering. 
 
 
1.3.1 Indole chemistry 
Due to the arising interest in indoles and indole chemistry, many attempts have been made to 
synthesize indoles and derivatives thereof. The first organic synthesis of indole was achieved 
by Baeyer et al. who oxidized indigo to isatin, reduced isatin to dioxindole and oxindole with 
zinc dust and further reduced the formed oxindole and dioxindole to indole by passing its 
vapor over hot zinc oxide (Scheme 15).  
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Scheme 15  Synthesis of indole performed by Baeyer et al.[72] 
 
Until now a variety of methods has been described for the synthesis of the indole moiety 
usually classified by the name of their inventors (Scheme 16).  
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Scheme 16  Selection of pathways for the synthesis of indoles. 
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The most popular herein is probably the Fischer indole synthesis which uses arylhydrazines 
and ketones. Here, two new bonds, the N–Cα and the Cβ–Cortho linkage, are formed in the 
same step. This is equally the case with the Bartoli-Reaction in course of which 
vinylmagnesium bromide adds nucleophilically to a nitrosoarene, generated in situ from a 
nitroarene precursor. [73]  
The Leimgruber-Batcho synthesis also starts with a nitroarene but herein a methyl group is 
attached in ortho position to the nitro group.[74] Due to the availability of anilines they were 
also often used for the formation of indoles. Two examples for this are the Berlinerblau-
Nordlander[75],[76],[77],[78],[79] and the Bischler-Möhlau[80] procedure. By both methods the 
aniline is alkylated with a side chain that contains a protected or unprotected β-oxo group 
which allows an intramolecular Friedel-Crafts hydroxylation by an acid catalyst. Further 
Fürstner et al. demonstrated that an ortho and doubly N-acylated aniline also delivers an 
indole when treated with McMurry low-valent titanium.[81],[82] 
The chemistry of indoles is rather versatile. Usually indigo is formed when indoles are subject 
to mild oxidation conditions such as to hydrogen peroxide or ozone. Reduction of indoles 
usually leads to 2,3-dihydroindole and is possible under electrolytic conditions or by catalytic 
hydration. (Scheme 17).[70] 
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Scheme 17  Reactions of indole under oxidative and reductive conditions. 
 
Furthermore, indole is highly activated in its 3-position towards electrophilic substitution 
reactions such as nitrations or formylations. One popular example for an electrophilic 
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substitution reaction that provides formylation in the 3-position is the Vilsmeier-Haack 
reaction [83] which gives high yields.[84] 
In the past, direct halogenation of the carbocycle was not feasible. This was usually done via 
build-up syntheses such as the Bartoli reaction starting from halogenated benzene derivatives. 
In contrast halogenations in the 2- or 3-position proceed smoothly. Thereby the choice of the 
reaction conditions and the substitution pattern of the indole determine whether the 2- or the 
3-position is halogenated.[85] This is similar with its alkylation which can also occur in the  
3-position or at the nitrogen atom depending on the reaction conditions.[86] 
Nowadays halogenation and electrophilic aromatic substitution at the carbocycle became 
possible due to the application of special conditions and reagents such as those described by 
Schlosser et al. (Scheme 18). [69]  
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Scheme 18   Electrophilic iodination of 1-TIPS-6-fluoroindole with sec-BuLi and I2 as 
 electrophile (top) and carboxylation of 1-TIPS-6-fluoroindole with sec-BuLi and 
CO2 as electrophile (bottom).
[69] 
 
1.4 -Amino acids 
-Amino acids are important organic compounds that are biologically active and necessary 
for a broad variety of biological processes, especially as building blocks for proteins. Every 
amino acid contains, as described by their name, an amino group and a carboxylic acid. The 
amino acids involved in biological processes are all α-amino acids. Those amino acids have a 
central carbon atom, the α-carbon, to which are attached the amino group, the carboxylic acid, 
a proton and a residue (R), which is often called side chain (see Figure 3). Except of glycine 
where the side chain is a proton all amino acids are chiral and are therefore D- or L-
stereoisomers. The form usually found in naturally occurring proteins is the L-form. [87],[88] 
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HOOC NH2
R H  
Figure 3  General structure of an α-L-amino acid. 
 
The 20 -amino acids that are mainly occurring in mammalian proteins are called “standard 
amino acids” and are divided in essential and non-essential amino acids. The essential -
amino acids cannot be synthesized by the human body and must be delivered by food while 
the non-essential amino acids can be synthesized by the human body.[89] Various ways for 
classification of the different types of -amino acids have been described in the past and can 
be found in the literature.[88] 
Some amino acids function not only for nutrition, as building blocks in protein synthesis and 
cell division but also as metabolic intermediates like in the biosynthesis of neurotransmitters 
such as L-DOPA or serotonin. The most important of such neurotransmitter amino acids are 
the ones taking part in the dopaminergic and serotonergic pathways namely phenylalanine, 
tyrosine and tryptophan. 
 
1.4.1  -Amino acid uptake through the cell membrane 
Generally there are two possibilities for transport of amino acids into cells. They can get into 
cells by diffusion through a concentration gradient which, however, plays a minor role under 
physiological conditions. The transport mainly occurs by carrier mediated processes that 
involve the binding of the substrate to a specific catalytic site on a transporter protein.[90]  
Various functionally and biochemically distinct amino acid transporter systems have been 
discovered and defined on the basis of their amino acid selectivity and physico-chemical 
properties. In most cases the transport of amino acids into the cytoplasm is an active process 
that requires binding of the amino acid to an active site on a complex protein that may contain 
several transmembrane regions. It is well known that most of the carrier proteins transport a 
special class of amino acids (i.e., neutrals, cationics, aromatics, amino acid amides) rather 
than one specific amino acid. 
Furthermore, many of the transporter systems require sodium for maximal activity and 
thereby the catalysis of the amino acid transport is coupled to the sodium ion. The transport 
process itself is established by a high extracellular/intracellular sodium gradient (ca. 140 mM 
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outside, ca. 10 mM inside). The initial step of the transport is the binding of sodium to the 
transporter. Thereby a conformational change occurs which increases the affinity of the 
extracellularly oriented cotransporter site for subsequent amino acid binding. A sodium/amino 
acid cotransporter complex is formed and another conformational change results in the release 
of the amino acid and the sodium ion into the cytoplasm inside the cell. The sodium ion is 
then transported out of the cell via an energy requiring Na+/K+ ATPase against its gradient to 
maintain the electrochemical potential and the sodium gradient of the cell while the released 
amino acid undergoes intracellular metabolism or functions in signal transduction  
(Figure 4).[91],[92] 
 
Figure 4  Conceptual scheme of a membrane-bound sodium-dependent α-amino acid 
carrier.[93] 
 
The driving force of this process is the sodium gradient as well as the electrical potential 
which promotes the initial binding of the sodium ion within the carrier and thereby activates 
the channel.  
For the other group of amino acid transporters – the sodium independent systems – the 
vectorial movement of amino acid transport generally depends on the relative concentrations 
of the concerned amino acid inside and outside of the cell and follows the concentration 
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gradient.[93] There are also examples where the transport occurs against the concentration 
gradient under appropriate conditions. For example due to it’s high “exchange” transport 
properties, system L, which is responsible for the transport of aromatic amino acids, can 
accumulate amino acids against their gradient by counter-transporting a second amino acid 
whose gradient has been established by one or more of the sodium-dependent systems.[94] 
 
 
1.4.2  Organic synthesis of -amino acids 
In the past many attempts have been made for the synthesis of different types of -amino 
acids. One of the first methods was described by Strecker[95] who first synthesized alanine by 
reacting acetaldehyde with potassium cyanide and ammonia followed by the addition of an 
excess of hydrochloric acid (Scheme 19). 
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Scheme 19  Synthesis of racemic α-amino acids via Strecker's approach.[95] 
 
The reaction itself is a Mannich type reaction and proved useful for the synthesis of several 
amino acids. The major drawback herein is that the produced amino acids are only available 
as a racemic mixture.  
Another important pathway for the preparation of amino acids is the Hell-Vollhard-Zelinsky 
reaction in combination with Gabriel’s synthesis. Hereby a carboxylic acid is brominated with 
phosphorous tribromide and elemental bromine followed by a reaction of the resulting  
α-bromide with potassium phthalimide and subsequent hydrolysis (Scheme 20).[96] 
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Scheme 20  Synthesis of racemic amino acids via the Gabriel synthesis.[96] 
 
As described with the Strecker method it is not possible to get the desired amino acid in a 
pure enantiomeric form. Since the separation of two enantiomeric forms usually results in 
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complicated chiral derivatization into diastereomers followed by separation, procedures are of 
great advantage, that deliver the desired amino acid with high enantiomeric purity.  
A general method for this purpose is based on an electrophilic alkylation of optically active 
derivatives of glycine. Two reagents are often used for that and are described in detail below.  
One of such glycine derivatives that allows a stereoselective synthesis of amino acids was 
developed by Schöllkopf and is based on a chiral bislactimether that is derived from glycine 
and D- or L-valine. The two amino acids are condensed and the carbonyl oxygens are 
methylated (Scheme 21).  
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Scheme 21 Preparation of Schöllkopf's auxiliary.[97] 
 
The Schöllkopf’s auxiliary is converted into an amino acid by deprotonation and subsequent 
reaction with an alkyl or aryl halide. Deprotonation of the auxiliary results in a planar 
transition state (Scheme 22) where an attack of the halide is only possible from the site which 
is not sterically occupied by the isopropyl residue, resulting in an amino acid with inverted 
stereochemistry compared to the bislactimether.[97] 
 
N
N
O
O
H
-
Li
+
X R
 
Scheme 22  Transition state of the alkylation with Schöllkopf’s auxiliary.[97] 
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Enantiomeric purities obtained using this procedure are generally > 95 %. An improved 
method was developed using D- or L- tert-leucine instead of the naturally occurring form 
resulting in enantiomeric purities of > 98 %.[98] 
Another method relying on a chiral auxiliary is the one developed by Seebach et al.[99] The 
auxiliary herein is based on an imidazolidinone that is prepared in a multi-step synthesis 
(Scheme 23). The major drawback is that the auxiliary is obtained in racemic form and needs 
to be separated by co-crystallisation with L- madelic acid. 
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Scheme 23  Preparation of Seebach's reagent.[100] 
 
After crystallization the free amine needs to be protected with a Boc- or Z-group. The 
stereoselectivity results from the bulky tert-butyl group that prevents a nucleophilic attack 
from the site of the imidazolidinone that is occupied by this group. Using this method 
enantiomeric purities of > 98 % are usually obtained. 
  
1.4.3  Tumor imaging with radiolabeled -amino acids 
Tumor imaging with radiolabeled amino acids is based on the elevated uptake of radiotracer 
in the malignant tissue.[101] Amino acids are required by all types of cells for energy 
production, protein synthesis and cell duplication. Malignant tumor cells are known to be 
most often hypermetabolic in glucose metabolism, protein synthesis and amino acid 
uptake.[102] Furthermore, the transporter types LAT1 and A1 are often overexpressed in 
malignant tumor cells as compared to normal tissue.[103],[104],[105],[106] In the literature 
especially analogues of phenylalanine and tyrosine are described as useful for the imaging of 
tumors related to overexpression of the LAT1 transporter protein.[107]  
Several studies have described the measurement of both protein synthesis rate (PSR) or only 
the uptake of amino acids by the overexpressed transporters LAT and A1. It is also indicated 
that in some cases radiolabeled amino acids do have an advantage over FDG which is the 
standard PET tracer for tumor imaging. This is especially true when it comes to applications 
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where imaging with FDG is limited. Examples for this are areas of tissue with a high basic 
glucose uptake such as the brain, or if tumors must be differentiated from inflammatory 
lesions which is due to high FDG uptake in macrophages, e.g., after radiotherapy or 
inflammation. 
In the past it was suggested by several studies that for tumor imaging it is more important to 
measure the uptake of amino acids rather than the incorporation into proteins since the latter is 
slow and does not occur significantly during the time of the measurement. Therefore, it is 
likely that the fraction of amino acids which is incorporated into proteins does not 
considerably contribute to the szintigraphic visualization of the tumor.[108],[109],[110] 
Subsequently amino acid derivatives that are not subject to protein synthesis but undergo 
internalization have been developed for the quantification of the amino acid 
transport.[109],[111],[112],[113] The most prominent of those amino acid analogues is possibly O-(2-
[18F]fluoroethyl)-L-tyrosine which is widely used for tumor diagnosis.[114],[5],[115] The fact that 
those slowly metabolised, radiolabeled amino acids are not released from the cells into 
circulation allows simple kinetic modeling for quantification. 
Another major advantage of measuring amino acid uptake rather than protein incorporation is 
that it is a fast metabolic process and that therefore tumor imaging can be performed within 
20 min post injection.  
 
1.5 The serotonergic system 
The serotonergic system plays a central role in the regulation of cognitive, emotional and 
neuroendocrine processes and is related to a broad variety of behavioral functions. 
Dysfunctions in the signal transduction of the serotonergic system are therefore related to 
neuropsychiatric diseases as well as to alterations in emotional and cognitive functions. 
The serotonergic system is characterized by its broad allocation in the central nervous 
systems. The neurotransmitter serotonin (5-hydroxytyramine, 5-HT) itself shows a variety of 
mechanisms of action caused by the interaction with different receptor types and the resulting 
effects. Serotonin can interact with receptors located pre- and postsynaptic, and according to 
the subtype of the corresponding receptor, excitatory and inhibitory effects are possible. The 
main effects of serotonin are the modulation of dopaminergic, cholinergic and GABAergic 
neurons.[116] 
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Serotonin was first discovered as a vasoconstrictor substance in the blood[117] and has been 
revealed to be of importance in a broad range of physiological processes. It has been shown 
that serotonin is involved in the control of smooth muscle tone and vascular 
function[118],[119],[120], hemostasis and platelet function[121],[122] and hepatitis and liver 
regeneration[123],[124],[125],[126]. Further, it was found that it also plays an important role in 
mammary gland plasticity[127], insulin secretion[128], the development of neurons and sleep 
regulation. It is also involved in the control of appetite, the gastrointestinal motility, pain 
sensation, nociception, mood, stress, maternal or sexual behavior and aggression.[129],[130],[131] 
The biosynthesis of serotonin starts with the essential amino acid tryptophan which is 
hydroxylated in 5-position yielding 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan 
hydroxylase (TPH). This hydroxylation is the initial and rate limiting step[132] in the synthesis 
of serotonin. 5-HTP is then further decarboxylated (see Scheme 24) to serotonin  
(5-hydroxytaramine, 5-HT) by aromatic amino acid decarboxylase (AADC). TPH belongs to 
the family of aromatic amino acid hydroxylases that also includes tyrosine hydroxylase and 
phenylalanine hydroxylase. All of them are iron (Fe2+) dependent and have similarities in 
structure and mechanism.[133] 
 
 
Figure 5  Duality of the 5-HT-system. Functions of peripheral (TPH-1) and central (TPH-2) 
5-HT.[134] 
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Scheme 24  Metabolism of 5-hydroxytryptophan. AADC = aromatic amino acid decarb- 
oxylase, SNAT = serotonin N-acetyltransferase, HIOMT = hydroxy indole-O- 
methyl transferase, MAO = monoamine oxidase, ADH = alcohol 
dehydrogenase.[134] 
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In the past the existence of two independent systems of 5-HT formation has been discovered. 
The difference of the systems is the rate limiting enzyme TPH. TPH-1 is responsible for the 
synthesis of 5-HT in peripheral tissue and is found in the gastrointestinal enterochromaffin 
cells and blood platelets but also in the pineal gland where 5-HT is further metabolized into 
melatonin. TPH-2 is only expressed in the brain and mainly located in neurons of the raphe 
nucleus in the brainstem. According to their location both TPH-systems have very different 
effects on the human body. While TPH-1 has mainly peripheral effects, TPH-2 affects the 
central nervous system only (Figure 7). 
 
1.5.1 Serotonin receptors 
Up to now more than 20 receptors for the neurotransmitter serotonin have been discovered. 
They are divided into groups from 5-HT1 to 5-HT7. The 5-HT3 receptor is the only ligand-
gated ion-channel and belongs to the Cys-loop family of ligand-gated ion-channels such as the 
nicotinic acetylcholine receptors, the GABAA receptors, and the glycine receptors.  
 
Table 2  Signaling pathways, location and pharmacology of 5-HT receptor subtypes.[135] 
Receptor Major signaling pathway Neuronal Location Regional localization 
5-HT1A ↓cAMP 
Somatic autoreceptor, 
postsynaptic 
Raphe nuclei/hippo-
campus, cortex 
5-HT1B ↓cAMP 
Terminal autoreceptor, 
postsynaptic 
Striatum, nucleus 
accumbens, ventral 
tegmental area 
5-HT2A IP3 Postsynaptic Frontal cortex 
5-HT2c IP3 Postsynaptic Frontal cortex 
5-HT3 Ion channel Postsynaptic Cortex, amygdala 
5-HT4 ↑cAMP Postsynaptic 
Striatum, nucleus 
accumbens, cortex 
5-HT6 ↑cAMP Postsynaptic Hippocampus, cortex 
5-HT7 ↑cAMP Postsynaptic 
Suprachiasmatic nucleus, 
cortex 
 
The 5-HT3 receptors are distributed in both, the peripheral and the central nervous 
system.[136],[137] The other 5-HT receptors are of metabotropic nature and coupled to G-
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proteins. If a single receptor is of excitatory or inhibitory nature, depends on whether it is a 
presynaptic hetero- or autoreceptor or a postsynaptic receptor. It also depends on the type of 
second messenger activation the receptor causes. According to the anatomic distribution some 
receptors are more important for the interaction between serotonin and cognition than others.  
The receptors 5-HT1A/1B/1D, 5-HT2A/2B/2C, 5-HT3A/3B, 5-HT4A/4B, 5-HT5A/5B, 5-HT6 and 5-HT7 
seem to be highly involved in cognitive processes. They are located in the hippocampus, the 
basal ganglia, the amygdala, the frontal cortex and partially in other cortical regions.[138] An 
overview of 5-HT receptor subtypes is given in Table 2. 
 
1.6 Tryptophan 
Tryptophan (Trp, W) is one of the essential aromatic amino acids occurring in the human 
body and belongs to the group of non-polar amino acids. The isolation of tryptophan was first 
reported in 1901 by Hopkins through the hydrolysis of casein.[139] The biosynthesis of 
tryptophan in plants and microorganisms usually starts from shikimic acid or anthranilate. The 
latter condenses with phosphor-ribosylpyrophosphate (PRPP), generating pyrophosphate 
(PPi) as a by-product. After ring opening of the ribose moiety and following decarboxylation, 
indole-3-glycerinephosphate is produced which is then transformed into indole. The last step 
is catalyzed by the enzyme tryptophan synthase. This enzyme couples serine to indole and 
thereby creates tryptophan (Scheme 25).[140] 
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Scheme 25  Biosynthesis of tryptophan starting from anthranilate. 
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Industrial production of tryptophan also proceeds by the fermentation of indole with serine 
under the influence of tryptophan synthase. In the last few years tryptophan gained increased 
interest. It came out that some tumors have a highly elevated tryptophan consumption which 
could be of use regarding tumor imaging with PET or treatment.[141] Furthermore, tryptophan 
is the precursor for serotonin which is involved in a broad variety of neurological processes 
such as depression[134] and migraine[142]. Therefore, a 18F-labeled tryptophan analogue might 
be a potential radiotracer for imaging of the serotonin synthesis in vivo. 
 
1.6.1  Tryptophan in tumor imaging 
Recently the assumption came up that fast growing progressive cancers occur because of the 
failure of the immune system to maintain control over those tumors. Hence, the ability of 
cancers to escape immune response is attracting attention. There is evidence that the immune 
escape of those tumors is due to the consumption of tryptophan as a critical factor.[141] 
It was found by Opitz et al.[143] that some tumors upregulate the enzyme tryptophan 
dioxygenase (TDO) to drive tryptophan consumption. This enzyme converts tryptophan to 
kynurenine (Scheme 26) which is known to be a ligand for the aryl hydrocarbon receptor that 
mediates invasive tumor growth.[143]  
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Scheme 26  Conversion of tryptophan to kynurenine. 
 
Those facts may be crucial in the explanation of how tumors overcome immune barriers to 
cancer progression. It is assumed that the interplay between cancer cells and nearby immune 
cells plays an important role in whether the cancer is destroyed by the immune system, 
persists in a dormant, slow growing state or progresses to an aggressive and clinically 
challenging state. Therefore, immune escape drives the development of tumors towards 
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aggressive forms.[144] One such pathway is of emerging interest and involves the consumption 
of tryptophan and the upregulation of the enzymes TDO, IDO (indoleamine 2,3-dioxidase) 
and IDO2, which are all responsible for the generation of kynurenine through tryptophan 
metabolism. The crucial role of IDO in immune tolerance was discovered several years before 
it was connected with cancer. It is also by far the best studied tryptophan metabolizing 
enzyme.[145],[146] The generation of kynurenine by IDO and TDO inhibits the activation of the 
so called T cells through various mechanisms which also affect the activity of other immune 
cells. In patients with cancer the upregulation of IDO is often combined with a poor 
prognosis.[147] Therefore, radiolabeled tryptophan might be useful for the imaging of cancers 
with upregulated TDO and IDO. 
 
1.6.2  Radiolabeled tryptophan derivatives 
In the last 30 years several tryptophan analogues have been radiolabeled with the PET 
isotopes carbon-11 or fluorine-18. The motivation for this was to find either an amino acid 
tracer that is suitable for tumor imaging or a tracer that enables the measurement of serotonin 
levels and metabolism. The first attempt to the radiosynthesis of a radiofluorinated tryptophan 
analogue was made in 1972 by Atkins et al.[148] who developed a method for 5- and 6-
[18F]fluorotryptophan based on a Balz-Schiemann reaction on diethylformamido malonates. 
The radiosynthesis herein is complicated and time-consuming (>220 min) giving a low RCY 
between 7 % and 10 % and a specific activity of max. 12.6 µCi/mg. The pathway of this 
radiosynthesis is shown in Scheme 27. 
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Scheme 27  Radiosynthesis of 5- and 6-[18F]fluorotryptophan via a Balz-Schiemann  
 reaction.[148] 
Introduction 32  
In 1988 Chaly et al. developed a method for the radiosynthesis of n.c.a. α-[11C]methyl-
tryptophan (αMTrp) by alkylation with 11CH3I of an anion which was generated by reacting 
the Schiff base of L-tryptophan methylester with diisopropylamine (Scheme 28).[149] 
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Scheme 28  Schematic representation of the reaction sequence used in the synthesis of  
α-[11C]methyltrypytophan.[149] 
 
With this radiotracer the serotonin syntheses rate and the tryptophan uptake from the plasma 
were determined. The three compartment kinetic model used for the calculation of the 
 k-values is shown in Figure 6. One advantage of this method is, that αMTrp is converted in 
situ into α-methyl-serotonin, a serotonin tracer which was assumed to be distributed into the 
same compartments as serotonin itself.[150] The experiments were repeated by Muzik et al. 
who confirmed the results.[151]  
 
Figure 6  A schematic representation of a biological model representing the metabolic 
 pathway of αMTrp (tracer) and the respective part of tryptophan metabolism.[150] 
 33  Introduction 
Later, this was criticized by Gharib et al.[152] and Shoaf et al.[153] who suggested that the 
trapping of αMTrp is only related to tryptophan incorporation into proteins and thus only an 
indication of tryptophan uptake into the brain. Further experiments, where specifically one, 
tryptophan hydroxylase or the protein synthesis, was blocked, recommend that αMTrp is not 
incorporated into proteins but the uptake is related to serotonin synthesis since it gets 
metabolized to α-methyl-serotonin.[154] 
Also in 1988, a method for the radiosynthesis of [18F]fluoro-5-hydroxy-tryptophan was 
developed under electrophilic conditions.[155] Herein 5-hydroxytryptophan was directly 
radiofluorinated with [18F]F2 resulting in 4-[
18F]fluoro-5-hydroxytryptophan and  
6-[18F]fluoro-5-hydroxy-tryptophan in RCY of 9 % and 7 %, respectively, and molar 
activities of about 235 mCi/mmol (Scheme 29). Also a variety of side products was formed 
that were not further characterized.  
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Scheme 29  Radiosynthesis of 4- and 6-[18F]fluoro-5-hydroxytryptophan with [18F]F2. 
 
In 2012 Krämer et al. developed the potential radiotracer 5-(2-[18F]fluoroethoxy)-L-
tryptophan (FEHTP) for the purpose of tumor imaging with PET.[156] The radiotracer was 
prepared by 18F-fluoroethylation starting from [18F]fluoroethyltosylate in a RCY of about 
23 %, a specific activity of 50-150 GBq/µmol and a radiochemical purity of > 95 %. The 
tracer was tested in in vitro studies on PC-3, NCI-H69 and MDA-MB-231 cells and showed 
significantly higher uptake when compared with the uptake of [18F]FDOPA. When in vivo 
metabolism studies were done in xenograft mice, mainly the parent [18F]FEHTP was found in 
the blood and brain 60 min after injection while [18F]FDOPA could not be detected. The in 
vivo measurements of [18F]FDOPA and [18F]FEHTP showed similar results (Figure 7). 
In search of another potential radiotracer based on amino acids, several 18F-labeled 
fluoropropyltryptophan analogues have been synthesized and evaluated. The tryptophan 
derivatives investigated were 2-(3-[18F]fluoropropyl)-DL-tryptophan ([18F]2-FPTRP) and 5-
(3-[18F]fluoropropyl)-DL-tryptophan ([18F]5-FPTRP). Both compounds were obtained in  
a RCY of 29-34 % and a radiochemical purity of > 99 %. These tracers are also substrates for 
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amino acid transport and enter small cell lung cancer cells (NCI-H69) probably via the LAT 
transporter. In vivo PET measurements on xenograft mice showed a high tumor-to-
background ratio comparable to that obtained by [18F]FET.[157] 
 
 
Figure 7  PET analysis of xenograft-bearing mice with [18F]FEHTP and [18F]FDOPA.[156] 
 
 
 35  Aims and scope 
2 Aims and scope 
18F-labeled amino acids are widely used as radiopharmaceuticals for in vivo molecular 
imaging in tumor diagnostic with PET in nuclear medicine. Up to now procedures for the 
production of a variety of 18F-labeled amino acids such as 2-[18F]fluoro-L-phenylalanine, 2-
[18F]fluoro-L-tyrosine and 6-[18F]fluoro-L-tyrosine are available. Recently the amino acid 
tryptophan got special interest since there is evidence that many tumors have an increased 
tryptophan uptake due to overexpression of the enzyme tryptophan dioxygenase (TDO). 
Furthermore, tryptophan could possibly be used in order to determine biochemical 
abnormities connected with the serotonergic system, since it is the precursor of serotonin. In 
the past radiofluorinated tryptophan analogues have only been synthesized by electrophilic 
fluorination, through secondary groups which alter the original structure, or in a complex and 
time consuming build-up synthesis with low radiochemical yield and specific activity. 
Recently, for the radiosynthesis of 2-[18F]fluoro-L-phenylalanine and 2-[18F]fluoro-L-tyrosine, 
procedures became available with three steps only. Those consist of an isotopic 18F-for-19F 
exchange, followed by the removal of an activating aldehyde group by reductive 
decarbonylation, and a final step where the hydrolysis of the protecting groups was done. 
Therefore, the major aim of this work was the development of a nucleophilic radiosynthesis 
which provides L-[18F]fluorotryptophan where the fluorine-18 is attached directly to the 
carbocycle. This should be accomplished by the three step radiosynthetic concept described 
above. For this purpose a synthetic pathway was to be developed for the preparation of a 
suitable, carbonyl activated precursor, in order to realize the radiosynthesis according to the 
earlier realized concept mentioned above. 
In order to determine the optimum positions of the fluorine-substituent and of the formyl 
group in tryptophan facilitating the isotopic exchange, several ortho- and para-substituted 
fluoro-1H-indolecarbaldehydes should be prepared with different protecting groups on the 
indole nitrogen for comparison.  
With those compounds the isotopic exchange was to be optimized and to test, if the 
substitution pattern and the type of protecting group on the indole nitrogen have an influence 
on the RCY, the chemical stability of the precursor and the labeled compound. Furthermore, a 
method for a decarbonylation reaction on the fluoro-1H-indolecarbyldehydes had to be 
developed and optimized with respect to RCY. 
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With the experiences on fluoro-1H-indolecarbaldehydes, a route for the synthesis of a 
carbonyl activated precursor should then be developed that allowed an enantioselective 
radiosynthesis of L-[18F]fluorotryptophan. The positions of the fluorine and the activating 
carbonyl function herein should be similar to those of the fluro-1H-indole-carbyldehyde that 
gave the best results with respect to RCY and chemical stability. 
Subsequently, the radiosynthesis of L-[18F]fluorotryptophan should be realized and each 
reaction step be optimized on its own. Furthermore, the whole synthesis should be optimized 
with respect to total time of synthesis and enantiomeric purity of the final product in order to 
provide a new radiotracer for preclinical evaluation of its usefulness for molecular imaging 
application with PET.  
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3 Results and Discussion 
3.1 Synthesis of precursors for the radiosynthesis of 1-benzyl-[18F]fluoro-1H-
indole-carbaldehydes 
In recent years the indole moiety has become an important motive in radiopharmacy. Labeling 
of those compounds with nucleophilic fluorine-18 has only been performed by secondary 
groups or complex build-up syntheses. Since no literature data exists for the labeling of 
indoles in the carbocycle, it was attempted to achieve this by an isotopic 18F-for-19F exchange 
in this dissertation and to study if the substitution pattern has any influence on the RCY and 
stability of the labeled compounds. In order to reduce the electron density in the benzene ring 
and thereby activating it for nucleophilic aromatic substitution, an electron withdrawing group 
was attached in ortho- or para-position to the fluorine atom. For this purpose several ortho- or 
para-substituted fluoro-1H-indole-carbaldehydes were synthesized. The structures of the 
derivatives with ortho-substitution pattern are shown in Scheme 30. 
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Scheme 30  Derivatives of indole of interest for isotopic exchange labeling with 
[18F]fluoride. 
 
In 2012 Schlosser et al. developed a method for the synthesis of different fluoro-1H-indole-
carboxylic acids.[69] In this method the critical step was the introduction of the carboxylic acid 
that was performed by deprotonation of the fluoroindole followed by the addition of carbon 
dioxide. According to this procedure, a method was developed for the preparation of the 
ortho-substituted fluoro-1H-indolecarbaldehydes 1-3. The route for the whole precursor 
synthesis is show in Scheme 31 at the example of 6-fluoro-1H-indole-5-carbaldehydes (1d-h). 
The first step of the synthesis was the protection of the indole nitrogen which proceeded 
quantitatively. In this case TIPS (triisopropylsilyl) was the protection group of choice since it 
is a bulky group that is able to shield the 2-position of the indoles against an electrophilic 
d: PG = H 
e: PG = benzyl 
f: PG = methyl 
g: PG = Boc 
h: PG = tosyl 
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attack. Next, the formyl group was introduced ortho to the position of fluorine. This was 
accomplished referring to the procedure described by Schlosser et al.[69] using DMF (N,N-
dimethylformamide) as electrophile instead of carbon dioxide. The formylation gave yields of 
about 65 % with all fluoro-1H-indoles (1b – 3b). Hereby, it was essential to use at least four 
equivalents of DMF because otherwise much lower yields than 65 % were obtained. The 
deprotection of the nitrogen was performed with TBAF (tetrabutylammonium fluoride) at 
room temperature giving yields above 90 %.  
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Scheme 31 Synthesis of the ortho-substituted fluoro-1H-indole-carbaldehyde precursors 
exemplified by 6-fluoro-1H-indole-5-carbaldehyde.  
 
Finally, different protecting groups were attached to the indole nitrogen of the fluoro-1H-
indolecarbaldehydes. For this the benzyl, methyl, Boc and tosyl groups were used. Scheme 32 
shows the protection reactions of all ortho-substituted fluoro-1H-indolecarbaldehydes (1d-3d) 
at the example of 6-fluoro-1H-indole-5-carbaldehyde (1d). Except for the N-benzylation all 
protections were performed as described by literature methods.[158],[159],[160] According to the 
literature, N-benzylations of indoles proceed in good yields when THF or DMSO are used as 
solvent. But for the benzylation of all indole compounds described here (1d – 3d) the use of 
DMF as solvent was essential because otherwise decomposition of the final product was 
observed. With DMF as solvent the benzylation proceeded in good yields of about 85 %. The 
methylation gave moderate yields of about 58 % while the tosylation and Boc protection gave 
yields between 80 and 90 %.  
d: PG = H 
e: PG = benzyl 
f: PG = methyl 
g: PG = Boc 
h: PG = tosyl 
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Scheme 32  Protection of the fluoro-1H-indole-carbaldehydes exemplified by 6-fluoro-1H-
 indole-5-carbaldehyde.  
 
The only fluoro-1H-indole-carbaldehyde used with a para-substitution pattern was 1-benzyl-
4-fluoro-1H-indole-7-carbaldehyde (4e). An important intermediate for its synthesis was 7-
bromo-4-fluoro-1H-indole (4b) that was prepared in 52 % yield via a Bartoli[73] reaction 
(Scheme 33). The starting material 1-bromo-4-fluoro-2-nitrobenzene was synthesized 
following the procedure described by Smith et al.[161]  
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Scheme 33  Preparation of 7-bromo-4-fluoro-1H-indole (4b) by a Bartoli reaction. 
 
For the synthesis of the final precursor (4e) three synthetic approaches were attempted. The 
first one was based on a concept described by Schlosser et al[69] who used two equivalents  
n-BuLi followed by the addition of carbon dioxide. This route was modified regarding the 
reagent used for the bromine formyl exchange. Further DMF was used instead of carbon 
dioxide in order to generate an aldehyde instead of a carboxylic acid. 
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Scheme 34  Synthesis of 4-fluoro-1H-indole-7-carbaldehyde;  
i) i-PrMgCl.LiCl, THF, 0 °C.; ii) 2 eq. n-BuLi, THF, -78 °C. 
 
First, i-PrMgCl.LiCl was tested as reagent for the bromine-metal exchange, which has been 
used for similar reactions by Krasovskiy et al.[162]. In contrast to n-BuLi, those reagents are 
known to give high yields and selectivity under very mild conditions. This reaction was 
performed in THF starting at 0 °C and slowly warming to room temperature after the addition 
of DMF. Unfortunately, nothing of the desired compound 4c could be obtained when these 
conditions were applied. Even when the more active n-BuLi was used for the bromine-metal-
exchange, it was impossible to get any of the formylated fluoroindole 4c. But, however, with 
n-BuLi, the debrominated 4-fluorindole could be isolated which is an indication that the 
bromine-metal-exchange was successful but the following electrophilic substitution did not 
proceed. Hence, it was assumed that a stronger electrophile than DMF might be more suitable 
for this purpose. For this reason ethyl chloroformate was chosen as electrophile to give the 
corresponding benzyl ester. This ester should then be reduced to the alcohol and reoxidized to 
the aldehyde 4c (Scheme 35).  
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Indeed, the esterification and reduction proceeded in good yields of 67 % and 59 %, 
respectively. The oxidation was tested under various conditions. In the past 2-iodoxybenzoic 
acid (IBX) has been widely used for mild organic oxidation reactions[163] including the 
oxidation of benzylic alcohols to benzaldehydes.[164] However, the reoxidation of the benzyl 
alcohol to the corresponding aldehyde 4c was not successful with IBX. Instead of the desired 
indolecarbaldehyde 4c a variety of side products were found which are probably subject to the 
formation of di- and oligoindoles. This behavior is described in the literature when some tosyl 
protected indoles were reacted under oxidizing conditions.[165] Furthermore, the Swern 
oxidation was tested under standard conditions,[166] but the results were similarly negative 
compared to the reaction with IBX.  
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Scheme 35  Attempted synthesis of 4-fluoro-1H-indole-7-carbaldehyde (4c). 
 
Another approach was made using manganese dioxide (MnO2) as oxidant which is also 
generally used for the oxidation of benzyl alcohols to their corresponding benzaldehydes and 
has previously been used for the synthesis of indole-4-carbaldehyde.[167] However, this 
attempt was also unsuccessful. The starting material was not converted but could be recovered 
quantitatively which is an indication that the oxidation potential of MnO2 is too low for this 
purpose. Since all those approaches for the reoxidation failed, the synthesis of 4-fluoro-1H-
indole-7-carbaldehyde could not be accomplished by this pathway. Therefore, a new synthetic 
route was developed starting also from 7-bromo-4-fluoro-1H-indole (4b). Herein the nitrogen 
of the indole was first protected with a benzyl group followed by formylation by a lithium-
bromine exchange (Scheme 36). 
Results and Discussion  42  
N
F
Br H
N
F
Br
N
F
O
1) n-BuLi
2) DMF
THF, -78 °C
1) NaH
2) BnBr
DMF, 0 °C
4b                                             4d                                                  4e
 
Scheme 36  Synthesis of 1-benzyl-4-fluoro-1H-indole-7-carbaldehyde (4e) starting from  
7-bromo-4-fluoro-1H-indole (4b). 
 
The benzylation of 7-bromo-4-fluoro-1H-indole with NaH and benzyl bromide gave the 
protected indole 4d in a yield of 81 %. The following formylation was realized with n-BuLi 
and DMF giving 39 % of the desired 1-benzyl-4-fluoro-1H-inole-7-carbaldehyde (4e).  
In summary, ten ortho-fluoro-1H-indole-carbaldehydes (1d, 1e, 1f, 1g, 1h, 2d, 2e, 2g, 3d, 3e) 
with three different substitution patterns and one para-fluoro-1H-indole-carbaldehyde (4e) 
were successfully prepared and could now be examined for their properties on an isotopic 
exchange reaction. The ortho-fluoro-1H-indole-carbaldehydes were obtained in overall yields 
of 33 – 48 %, depending on the protecting groups that is attached to the indole nitrogen, while 
the synthesis of the para-fluoro-1H-indole-carbaldehyde 4e gave an overall yield of only  
16 % which is due to the moderate yield of the Bartoli reaction. 
 
3.2 Radiosynthesis of [18F]fluoro-1H-indole-carbaldehydes 
3.2.1 Isotopic exchange 
The first step in the radiosynthesis of the indolecarbaldehydes was an isotopic 18F-for-19F 
exchange. Since no data about this type of reaction on indoles exists in the literature the 
reactions were performed according to data from the literature on isotopic exchange reactions 
on fluorobenzaldehydes which were assumed to show a similar behavior. Previous work on 
this nucleophilic aromatic substitution has shown that DMF as solvent, tetrabutylammonium 
bicarbonate (TBAHCO3) as anion activator and temperatures above 100 °C gave the best 
RCY.[168],[169]  
The labeling reaction was first performed on the 6-fluoro-1H-indole-5-carbaldehydes (1d-h) 
where the influence of different protecting groups on the isotopic exchange reaction was 
examined (Scheme 37).  
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Scheme 37 Isotopic exchange on 6-fluoro-1H-indole-5-carbaldehydes (1d-h). 
 
According to the results of the previous works on isotopic exchange reactions on 
benzaldehyde[168],[169] the reaction was first done in DMF at 130 °C for 15 min with 
TBAHCO3 as anion activator. These reaction conditions were applied to the unprotected 
fluoroindole 1d and to the protected derivatives 1e-1h. The labeling results are shown in 
Table 3. Unfortunately, the Boc protected compound 1g which could be deprotected under 
mild conditions gave only a low RCY of ca. 6 %. Radiofluorination was impossible when the 
indole nitrogen was not protected or when it was protected with a tosyl group, which was not 
surprising since detosylation of indoles is commonly carried out with TBAF.[170] The best 
results could be obtained with the benzyl and methyl protected 6-fluoro-1H-indole-5-
carbaldehydes 1e and 1f where a RCY of about 25 % and 20 % was obtained, respectively. 
For further experiments the benzyl derivative was used since it gave a slightly higher RCY.  
 
Table 3 Dependence of the radiochemical yield on different protecting groups. 
Compound Protecting group RCY [%] 
1d none 0 
1e benzyl 25 ± 7 
1f methyl 20 ± 4 
1g Boc 6 ± 2 
1h tosyl 0 
 
Next, the temperature dependence and the influence of the substitution pattern of the benzyl 
protected fluoro-1H-indole-carbaldehydes 1e, 2e, 3e and 4e on the RCY were investigated. 
For this purpose the isotopic exchange reactions were done at temperatures between 60 and 
150 °C for 15 min. The results are shown in Figure 8. 
d: PG = H 
e: PG = benzyl 
f: PG = methyl 
g: PG = Boc 
h: PG = tosyl 
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Figure 8 Temperature dependence of the substitution pattern on the isotopic exchange 
on compounds 1e, 2e, 3e and 4e. 
 
Surprisingly, it showed that the substitution pattern of the ortho- and para-substituted indoles 
(1e, 2e, 3e, 4e) has a major impact on the optimum temperature for the isotopic exchange, the 
maximum RCY achievable and also the chemical stability.  
When the isotopic exchange was performed with 1-benzyl-6-fluoro-1H-indole-5-carbaldehyde 
(1e) at 130 °C a moderate RCY of about 24 % was obtained. With increasing temperatures the 
gained RCY was also slowly increasing. The maximum RCY was found at 160 °C where  
61 % of the labeled compound could be achieved while the formation of any side products 
was not observed, even at 160 °C. In order to apply higher temperatures than 160 °C, DMSO 
was used as solvent. However, with DMSO, the highest RCY obtained was 8 % and the 
formation of several side products was observed at any temperature tested.  
Due to the results obtained with 1-benzyl-6-fluoro-1H-indole-5-carbaldehyde (1e), the 
temperature was first set to 150 °C for 1-benzyl-4-fluoro-1H-indole-5-carbaldehyde (2e) 
which resulted in a RCY of about 94 %. Hence, the temperature was decreased until the RCY 
went down significantly which happened at 80 °C. Between 90 and 150 °C the obtained RCY 
was always in the area of 90 % or above. Similar to 1-benzyl-6-fluoro-1H-indole-5-
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carbaldehyde (1e), the formation of side products was not observed. Due to these findings it 
was not possible to determine if the isotopic exchange reaction on 1-benzyl-7-fluoro-1H-
indole-6-carbaldehyde (3e) or 1-benzyl-4-fluoro-1H-indole-7-carbaldehyde (4e) would rather 
give results similar to 1e, 2e or behave completely different. Therefore, the labeling reaction 
was investigated at temperatures between 60 and 150 °C for both compounds (3e and 4e). 
However, the results obtained with 3e and 4e were more similar to 2e than to 1e. For both 
compounds (3e and 4e) the maximum RCY that was achieved was around 90 % even though 
the ortho-substituted 3e gave slightly higher RCY than the para-substituted 4e. The optimum 
temperature for both compounds was found at about 90 °C. However, decomposition of the 
labeled product was observed for 1-benzyl-4-fluoro-1H-indole-7-carbaldehyde (4e) as well as 
for 1-benzyl-7-fluoro-1H-indole-6-carbaldehyde (3e) at temperatures higher than 100 °C, 
which has not been observed for 1-benzyl-4-fluoro-1H-indole-7-carbaldehyde (2e). The 
isotopic exchange reaction on the 1-benzyl-fluoro-1H-indolecarbaldehyes 2e, 3e and 4e was 
also done in DMSO and MeCN, but both solvents proved as not suitable for this purpose 
since low maximum RCY of 8 and 10 %, respectively, were obtained for all compounds along 
with a variety of side products. 
It can be summarized that the substitution pattern has an influence on the properties of the 
corresponding isotopic exchange reactions. However, not only the position of the fluorine has 
an influence on the isotopic exchange but also the position of the formyl groups which is 
significantly exemplified by different results found with the compounds 2e and 4e, which 
both have the fluorine attached in the 4-position and the compounds 1e and 2e, that both had 
the formyl group in the 5-position. 
In order to improve the process of the isotopic exchange, a microwave assisted setup was 
tested on the compounds 1e and 2e. It should be examined whether an improvement of the 
RCY of 1e and/or a reduction of the reaction time can be obtained. Microwave irradiation 
produces efficient internal heating (in-core volumetric heating) by direct coupling of 
microwave energy with the molecules (solvents, reagents, catalysts) that are present in the 
reaction mixture resulting in an inverted temperature gradient compared to conventional 
thermal heating.[171] For this purpose the fluoroindoles 1e and 2e, TBAHCO3 and dry 
[18F]fluoride in DMF were irradiated with 20-140 W microwaves during 1 min or 3x1 min, 
respectively. It proved that the maximum RCY could not be increased for both compounds, 
but was at least similar as with conventional heating. However, when the reaction mixtures 
were irradiated for 3x1 min, the RCY of 1-benzyl-4-fluoro-1H-indole-5-carbaldehyde (2e) 
decreased at energies higher than 70 W which was not observed under conventional heating. 
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This was probably due to decomposition of the labeled compound 2e. A similar behavior was 
found for 1-benzyl-6-fluoro-1H-indole-5-carbaldehyde (1e) at energies higher than 110 W. 
Furthermore, with microwave heating an asymptotical dependence of the RCY on the 
microwave energies was observed for 1e while a linear dependence was found with 
conventional heating, which was probably due to the fact that higher temperatures than  
160 °C were not applied with DMF as solvent. In summary, the RCY could not be increased 
but the reaction time can be reduced to 1 min when the labeling reaction is performed with 
microwave heating. 
 
Figure 9 Microwave assisted performance of the isotopic exchange for 1d and 2d. 
 
Due to the excellent labeling properties of 1-benzyl-4-fluoro-1H-indole-5-carbaldehyde (2e) 
and the opportunity of a mild deprotection, the isotopic exchange reaction was also tested on 
the Boc-derivative of this compound, 1-Boc-4-fluoro-1H-indole-5-carbaldehyde (2g). As 
expected, after optimization of the reaction temperature, a RCY of about 28 % was obtained 
when the isotopic exchange was performed at 80 °C in DMF with TBAHCO3 as anion 
activator. At higher temperatures than 100 °C the RCY decreased due to decomposition. 
However, the Boc-derivative 2g results in lower RCY than its benzyl derivative, but 
deprotection of this compound proceeded under mild conditions (2 M HCl, 15 min) in 
quantitative yields. 
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In summary, a complex molecule containing the indole moiety should preferably be 
radiofluorinated in the 4- position, because this position provides outstanding properties with 
respect to RCY and chemical stability. 
 
3.2.2  Reductive decarbonylation of 1-benzyl-fluoro-1H-indole-carbaldehydes 
Since the activating aldehyde function is only necessary for the nucleophilic aromatic 18F-for-
19F isotopic exchange the possibilities of a removal of this group by a reductive 
decarbonylation were examined (Scheme 38). This reaction has not been tested on 
indolecarbaldehydes in the past. For this reason the parameters of previously described 
decarbonylation reactions on several benzaldehydes with Wilikinson’s catalyst (Rh(PPh3)3Cl) 
were applied here.[172],[169],[173] Using this reagent for decarbonylation stoichiometric amounts 
of Rh(PPh3)3Cl are required due to the formation of stable Rh(PPh3)3(CO)Cl as secondary 
product.  
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Scheme 38  Reductive decarbonylation of 1-benzyl-fluoro-1H-indolecarbaldehydes (1e, 2e, 
3e and 4e) using Wilkinson's catalyst. 
 
Conditions, firstly published in 1992 by Pleneveaux et al.[172], were examined. Dioxane was 
used as solvent and the reaction was stirred for 20 min at 150 °C in an oil bath. In this setup 2 
equivalents of Wilkinson’s catalyst were used. With those conditions that gave a good RCY 
when applied to the benzaldehydes described by Pleneveaux et al. the total conversion of the 
compound [18F]1e was only 29 % while the rest of the starting material remained unchanged. 
Additionally to the desired product [18F]6 which was obtained in a RCY of about 6 % the 
formation of several side products was observed. Due to these disappointing results the 
reaction was not further optimized with dioxane as solvent.  
[18F]1e: R1 = H, R2 = CHO, R3 = 
18F, R4 = H 
[18F]2e: R1 = 
18F, R2 = CHO, R3 = H, R4 = H 
[18F]3e: R1 = H, R2 = H, R3 = CHO, R4 = 
18F 
[18F]4e: R1 = 
18F, R2 = H, R3 = H, R4 = CHO 
 
 
 
[18F]5: R1 = 
18F, R2 = H, R3 = H 
[18F]6: R1 = H, R2 = 
18F, R3 = H 
[18F]7: R1 = H, R2 = H, R3 = 
18F 
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In 2007 Shen et al.[169] published a method for the decarbonylation of benzaldehydes using 
benzonitrile as solvent and 3 equivalents of Wilkinson’s catalyst. Those conditions were also 
applied to compound [18F]1e. The reaction mixture was again heated to 150 °C for 20 min 
resulting in a conversion of > 99 %. The desired 1-benzyl-6-[18F]fluoro-1H-indole ([18F]6) 
was obtained in an excellent RCY of > 95 %. Applying those conditions to the other  
1-benzyl-[18F]fluoro-1H-indole-carbaldehydes, [18F]2e, [18F]3e and [18F]4e resulted in similar 
RCY, independent of their substitution pattern, which suggests these conditions for the 
application in decarbonylation reactions on indole compounds. 
Furthermore, the decarbonylation reaction was also carried out under microwave heating, 
based on a method developed by Castillo et al.[173] Herein, benzonitrile was preferred over 
dioxane as reaction solvent since it gave higher RCY compared to conventional heating as it 
shows better absorption of microwaves. First, the reaction was tested on [18F]1e by irradiation 
with 100 W microwaves for 50 s using 3 equivalents of Wilkinson’s catalyst. This resulted in 
a RCY of about 85 % of [18F]6 while no side products could be detected. However, the total 
conversion was only about 88 % and thereby incomplete. In order to further increase the RCY 
the reaction time was prolonged to 120 s while the energy of the microwaves was kept at  
100 W. This resulted in a conversion of > 99 % and a RCY of about 95 % for [18F]6. These 
results could also be transferred to the compounds [18F]2e, [18F]3e and [18F]4e giving similar 
RCY as listed in Table 4. In contrast to the obtained RCY on the isotopic exchange on the 
fluoroindolecarbaldehydes 1e, 2e, 3e and 4e, the substitution pattern had no impact on the 
RCY during the decarbonylation reaction. 
The introduction of the microwave assisted setup did not change the RCY or the formation of 
side products under the optimum reaction time of 2 min. However, it was possible to reduce 
the reaction time from 20 min to 2 min. 
In summary, a reductive decarbonylation on all tested 1-benzyl-4-fluoro-1H-indolecarb-
aldehydes was successful. When benzonitrile was used as solvent, a RCY of > 95 % was 
obtained for all compounds under conventional heating as well as under microwave heating. 
However, the reaction time could be reduced from 20 min to 2 min with microwave heating of 
100 W for 2 min.  
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Table 4  Reductive decarbonylation on 1-benzyl-[18F]fluoro-1H-indole-carbaldehydes 
[18F]1e, [18F]2e, [18F]3e and [18F]4e comparing conventional and microwave 
heating; RCY of the reductive decarbonylation were similar for all compounds and 
independent of their substitution pattern. 
Solvent eq. Wilkinson Conditions Conversion [%] RCY [%] 
benzonitrile 3 150 °C, 20 min [169] > 99 95 ± 6 
benzonitrile 3 100 W, 50 s [173] 85 ± 2 85 ± 2 
benzonitrile 3 100 W, 120 s > 99 95 ± 3 
dioxane 2 150 °C, 20 min [172] 29 ± 4 6 ± 3 
 
3.3  Attempts for the debenzylation of 1-benzyl-fluoro-1H-indoles 
Since most bioactive molecules and pharmaceuticals that contain the indole moiety do not 
have a protecting group attached to the indole nitrogen and due to the fact that this protecting 
group provided the best RCY for the isotopic exchange it was examined if it was possible to 
remove this group during the radiosynthesis (Scheme 39).  
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Scheme 39 Attempts for the debenzylation of 1-benzyl-fluoro-1H-indoles. 
 
This was first tested with non-radioactive conditions in order to allow more experiments in 
time. Several previously published methods were investigated for the debenzylation. First the 
debenzylation was examined with the help of palladium on activated charcoal (Pd/C) in 
combination with ammonium formate (NH4HCO2) in ethanol.
[174] Applying these conditions 
no conversion of the starting material could be detected even when heating the reaction 
mixture to reflux. Next, a procedure previously described by Petras et al.[175] was studied 
5: R1 = F, R2 = H, R3 = H 
6: R1 = H, R2 = F, R3 = H 
7: R1 = H, R2 = H, R3 = F 
8: R1 = F, R2 = H, R3 = H 
9: R1 = H, R2 = F, R3 = H 
10: R1 = H, R2 = H, R3 = F 
Results and Discussion  50  
where hydrogen gas was passed through a solution of Pd/C in acetic acid, but again no 
conversion was detected. It has also been described in the literature that the debenzylation of 
indoles proceeds good with an excess of AlCl3 in aromatic solvents such as benzene, toluene 
or anisole when the 3-position of the indole is occupied.[176],[177] Although this position was 
not occupied the procedure was examined. None of the desired debenzylated fluoroindole 
could be detected but the formation of a variety of side products was observed, probably 
resulting from the formation of di- or oligoindoles which has previously been observed by 
Fujino et al. when indoles with an unoccupied 3-position were reacted with AlCl3 under 
similar conditions.[165] Even if these conditions did not give the desired debenzylated 
compound, this method is more promising than the ones investigated so far since the 3-
position which seems to be the critical part is alkylated in most natural products and 
pharmaceuticals that contain the indole moiety. Furthermore, a method described by Jorand-
Lebrun et al.[178] was examined that was originally used for the debenzylation of tertiary 
amines such as benzylpiperdidines. Hereby, triphosgene was used to convert the benzylamine 
into the corresponding carbamoyl chloride which was then hydrolyzed under acidic 
conditions. This procedure also resulted not in a conversion of the starting material. Also the 
attempt of an acidic hydrolysis with conc. hydrochloric acid at 150 °C failed, and no 
conversion was observed. Table 5 summarizes the results obtained for the debenzylation of 
the different 1-benzyl-fluoro-1H-indoles.  
 
Table 5 Approaches for the debenzylation of 1-benzyl-fluoro-1H-indoles. 
Reagent/Catalyst Solvent Temperature [°C] Conversion [%] Yield [%] 
Pd/C, NH4HCO2 EtOH RT 0 0 
Pd/C, NH4HCO2 EtOH 110 °C 0 0 
Pd/C, H2 AcOH RT 0 0 
AlCl3 benzene RT >99 0 
AlCl3 toluene RT >99 0 
AlCl3 anisole RT >99 0 
triphosgene DCM RT 0 0 
HCl H2O 150 °C 0 0 
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However, a procedure for the successful debenzylation of these 1-benzyl-fluoro-1H-
indolecarbaldehydes was not found. The approach with AlCl3 is nevertheless promising when 
indoles are subject to debenzylation where the 3-position is occupied.  
 
 
3.4 Synthesis of precursors for the radiosynthesis of  
L-6-[18F]fluorotryptophan 
Although the previous results on 1-benzyl-fluoro-1H-indole-carbaldehydes have shown that 
molecules containing the indole moiety should be preferably radiofluorinated in the aromatic 
ring in the 4-position, a pathway for a precursor could be developed, which is fluorinated in 
the 6-position , since a promising route for this synthesis was available and previously 
described by Ma et al.[179] Furthermore, it was shown in this work that indoles carrying a 
fluorine in this position have proved to be very stable under acidic conditions as well as under 
basic conditions and are also insensitive towards elevated temperatures which allows a broad 
variety of reaction conditions during precursor synthesis. 
 
3.4.1  Precursor for the radiosynthesis via a build-up synthesis 
The general concept of the route for the synthesis of the precursor is based on a method for 
the synthesis of tryptophan analogues via a palladium mediated heteroannulation.[179] Herein 
an ortho-iodoaniline is coupled to a functionalized trimethylsilylalkyne. In this case the 
trimethylsilylalkyne should be functionalized with Seebach’s auxiliary in order to generate a 
stereocenter that enables a stereoselective synthesis of only one enantiomer of 6-
[18F]fluorotryptophan. In this case Seebach’s auxiliary was preferred over Schöllkopf’s 
auxiliary since it is known to give higher enantiomeric purities. The functionalized alkyne 
should be coupled to one of the ortho-iodoanilines (11 - 14). In order to generate the  
L-enantiomer of tryptophan, the S-enantiomer of Seebach’s auxiliary was used for the 
introduction of the chiral center. 
Results and Discussion  52  
15                                                                        16 
I
NH2F
X
TMS
N
N
O
Boc
N
H
N
N
O
Boc
X
F
+
Pd(OAc)2
 
 
 
Scheme 40 Synthetic concept for the preparation of a precursor for L-6-[18F]fluorotryptophan. 
 
First, the alkyne 15 was prepared following a modified pathway to the one described earlier 
by Ma et al.[179] starting from propargyl alcohol. The synthetic route is shown in Scheme 41. 
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Scheme 41 Preparation of Seebach functionalized alkyne 15. 
 
The first step herein was the introduction of the TMS group. This was accomplished through a 
deprotonation of both, the alcohol and the alkyne group with n-BuLi followed by the addition 
of two equivalents of TMS-Cl. The TMS group on the alcohol was removed through an acidic 
work-up yielding the intermediate 17 in 96 % yield. The introduction of the tosyl group was 
first performed with KOH in Et2O at room temperature which resulted in varying, rather low 
yields of 14 - 18 % and a major tosylated but desilylated side product. Therefore, the reaction 
was examined with triethylamine as base and a reaction temperature of 0 °C giving less than 
11: X = CHO 
12: X = Ac 
13: X = Dithiolan 
14: X = I  
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10 % yield and also the desilylated side product. When the reaction was performed with 
DMAP (N,N-dimethylaminopyridine) as catalyst in DCM, no conversion of the starting 
material could be observed. Using pyridine as base and solvent at 0 °C resulted in 
decomposition of 17 while it was impossible to recover any of the starting material. The only 
procedure that was suitable for this reaction was the use of powdered KOH in Et2O, starting 
the reaction at -50 °C and slowly warming it to 0 °C during 2 h. Thereby, the alkyne 18 could 
be obtained in 87 % yield. Table 6 summarizes the conditions examined for this reaction.  
The following coupling to Seebach’s auxiliary was performed under standard conditions with 
LDA (lithium diisopropylamide) as base at -78 °C giving the chiral alkyne 15 in 82 %. 
 
Table 6 Conditions for the tosylation of the alkyne 17. 
Solvent Base Temperature Time Conversion [%] Yield [%] 
Et2O KOH RT 2 h >99 14 - 18 
Et2O Et3N 0 °C 2 h >99 <10 
DCM DMAP RT 24 h 0 0 
Pyridine Pyridine 0 °C – RT 2 h >99 0 
Et2O KOH -50 °C – 0 °C 2 h >99 87 
 
Next, a pathway for the preparation of a suitable ortho-iodoaniline was developed. An 
overview of the selected routes is shown in Scheme 44. The aim hereby was the preparation 
of an ortho-iodoaniline that contains a fluorine atom as well as an electron withdrawing group 
such as an aldehyde. 
The first approach started with 3-fluoroaniline (19) which was iodinated in the 4-position with 
NaIO4 and KI in aqueous acetic acid
[180] giving the desired 3-fluoro-4-iodoaniline (20) in  
82 % yield. This reaction was carried out at 25 °C for 3 h. Longer reaction times or elevated 
temperatures promoted the formation of the diiodinated 5-fluoro-2,4-diiodoaniline (14) and 
resulted in decreasing yields for the monoiodinated aniline 20.  
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Scheme 42 Synthetic route for the synthesis of 4-amino-2-fluorobenzaldehyde (21a,b). 
 
The iodoaniline 20 should afterwards be converted into the corresponding amino-
benzaldehyde 21a. For this purpose, a method for the formylation of anilines described by 
Gilman et al.[181] was studied where three equivalents n-BuLi were applied to the aromatic 
amine followed by the addition of DMF at –78 °C. Unfortunately, this reaction led to 
decomposition of the starting material and none of the desired aminobenzaldehyde 21a could 
be isolated. Furthermore, a procedure that has been described by Krasovskiy et al.[162] was 
examined, which has been applied successfully during the synthesis of the 1-benzyl-fluoro-
1H-indole-carbaldehydes (see chapter 3.1) and proceeds under milder conditions. Hereby, the 
reagent for the iodine-metal exchange is i-PrMgBr. Equally as under the conditions described 
above, none of the desired aminobenzaldehyde 21a could be isolated. Due to the fact that the 
introduction of the aldehyde function failed, the introduction of an acetyl group was studied. 
For this purpose the same conditions that have been tried for the formylation of the 
iodoaniline 20 were applied, but using acetyl chloride as electrophile instead of DMF, since it 
is known to have a higher electrophilic activity. With this procedure, it was still impossible to 
isolate the desired aniline 21b. 
Next, a new pathway starting again from 3-fluoroaniline (19) was examined. The first step 
hereby was the introduction of a bromine para to the amino group followed by the protection 
of the free amine with a Boc-group and a formylation via a halogen-metal exchange (Scheme 
43).  
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Scheme 43  Preparation of tert-butyl (3-fluoro-4-formylphenyl)carbamate (25). 
21a: R1 = H 
21b: R1 = CH3 
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The bromination of the fluoroaniline was done with HBr in DMSO according to a procedure 
described by Majetich et al.[182] giving the bromoaniline 22 in 82 % yield. The introduction of 
the Boc-group was done with the help of Boc2O and K2CO3 yielding the bromoaniline 23 in  
64 % yield. The bromine-formyl substitution was performed by a halogen-magnesium 
exchange with the help of i-PrMgCl.LiCl at 0 °C following again the procedure described by 
Krasovskiy et al.[162] and giving the corresponding benzaldehyde 25 in 97 % yield. 
Furthermore, an improved pathway to this procedure was developed starting from 4-bromo-2-
fluorobenzaldehyde (24) with the introduction of a Boc-protected amine via a palladium 
catalyzed heteroamidation (Scheme 45) which was described by Qin et al.[183] giving the 
protected aminobenzaldehyde 25 in 97 % yield while reducing the number of necessary 
synthetic steps from three to one (Scheme 45).  
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Scheme 44  Overview of the synthetic concepts considered for the preparation of ortho-
   iodoanilines. 
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Scheme 45  One step synthesis for the preparation of tert-butyl (3-fluoro-4-
 formylphenyl)carbamate (25). 
 
The next steps were the protection of the benzaldehyde 25 and the deprotection of the amine 
(Scheme 46). For the protection of the benzaldehyde 25 a 1,3-dithiolane group was chosen, 
since dithiolanes are known to be stable towards a wide variety of reagents and conditions  
and can be removed with high selectivity under mild conditions.[184],[185] The introduction of 
the 1,3-dithiolan was performed as previously published by Firouzabadi et al.[186] with 1,2-
ethandithiol in DCM and 10 % elemental iodine as catalyst. Using this procedure the dithiolan 
26 could be obtained in yields of ca. 90 %. 
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Scheme 46  Preparation of 4-(1,3-dithiolan-2-yl)-3-fluoroaniline (27). 
 
The removal of the Boc group was done under standard conditions with TFA in DCM at room 
temperature yielding the desired aniline 27 in 77 %. Now, the introduction of the iodine in 
ortho-position to the amine had to be done (Scheme 47). This should be accomplished by the 
procedure of Emmanuvel et al.[180] which gave good yields when it was applied to 3-
fluoroaniline (19). With 27, however, neither the desired ortho-iodoanilie 13 nor the starting 
material 27 could be obtained due to decomposition which was probably caused by the 
dithiolan group.  
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Scheme 47  Attempts for the iodination of the aniline 27;  
 i) NaHCO3, I2, H2O; ii) NaIO4, KI, NaCl, AcOH/H2O. 
 
Furthermore, a method for the iodination of fluorobenzenes was examined that has been 
successfully used by Layek et al..[187] Hereby, sodium bicarbonate in combination with 
elemental iodine in water was used. As well as under the conditions tested before 
decomposition of the starting material was detected, but not the formation of the iodoaniline 
13 which was possibly also due to cleavage of the dithiolan group.  
Due to the fact that the previous results for the synthesis of a suitable ortho-iodoaniline failed, 
the diiodoaniline 14 was used for the coupling with the Seebach alkyne 15 in order to prepare 
a precursor for the radiosynthesis of a L-tryptophan derivative that could possibly be 
formylated by an iodine-metal exchange and thereby generate an aromatic system that is 
suitable for a nucleophilic 18F-for-19F isotopic exchange (Scheme 48). 
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Scheme 48  Pd-catalyzed synthesis of the L-tryptophan derivative 30. 
 
The Pd-mediated coupling itself was done following a modified procedure to the one 
previously described by Ma et al..[179] In the original method only monoiodinated 
fluoroiodoanilines and Schöllkopf functionalized alkynes have been used for this reaction 
while this reaction should be examined with a diiodinated ortho-iodoaniline which has not 
been investigated before.[179] Since the original setup with Pd(OAc)2, LiCl and Na2CO3 in 
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DMF and heating to 100 °C for 20 h did not give any of the desired product, but a large 
amount of side products instead, the method was altered regarding reagents, solvent and 
temperature. Hereby, an increase of temperature to 120 °C did not change the obtained results 
as well as a change of the solvent from DMF to NMP (N-methyl-2-pyrrolidone) and rising the 
temperature to 140 °C. The base was also changed from Na2CO3 to Cs2CO3 but again none of 
the desired product could be achieved. However, the desired compounds could not be 
obtained regardless the applied conditions. The investigated setups are summarized in Table 
7. Since the desired compound 30 could not be isolated the reaction was performed with 2-
iodoaniline which has been used by Ma et al. and gave high yields of about 87 % of the 
corresponding tryptophan analogue. This was done in order to verify that the alkyne 15 which 
was functionalized with Seebach’s auxiliary instead of Schöllkopf’s is suitable for this 
reaction and whether the observed side products are due to the diiodinated iodoaniline 14 or to 
the alkyne 15.  
 
Table 7  Conditions tested for the Pd-mediated formation of 30. 
 
For this purpose, the reaction was performed under the conditions described by Ma et al.[179] 
giving 6-fluorotryptophan in similar yields of about 78 %. However, this tryptophan analogue 
was not suitable as precursor for L-6-[18F]fluorotryptophan since there is no ability of the 
introduction of a formyl group. Furthermore, it was proven that the preparation of tryptophan 
analogues by this procedure is possible, but is limited to iodoanilines that do not carry a 
second iodine. Due to the fact that the preparation of a precursor for the radiosynthesis of L-6-
[18F]fluorotryptophan failed via this approach a new synthetic pathway had to be developed.  
Solvent Reagents Temperature [°C] Time [h] 
DMF LiCl, Na2CO3 100 20  
DMF KI, Na2CO3 100 20  
DMF LiCl, Cs2CO3 100 20  
DMF LiCl, Na2CO3 120 20  
NMP LiCl, Na2CO3 100 20  
NMP LiCl, Na2CO3 140 20  
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3.4.2  Precursor for the radiosynthesis via a linear synthetic pathway 
In 2012 Konas et al.[160] developed a method for the enantioselective synthesis of L-4-
fluorotryptophan via a seven step linear synthesis starting from 4-fluorindole.[160] The original 
synthetic pathway is depicted in Scheme 49. This route was also used here for the synthesis of 
the standard L-6-fluorotryptophan, but starting from 6-fluoroindole instead of 4-fluoroindole.  
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Scheme 49  Original pathway by Konas et al. for the synthesis of L-4-fluorotryptophan.[160] 
 
In order to prepare a precursor that is suitable for a nucleophilic isotopic exchange the 
introduction of an electron withdrawing group for the activation of the aromatic system was 
necessary. This should be accomplished by an early introduction of a formyl group ortho to 
the fluorine substituent. The formyl group should be protected subsequently in order to 
prevent undesired side reactions. In this case 6-fluoroindole was chosen as starting material to 
realize a precursor for L-6-[18F]fluorotryptophan. An overview of the first steps of the 
synthetic pathway is given in Scheme 50. 
Compound 1c was prepared following the procedure described in chapter 3.1. The formyl 
group was then protected with a 1,3-dithiolane group under the conditions used by 
Firouzabadi et al.[186] yielding the dithiolane 31 in 40 % yield. Here, the dithiolan group was 
preferred over an oxalane group since oxalanes are labile under acidic conditions and the 
introduction of a second formyl group later in the pathway in the 3-position was planned 
through a Vilsmeier-Haack reaction requiring acidic conditions. The deprotection of the 
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indole nitrogen was done with TBAF giving the free indole 32 in a yield of 92 %. The 
introduction of the formyl group should be done under standard Vilsmeier-Haack conditions 
with POCl3 in DMF as published by Smith et al.
[84] in order to attach another carbon atom to 
the indole which could then be further reduced to the alcohol, brominated and alkylated 
according to the procedure described by Konas et al.[160] The formylation under Vilsmeier-
Haack conditions, however, was not successful, and the desired formylindole 33 could not be 
obtained due to decomposition of the starting material, which was probably due to the 
dithiolane group, since the reaction proceeded in good yields during the synthesis of the 
standard L-6-fluorotryptophan. 
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Scheme 50  Attempt for the synthesis of a precursor which is suitable for the radiosynthesis 
of L-[18F]fluorotryptophan by isotopic exchange. 
 
Since a suitable precursor for the radiosynthesis of [18F]fluorotryptophan was not possible via 
this approach, the route shown above was altered in a way that the formyl group in the indole 
1c was substituted by an iodine which can be converted into a formyl group by a halogen-
metal exchange at a later stage of the whole synthesis and thereby generating a molecule that 
is more stable towards a wide range of reaction conditions. The introduction of the iodine was 
first done following a procedure described by Schlosser et al.[69] using sec-BuLi in 
combination with N,N,N’,N’’,N’’-pentamethyl-diethylenetriamine (PMDTA) for the de-
protonation of the indole and elemental iodine as electrophile for the iodination (Scheme 51).  
Due to the fact that separation of the compounds 1b and 34 was not possible, the deprotection 
with TBAF was always done with crude 34 followed by separation of the desilylated 
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compounds 1a and 35 by column chromatography. The yields were calculated over both 
steps, i.e. iodination and deprotection. 
 
Scheme 51  Iodination and deprotection of 1b;  
 i) sec-BuLi, PMDTA, I2, THF; ii) sec-BuLi, PMDTA, 1,2-diiodoethane, THF. 
 
The iodination of the fluoroindole 1b is a crucial step in the synthetic sequence of the 
precursor. For this reaction the addition of equimolar amounts of PMDTA was essential. 
PMDTA is commonly used in organic synthesis for the activation of organolithium 
compounds, such as n-BuLi or sec-BuLi. Usually simple alkyllithum compounds occur as 
oligomers (e.g. hexameric n-BuLi) in solution. This inhibits or prevents precoordination to the 
reactive site of other reagents.  Through the addition of bi- or tridentate ligands such as 
PMDTA those oligomers are broken up and reactive monomeric lithium-species are formed 
(Scheme 52).[188] 
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Scheme 52  Lithiation of the central and terminal methyl groups of PMDTA with n-BuLi. 
 
When the reaction was performed without the addition of equimolar amounts of PMDTA the 
desired free iodoindole 35 could not be obtained and the starting material, 6-fluoroindole, was 
recovered. Furthermore, it was necessary that the reaction was kept at -78 °C for at least six 
hours after the addition of sec-BuLi. Otherwise decreasing yields were obtained while 
keeping the reaction mixture at -78 °C for more than six hours did not result in higher yields. 
In the beginning elemental iodine was used as electrophile for this reaction giving the desired 
iodoindole 35 in about 65 % yield after deprotection and purification. Later, the reaction was 
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carried out using 1,2-diiodoethane as iodination agent which resulted in similar yields but a 
much easier handling of the reaction. 
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Scheme 53  Preparation of 6-fluoro-5-iodo-1H-indole-3-carbaldehyde (37a,b). 
 
 
The next step in the synthesis was the formylation of the iodoindole 35 in the 3-position. This 
was done under standard Vilsmeier–Haack conditions[84] giving the indole-3-carbaldehyde 36 
in 64 % yield.  
For the protection of the indolecarbaldehyde 36 two different protecting groups were studied. 
On one hand a tosyl group was selected which was also chosen by Konas et al. and should be 
suitable for the following reactions. On the other hand the previous studies on the 
radiofluorination of the indolecarbaldehydes in chapter 3.2 have shown that the best RCY was 
obtained when the nitrogen of the indole was protected with a benzyl group. In order to avoid 
additional steps for the change of protecting groups later in the synthetic pathway, the 
indolecarbaldehyde 36 was alternatively protected with both protecting groups, yielding the 
tosyl- and benzyl-protected indolecarbaldehydes 37a and 37b in 81 % and 60 % yield, 
respectively. It was also promising that the benzyl group could be removed after the 
radiosynthesis since the 3-position was occupied in the precursor which should allow 
deprotection with AlCl3 in benzene or another aromatic solvent. 
The following reduction of the indolecarbaldehydes 37a and 37b was done with NaBH4 in a 
mixture of THF and EtOH (Scheme 54) giving 38a in quantitative yields while 38b could 
only be obtained in 65 % yield. 
 
37a: PG = tosyl 
37b: PG = benzyl 
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a: PG = tosyl 
b: PG = benzyl 
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Scheme 54  Reduction of the indolecarbaldehydes 37a and 37b to the corresponding alcohols 
 38a and 38b. 
 
In order to enable an alkylation with Seebach’s auxiliary the alcohol should be converted into 
a bromide. This was done via an Appel reaction using CBr4 and PPh3 in DCM.
[189] Using this 
procedure the tosyl protected bromine 39a could be synthesized in 56 % yield when the 
reaction temperature was kept at 0 °C and not allowed to get higher than 25 °C until the 
bromide was separated from triphenylphosphine oxide which is formed during the reaction. 
Otherwise isolation of the desired product 39a was impossible due to instability 
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Scheme 55  Bromination of the indolylalcohols 38a and 38b; 
  i) PPh3, CBr4, DCM, 0 °C; ii) PBr3, DCM. 
 
Applying the conditions described above to the benzyl protected alcohol 38b resulted in 
decomposition of the starting material and formation of a wide range of side products even 
when the reaction temperature was reduced to -20 °C. Furthermore, the reaction was 
performed in DCM using PBr3 as bromination agent
[190] but those conditions also resulted in 
decomposition. Later it was found that compound 38b shows high instability when dissolved 
in chlorinated solvents such as DCM, chloroform or carbon tetrachloride, which makes 
bromination of this molecule impossible, since aliphatic bromine for hydroxyl nucleophilic 
substitution reactions are usually realized in chlorinated solvents. Hence, compound 39b 
could not be synthesized successfully. 
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Therefore, the synthetic pathway was continued with the tosyl protected bromine 39a. 
Hereby, it was important that the alkylation with Seebach’s auxiliary needs to be done directly 
after purification of the bromide 39a because otherwise it was subject to slow decomposition, 
especially when exposed to light. 
The introduction of the chiral center by alkylation with Seebach’s auxiliary was carried out 
under standard conditions at –78 °C in THF using LDA as base and proceeded with 73 % 
yield giving the iodofluoroindole 40 (Scheme 56). 
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Scheme 56  Synthesis of (2S)-2-tert-butyl-5-[(4-fluoro-5-iodo-1-methyl-1H-indol-3-
 yl)methyl]-1,3-dimethylimidazolidin-4-one (40). 
 
Further on, the aldehyde function was introduced which is necessary for the activation of the 
carbocycle for the planned isotopic exchange. This aim was accomplished by a procedure 
previously described by Boymond et al.[191] and Armstrong et al.[192]. The method based on a 
Grignard reaction with i-PrMgBr which mediates the iodine-magnesium exchange followed 
by the addition of DMF (Scheme 57). i-PrMgBr is commonly used in Grignard-like reactions 
for iodine-magnesium exchanges. Reactions where i-PrMgBr is applied instead of elemental 
magnesium can generally be carried out under milder conditions which results in the 
formation of less side products and often higher yields. 
Performing the reaction under the conditions described by Boymond et al.[191] gave the 
corresponding aldehyde 41 in 78 % yield. During the formylation procedure it was essential to 
use at least four equivalents of DMF, because otherwise only yields of less than 50 % were 
achieved.  
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Scheme 57  Formylation of 40 with i-PrMgBr and DMF. 
 
The final steps in the synthetic pathway of the precursor were the removal of the tosyl group 
and the protection of the indole nitrogen with a benzyl group which gave the best RCY when 
studied on the indole-1H-carbaldehydes (see chapter 3.2). The detosylation was done 
according to a procedure described by Yasuhara et al.[170] using TBAF in THF for this 
purpose. The reaction was performed at room temperature giving the desired free 
indolecarbaldehyde 42 in 91 % yield (see Scheme 58). The subsequent benzylation was 
carried out following the procedure that was also used for the benzylation of the indole-1H-
carbaldehydes in chapter 3.1 giving the precursor for L-6-[18F]fluorotryptophan (43) in 78 % 
yield. Finally, a potential precursor for the radiosynthesis of L-6-[18F]fluorotryptophan could 
be synthesized by an eleven step linear synthesis in an overall yield of 7 %. An overview of 
the synthetic sequence is shown in Scheme 59. 
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Scheme 58  Final reaction steps for precursor of L-6-[18F]fluorotryptophan 43. 
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Scheme 59  Overview of the elaborated (11 step) synthetic pathway of a precursor for the 
 radiosynthesis of L-6-[18F]fluorotryptophan (43) by isotopic exchange. 
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3.5 Radiosynthesis of L-6-[18F]fluorotryptophan 
The radiosynthesis of L-6-[18F]fluorotryptophan ([18F]45) was planned to proceed in three 
steps, isotopic exchange, reductive decarbonylation and removal of protecting groups 
according to a modified procedure previously used by Castillo et al.[173] for the radiosynthesis 
of aromatic amino acids (Scheme 60). 
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Scheme 60  Synthetic concept for the radiosynthesis of L-6-[18F]fluorotryptophan [18F]45. 
 
The first step in this route was the introduction of the [18F]fluoride by an isotopic 18F-for-19F 
isotopic exchange. This was done under the optimum conditions elaborated for the isotopic 
exchange on 1-benzyl-6-fluoro-1H-indole-5-carbaldehyde (1e) which has a similar 
substitution pattern. Therefore, the reaction was first examined at 150 °C in DMF with 
TBAHCO3 as anion activator.  
Since the tosyl-protected precursor 41 was available through the same pathway as the benzyl 
protected precursor 43 its radiofluorination was examined which would shorten the synthesis 
of the precursor by two steps. Unfortunately, radiolabeling of tosyl-protected 41 could not be 
obtained under any conditions studied. The applied temperatures that were investigated for 
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this purpose reached from 120 – 150 °C. No radiofluorinated product could be detected at 120 
°C while at 150 °C an unpolar product was found which could be identified as tosyl-
[18F]fluoride. This was not surprising since detosylation has been observed before as fluoride 
is also used for the detosylation of indoles, but usually a large excess of fluoride is used for 
this purpose.  
In first radiolabeling experiments using the benzyl-protected precursor 43 at 150 °C a RCY of 
only 9±4 % could be found. Furthermore, racemization was observed during the 
radiofluorination at this temperature giving the L- and D- diastereomer of [18F]43 in a ratio of 
about 70:30. Also, several radioactive side products could be detected. When temperatures 
lower than 150 °C were applied the desired radiolabeled product [18F]43 could not be 
obtained at all.  
A reductive decarbonylation step was also examined under the conditions that gave the best 
RCY for 1-benzyl-6-fluoro-1H-indole-5-carbaldehyde (1e) (see chapter 3.2.2) with 3 
equivalents of Wilkinson’s catalyst and microwave assisted heating (100 W, 2min) in 
benzonitrile. Thereby, however, the decarbonylated [18F]44 could be obtained in a RCY of 
11±2 % along with several side products, that were not further characterized while this 
reaction gave yields of > 95 % when it was done on the indolecarbaldehydes [18F]1e, [18F]2e, 
[18F]3e and [18F]4e under the conditions applied here. 
The final step in the radiosynthesis was the removal of the benzyl group which was first tested 
under acidic conditions using conc. HCl and heating to 150 °C for 30 min. This resulted in 
decomposition of [18F]44 while free 6-[18F]fluorotryptophan [18F]45 could not be observed. 
Furthermore, the debenzylation reaction was performed  according to the procedure of 
Murakami et al.[176] with AlCl3 in benzene followed by removal of the solvent and an acidic 
hydrolysis of the Seebach group with conc. HCl at 150 °C for 30 min. But under those 
conditions neither the desired product L-6-[18F]fluorotryptophan [18F]45 nor the starting 
material [18F]44 could be detected.  
In summary, L-6-[18F]fluorotryptophan ([18F]45) could not be obtained from the precursor 43 
via the synthetic pathway shown in Scheme 60. This is due to the fact that the benzyl 
protecting group and thereby the hydrolysis of the protecting groups did not succeed. Though, 
the isotopic exchange on 43 and the reductive decarbonylation on [18F]43 were possible even 
if only a low RCY of about 9 % and 11 %, respectively, was obtained. This is probably due to 
the low reactivity for precursor 43 towards the isotopic exchange that was also observed with 
1-benzyl-6-fluoro-1H-indole-5-carbaldehyde (1e) and different to the other indolecarb-
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aldehydes (2e, 3e and 4e). These results confirm those ones obtained in chapter 3.2. For this 
reason a new precursor needed to be prepared carrying the fluorine in the more activated 4-
position and the formyl group in the 5-position, if possible, since this substitution pattern gave 
by far the best RCY on the isotopic exchange and showed the best properties regarding 
chemical stability. Furthermore, labeling of fluoro-1H-indolecarbaldehydes with this 
substitution pattern gave already the maximum RCY at temperatures of about 90 C. Hereby, it 
might be possible to avoid racemization or at least to minimize it. 
 
3.6 Synthesis of precursor for the radiosynthesis of  
L-4-[18F]fluorotryptophan 
In addition to the precursor for 6-fluorotryptophan a synthetic pathway should be developed 
for the synthesis of a precursor that is suitable for the radiosynthesis of 4-[18F]fluoro-
tryptophan since this substitution pattern gave high RCY when it was tested on the fluoro-1H-
indolecarbaldehdes, as described in chapter 3.2.  
 
3.6.1  Precursor for the radiosynthesis via build-up synthesis 
In 2012 Levesque et al. published a new method for the preparation of substituted indoles by 
an [1,2]-aryl shift condensation.[193] The starting materials for this are an alkylated amino-
benzaldehyde and ethyl diazo acetate. The reaction mechanism is shown in detail in  
Scheme 61. 
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Scheme 61  Mechanism of the preparation of indoles via an [1,2]-aryl shift condensation as 
 proposed by Levesque et al. [193] 
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Ethyl diazoacetate is commercially available but the functionalized aminobenzaldehyde needs 
to be prepared prior to the cyclization reaction. The aminobenzaldehyde of choice is shown in 
Figure 10. The positions of the fluorine and iodine were chosen in order to generate a  
4-fluoroindole where a formyl group can be easily introduced in the 5-position, since this 
substitution pattern gave the best RCY in the experiments described in chapter 3.2. A benzyl 
group was chosen as protecting group for the amine since benzyl protected 
aminobenzaldehydes gave the best yields in the indole formation described be Levesque et 
al.[193] Furthermore, the best RCY on the isotopic exchange could also be achieved with 1-
benzyl-4-fluoro-1H-indole-5-carbaldehyde (2e). 
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Figure 10  6-(Benzylamino)-2-fluoro-3-iodobenzaldehyde as building block for the indole 
  formation via the method described by Levesque et al. 
 
A route for the synthesis of the amino benzaldehyde (52) was developed starting from 2-
amino-6-fluorobenzoic acid (46) which is shown in Scheme 62. 
The first step of this procedure was the cyclisation of the aminobenzoic acid 46 which was 
previously done by Tedesco et al.[194] with phosgene in THF. Due to the fact that phosgene is 
highly toxic and difficult to handle, since it is a gas, triphosgene was used instead giving also 
quantitative yields of 47. The methyl ester 48 was prepared by refluxing 47 in ethanol with a 
catalytic amount of DMAP in 97 % yield. The iodination of 48 was realized following a 
method described by DeVita et al.[195] using elemental iodine and Ag2SO4 in ethanol. Thereby 
methyl 6-amino-2-fluoro-3-iodobenzoate (49) could be obtained in 80 % yield. The 
benzylation of the amine was carried out by a reductive amination with benzaldehyde and 
NaBH3CN following a procedure described by Levesque et al.
[193] who performed this 
reaction in methanol at room temperature. This approach, however, did not give the desired 
compound 50. Refluxing was necessary to convert the free amine into the corresponding 
benzylamine in about 78 % yield. The following reduction of the methyl ester 50 was first 
studied under standard conditions using LiAlH4 in THF followed by an acidic workup.  
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Scheme 62  Synthetic pathway for the preparation of the aminobenzaldehyde 52. 
 
Unfortunately, the application of these conditions led to the formation of the deiodinated 
alcohol 51b (Scheme 63). This might be due to a mechanism proposed by Twum et al.[196] 
who also observed aromatic deiodination when ortho- or para-iodoanilines were handled 
under acidic conditions. The proposed mechanism is shown in Scheme 64 at the example of 
the deiodination of 50. An alternative explanation for the deiodination might be an 
electrophilic retroiodination which would result the same compound 51b.  
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Scheme 63  Reduction of 50 with LiAlH4 followed by an acidic workup yielding the 
 deiodinated benzyl alcohol 51b. 
 
In order to avoid acidic conditions during work-up the reaction was quenched rather with 
water than with 1M HCl. The resulting slurry was filtered and intensively washed with DCM 
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to get the desired benzyl alcohol 51a in 57 % yield. The yield could be increased to 85 % after 
purification when DIBAL (diisobutylaluminiumhydride) was used as reducing agent. This is 
probably due to the fact that DIBAL forms a colorless solid when water is added which can be 
filtered off more easily. 
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Scheme 64  Mechanism proposed by Twurm et al. for aromatic deiodination under acidic 
 conditions at the example of 51b.[196] 
 
The following oxidation of the benzyl alcohol 51a was first performed with IBX (2-
iodoxybenzoic acid), a hypervalent iodine oxidant that is commonly used for the oxidation of 
alcohols to aldehydes.[197],[198] The reaction itself was carried out under the conditions used by 
Levesque et al.[193] Unfortunately, when these conditions were applied, not only the alcohol 
was oxidized to the corresponding benzaldehyde, but also the benzyl group on the amine was 
removed giving the aminobenzaldehyde 52b in 78 % yield (Scheme 65). When Dess-Martin-
periodane (DMP), a derivative of IBX, was used, decomposition of the starting material 
occurred, which was probably due to the higher reactivity of DMP. 
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Scheme 65  Oxidation of the benzyl alcohol 51a with IBX resulting in the debenzylated 
 aminobenzaldehyde 52b. 
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Finally, activated manganese dioxide (MnO2) was applied as oxidant which is also a common 
reagent for the oxidation of benzyl alcohols to benzaldydes under extremely mild conditions. 
Usually an excess of MnO2 is used and DCM is the solvent of choice. With this procedure the 
desired benzaldehyde 52a was obtained in about 67 % yield.  
Next, the prepared benzaldehyde 52a was reacted with ethyl diazoacetate under the conditions 
described by Levesque et al. giving the desired fluoro-iodo-indole 53 in 83 % yield  
(Scheme 66). 
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Scheme 66  Preparation of the fluoroiodoindole 53. 
 
Since the preparation of 53 was successful and could be accomplished with high yields, the 
ester in the 3-position of the indole should be reduced to the corresponding alcohol followed 
by the introduction of a leaving group and the alkylation with Seebach’s auxiliary. The 
reduction was first tried with LiAlH4 in THF. The alcohol 54 could be detected by TLC but 
during purification decomposition already occurred. Due to the observed instability of the 
alcohol 54 it was directly used for the next reaction step without further purification.  
When the conversion of the alcohol 54 into the corresponding bromide (55a) or tosylate (55b) 
was examined, decomposition of the starting material occurred immediately and none of the 
compounds could be isolated.  
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Scheme 67  Attempts for the preparation of the compounds 55a,b,  
 i) CBr4, PPh3, DCM; ii) NEt3, Tos-Cl, MeCN. 
 
55a: LG = Br 
55b: LG = OTos 
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The bromination of the instable alcohol 54 was done by an Appel reaction at 0 °C resulting in 
decomposition of the starting material as soon as it was dissolved in DCM. This was similar 
to the benzyl protected indole 38b described in chapter 3.4.2. Therefore, a tosylation was 
attempted in acetonitrile with triethylamine as base, since decomposition of benzyl-protected 
indoles was not observed under those conditions. Using these conditions, neither the starting 
material nor the tosylate 55b could be obtained due to immediate decomposition of the labile 
alcohol 54. 
Since the introduction of a suitable leaving group for the alkylation with Seebach’s auxiliary 
was impossible, the benzyl group should be removed and substituted by a protecting group, in 
another attempt, resulting in a compound that is stable under the conditions required for the 
following reactions. In this case a tosyl-group should be introduced which indeed worked well 
for bromination of the alcohol 38a. 
The removal of the benzyl group was performed under the conditions previously described by 
Murakami et al. using 5 equivalents of AlCl3 in benzene.
[176] When these conditions were 
applied, the debenzylated indole 56a could not be obtained. Instead, the formation of the 
debenzylated and deiodinated indole 56b was observed which could be isolated in 78 % yield 
(Scheme 68). In order to avoid the deiodination during the debenzylation step the impact of 
the solvent on the deiodination was tested. Therefore, toluene and anisole were also tested as 
solvents for this reaction since they have been used previously for those kinds of 
reactions.[177],[158] Inopportunely using these solvents gave the same results that have been 
observed before. 
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Scheme 68  Debenzylation of 53 using AlCl3 in various solvents. 
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Moreover, it was studied whether the use of one equivalent of AlCl3 is effective for the 
debenzylation of 53. This was done in order to find out whether the benzyl-group is more 
reactive to AlCl3 than the iodine. If this was the case, debenzylation would be possible 
without deiodination, which would potentially result in longer reaction times while yielding 
the desired 56a. Since no conversion could be observed with one equivalent, the amount of 
AlCl3 was increased slowly in order to find a ratio of starting material and reagent where the 
desired debenzylation proceeds, but the undesired deiodination does not. This was not 
possible, since debenzylation was not observed without deiodination. Therefore, the removal 
of the benzyl group was examined under various conditions. First, the reaction was carried out 
with Pd/C and NH4HCO2 in EtOH which did not result in any conversion of the starting 
material. The same results were obtained when Pd/C and the benzyl protected indole 53 were 
dissolved in MeOH and hydrogen gas was passed through the solution. However, it was 
impossible to obtain the debenzylated iodoindole 56a and it was studied whether the 
formylation of the benzylinolde 53 is possible followed by protection of the aldehyde and 
debenzylation of the indole nitrogen (Scheme 69).  
The formylation was done by an iodine-magnesium exchange under the conditions previously 
described by Boymond et al.[191] starting from the iodoindole 53 using i-PrMgBr and DMF at 
0 °C. Due to the fact that these conditions led again to fast decomposition of the starting 
material, the reaction was carried out with the same reagents at -78 °C. Thereby, the desired 
indolecarbaldehyde could be obtained in 25 % yield. The following protection was tried under 
standard conditions[186] with 1,2-ethandithiol in DCM and catalytic amounts of elemental 
iodine. Unfortunately, decomposition of the starting material started immediately after it was 
dissolved in DCM as it has been observed before for compound 53.  
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Scheme 69  Planned synthetic pathway for the formylation and debenzylation of 53. 
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These observations are similar to those that were made when the benzyl protected indole 38b 
was dissolved in DCM and might be a further evidence for the instability of some benzyl 
protected indoles in DCM. Due to the complications that come along with this route, 
especially the debenzylation and the reduction, it was not as promising as previously assumed 
and therefore not further investigated. 
 
3.6.2  Precursor for the radiosynthesis via a linear synthetic pathway 
The experiments in context of a linear synthesis of a precursor for L-6-[18F]fluorotryptophan 
(43) revealed to be a good strategy. Since 4-fluoro-1H-indole (2a) became commercially 
available at reasonable prices, the synthetic concept developed in chapter 3.3.2 could be 
adapted to the synthesis of a suitable precursor for L-4-[18F]fluorotryptophan starting from  
4-fluoro-1H-indole here. 
The whole synthetic route of the precursor of L-4-[18F]fluorotryptophan is shown in Scheme 
70 (see also Scheme 59, chapter 3.4.2) . The protection of 4-fluoroindole (2a) was carried out 
as discussed in chapter 3.1 giving the desired TIPS-indole 2b in 94 % yield. The iodination 
was done with sec-BuLi, PMDTA and diiodoethane at -78 °C followed by removal of the 
TIPS group. This was performed without characterization of the TIPS protected iodoindole 59 
since the separation of the iodinated and not iodinated TIPS-protected indoles 59 and 2b was 
also impossible for those compounds. The yield for both steps was about 65 %. The 
Vilsmeier-Haack formylation was realized under standard conditions[84] as described in 
chapter 3.4.2. In contrast to the 6-fluoroindole-3-carbaldehyde 36 which gave about 64 % 
yield, the 4-fluoro derivative 61 could be obtained in yields as high as 89 % which has to be 
due to the substitution pattern of the fluorine on the indole. The following tosylation was 
accomplished in THF with TosCl and NaH giving the tosylated indolecarbaldehyde 62 in  
74 % yield. The reduction was carried out with NaBH4 in THF/EtOH yielding the alcohol 63 
quantitatively. Bromination of 63 via an Appel reaction gave the bromide 64 in yields of 
about 63 %. The bromide 64 was stable at room temperature and not as sensitive to light as 
the 6-fluoroderivative 39 which had to be used immediately after preparation in order to avoid 
decomposition. With the bromide 64, storage at 8 °C was possible for at least 2 weeks which 
simplified the handling with this compound. The alkylation with Seebach’s auxiliary was 
performed under standard conditions with LDA at -78 °C giving compound 65 in 73 % yield. 
The following introduction of the formyl group in 5-position was done by an iodine-
magnesium exchange with i-PrMgBr followed by the addition of DMF, thus, yielding the 
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resulting formylindole 66 in about 73 % yield. Hereby, the use of four equivalents of DMF 
was also essential. When less DMF was used the obtained yields were below 50 %.  
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Scheme 70  Synthetic pathway for precursor 68 for the radiosynthesis of  
L-4-[18F]fluorotryptophan. 
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The removal of the tosyl group was performed with TBAF in THF at room temperature 
yielding the unprotected indole 67 in about 42 % besides a variety of side products. This 
behavior, however, was not observed, when the 6-fluoro derivative 41 was subject to 
detosylation where yields above 90 % were obtained, and the formation of side products was 
not observed. Finally, the Boc-group was chosen for the protection of the precursor over the 
benzyl-group which was used for the protection of the precursor of L-6-fluorotryptophan (43) 
for several reasons. The 1-Boc-4-fluoro-1H-indole-5-carbaldehyde (2g) which has a similar 
substitution pattern gave RCY of about 28 % and the removal of the Boc-group can be 
accomplished under much milder conditions than the removal of a benzyl-group. This might 
lead to lower RCY in the isotopic exchange, but has some advantages during the planned 
radiosynthesis. It reduces the radiosynthesis by one step, avoids the removal of the very stable 
benzyl group as well as the use of AlCl3 and avoids benzene as solvent which is known to be 
toxic. The introduction of the Boc-group was done with Boc2O and catalytic amounts of 
DMAP in THF giving the desired precursor 68 in about 86 % yield. 
In summary, a precursor for the radiosynthesis of L-4-[18F]fluorotryptophan was successfully 
synthesized in an eleven step linear synthesis in an overall yield of about 8 % following the 
synthetic pathway that has been developed before in this work for the preparation of a similar 
precursor for L-6-[18F]fluorotryptophan. 
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3.7 Radiosynthesis of L-4-[18F]fluorotryptophan  
The radiosynthesis of L-4-[18F]fluorotryptophan was carried out in three steps following again 
the concept that was previously developed by Castillo et al.[173] and also used for the attempts 
of the radiosynthesis of L-6-[18F]fluorotryptophan. The three steps consist of a nucleophilic 
isotopic 18F-for-19F exchange, a reductive decarbonylation with Wilkinson’s catalyst and the 
hydrolysis of the protecting groups. The whole synthesis sequence is illustrated in Scheme 71.  
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Scheme 71  Synthetic concept for the radiosynthesis of L-4-[18F]fluorotryptophan ([18F]70). 
 
3.7.1  Isotopic exchange  
The first step in the radiosynthesis is the isotopic exchange. Since complex molecules 
containing the indole moiety have not been labeled with nucleophilic fluorine-18 directly in 
the carbocycle, the reaction was first tried under the conditions that gave the highest RCY for 
1-Boc-4-fluoro-1H-indole-5-carbaldehyde (2g). The best RCY for this compound was 
obtained at 90 °C where 28 % RCY could be obtained. Therefore, the precursor 68 was 
reacted for 15 min at this temperature using TBAHCO3 as anion activator and DMF as 
solvent.[173],[168] 
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The RCY obtained using the conditions described above was about 17 %. Furthermore, it was 
examined whether increasing temperatures result in a higher RCY. However, at temperatures 
higher than 90 °C decomposition occurred. When temperatures higher than 110 °C were used 
complete decomposition of the somehow temperature sensitive starting material occurred. The 
isotopic exchange was therefore also investigated at temperatures between 85 °C and 60 °C. 
The best RCY that could be obtained was about 51 %, and surprisingly the optimum 
temperature was 80 °C. This was unexpected since it can be found in the literature that 
isotopic exchange reactions on fluorobenzaldehydes gave the best RCY at temperatures above 
100 °C.[168],[169] With temperatures lower than 80 °C the RCY decreased significantly. The 
temperature region where a good RCY of above 40 % can be obtained is very narrow and is 
limited from 75 °C to 85 °C. The temperature dependence on the RCY is graphically shown 
in Figure 11. The isotopic exchange was also tested with DMSO and MeCN as solvents but 
the RCY obtained thereby were always below 8 % combined with the formation of several 
side products which was similar to the radiofluorination of the 1-benzyl-fluoro-1H-
indolecarbaldehydes (1e-4e). For this reason, it is suggested to prefer DMF over DMSO and 
MeCN as solvent for the isotopic fluorine-exchange on indoles. 
 
Figure 11  Temperature dependence of the isotopic exchange of 68 on the RCY of [18F]68. 
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Due to the fact that the isotopic exchange on 68 strongly depends on the temperature of the 
reaction, it was additionally studied whether a reaction time of 15 min is useful or whether 
decomposition is already occurring after this time. For those investigations, the isotopic 
exchange was performed at the optimum temperature of 80 °C and samples of the reaction 
mixture were taken and analyzed by radio HPLC after 5, 10, 15, 20, 25, 30 and 45 min. The 
obtained yields over time are shown in Figure 12. It showed that the maximum RCY is 
already reached after 10 min under the studied conditions. Furthermore, a plateau of the RCY 
was observed for reaction times between 10 and 20 min. Decomposition of the labeled 
intermediate [18F]68 started at reaction times longer than 20 min. The decomposition, 
however, was slow but led to a total loss of [18F]68 of about 13 % during 45 min. According 
to these results, the initially used reaction time of 15 min was optimal, since it is placed in the 
middle of the plateau. After this time, it can be assumed that the isotopic exchange is 
completed but decomposition of the product has not started at this time point. 
Figure 12  Optimization of the isotopic exchange with respect to reaction time. 
 
Moreover, it was investigated if a microwave assisted setup, which gave excellent RCY with 
the 1-benzyl-fluoro-1H-indole-carbaldehydes (see chapter 3.2.1), is also suitable for the 
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HPLC. The results obtained with the microwave assisted setup are shown in Figure 13. It was 
found that radiolabeling is possible using microwave heating with low microwave energies of 
30 to 40 W. At energies of 60 W decomposition of the precursor was observed which was 
probably due to temperatures above 90 °C in the reactor and the high sensitivity of the 
precursor towards elevated temperatures. The best results were obtained when irradiation was 
done with 40 W which yielded [18F]68 in a RCY of about 40 %. However, this was ca.  
10 % less than under conventional heating. Furthermore, the variance of the RCY obtained 
under microwave heating was higher than under conventional heating e.g. at 40 W, RCY 
between 25 % and 44 % were obtained. This is in contrast to previous results from the 
literature where the RCY was described as more stable with microwave heating than under 
conventional heating.[173] The most positive result of the microwave assisted conditions was 
that it was again possible to reduce the reaction time from 15 to 1 min.  
Figure 13  Isotopic 18F-for-19F exchange on the precursor 68 under microwave heating. 
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of 43 could not be detected with 68 and was probably due to the lower temperatures during 
the isotopic exchange reaction. 
 
3.7.2  Reductive Decarbonylation of [18F]68 
The second step in the synthetic pathway of the radiosynthesis of L-4-[18F]fluorotryptophan 
([18F]70) was the removal of the formyl group that was previously attached for the activation 
of the isotopic exchange. The removal was again carried out with Wilkinson’s catalyst 
(Rh(PPh3)3Cl).
[173] The reaction itself was performed under the conditions that gave the best 
RCY with the 1-benzyl-[18F]fluoro-1H-indolecarbaldehydes [18F]1e, [18F]2e, [18F]3e and 
[18F]4e. Thus, all reactions were carried out in benzonitrile. The first attempt was made with 3 
equivalents of Rh(PPh3)3Cl. However, it was not possible to obtain the decarbonylated 
intermediate [18F]69 without the loss of the Boc-group that was attached to the indole 
nitrogen. This was not a problem since it had to be removed in the hydrolysis step anyway 
(Scheme 72).  
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Scheme 72  Loss of the Boc group during the reductive decarbonylation on [18F]68. 
 
When the reaction was examined with 3 equivalents of Rh(PPh3)3Cl under conventional 
heating to 150 °C for 20 min the decarbonylated and deprotected [18F]69a was obtained in a 
RCY of about 45 % while the formation of a polar side product was also observed but could 
not be identified. Therefore, the amount of Rh(PPh3)3Cl was risen in order to get a higher 
RCY. Increasing the amount of Rh(PPh3)3Cl to 4 equivalents decreased the RCY to only  
35 %, while the formation of the side product was increasing. Hence, the amount of 
Rh(PPh3)3Cl was reduced to 2 equivalents which resulted in a reduced RCY of about 15 % 
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and only minor amounts of the polar side product (< 10 %) but a total conversion of only 
about 22 %. Due to these results the initially used amount of Rh(PPh3)3Cl resulted in the 
highest RCY with conventional heating. 
A microwave assisted setup was also studied for the reductive decarbonylation in order to 
increase the obtained RCY or reduce the time needed for the reaction. First, the amount of 
catalyst that worked best for the reductive decarbonylation of [18F]68 under conventional 
heating, which were 3 equivalents, was also used and the solution was irradiated with 100 W 
microwaves for 2 min. This microwave energy and reaction time were chosen, since good 
results were obtained before with the 1-benzyl-fluoro-1H-indolecarbaldehydes [18F]1e, 
[18F]2e, [18F]3e and [18F]4e. Under those conditions, a RCY of ca. 75 % was achieved which 
was significantly higher than under conventional heating. Reducing the amount of catalyst to 
1 equivalent led to a decrease of the RCY to about 58 %. When the amount of Rh(PPh3)3Cl 
was again risen to 2 equivalents the RCY was also increasing to ca. 69 %. Further increasing 
of the amount of Rh(PPh3)3Cl  to 4 equivalents did, however, not result in a significantly 
higher RCY. The formation of the same polar side product detected under conventional 
heating was always observed. The results are summarized in Table 8. 
 
Table 8  Results of the reductive decarbonylation of [18F]68; CH: conventional heating for 
 20 min, MH: microwave heating for 2 min. 
Conditions eq. Rh(PPh3)3Cl Time [min] Conversion [%] RCY [%] 
CH, 150 °C 2 20 22 ± 8 15 ± 6 
CH, 150 °C 3 20 65 ± 9 45 ± 8 
CH, 150 °C 4 20 45 ± 6 35 ± 3 
MH, 100 W 1 2 > 99 58 ± 11 
MH, 100 W 2 2 > 99 69 ± 9 
MH, 100 W 3 2 > 99 75 ± 7 
MH, 100 W 4 2 > 99 78 ± 6 
 
In order to reduce the amount of the undesired side product that is formed during reductive 
decarbonylation, the reaction was tested with an irradiation time of 60 s and 3 equivalents of 
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Wilkinson’s catalyst. This led to surprising results: The formation of four products, the 
starting material [18F]68, the decarbonylated but still Boc protected intermediate [18F]69, the 
decarbonylated and deprotected intermediate [18F]69a and the unknown side product, always 
formed during reductive decarbonylation. This shows that the reaction time does not correlate 
with the unknown side product and that this has to be subject to something else. Furthermore, 
those results were interesting since they indicate that the irradiation time of 2 min is necessary 
to guarantee a complete conversion during the reaction. 
In summary, the reductive decarbonylation could be performed under both conventional and 
microwave assisted heating. However, when microwave heating was applied, the obtained 
RCY was significantly higher than under conventional heating. The reaction times could thus 
be reduced from 20 min to 2 min, which is of great advantage in radiochemistry. The 
decarbonylated products were purified as described in the Experimental part (see chapter 
4.7.4). 
 
3.7.3  Hydrolysis of protecting groups 
The last step in the radiosynthesis of L-4-[18F]fluorotryptophan was the hydrolysis of the 
Seebach auxiliary which masks the amino acid function. Due to the fact that the Boc-group 
was already removed during reductive decarbonylation the focus for the conditions of the 
hydrolysis was adapted to Seebach’s auxiliary. The amide bond in this group is quite stable 
and its cleavage requires rather harsh reaction conditions. 
In the past this was done using concentrated HBr or HI and temperatures as high as 150 °C 
and 200 °C, respectively.[168],[199] In a work published in 2011 concentrated HCl and heating 
to 150 °C for 30 min was used for the hydrolysis of the Boc-protected derivative of Seebach’s 
auxiliary.[173] Here, these conditions were adapted giving a RCY of only ca. 34 % which was 
unexpected, since those types of reactions were described as quantitative in the past. 
Additionally, a side product was formed in about 13 % of the total activity that could not be 
characterized (see Figure 14). Due to the possibility that the side product might be subject to 
incomplete hydrolysis of the protecting groups it was studied if longer reaction times would 
provide a higher RCY. Therefore, the hydrolysis was performed for 2 h and samples were 
taken every 30 min. It proved that the unknown peak is not a result of incomplete hydrolysis, 
since the ratio of L-4-[18F]fluorotryptophan and of this peak stayed the same over the whole 
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reaction time. Hence, it was assumed that decomposition of the temperature sensitive starting 
material might be the reason for the occurrence of the side product. 
Furthermore, changes in reaction temperatures could provide a better RCY for this reaction 
and those were varied from 110 to 160 °C. While at temperatures lower than 130 °C the RCY 
fell down due to incomplete hydrolysis, a reaction temperature of 160 °C resulted in complete 
decomposition of the starting material. In total the conditions first tested (150 °C, 30 min) 
gave the best results and were used for further experiments. 
 
 
Figure 14  HPLC-analysis of L-4-[18F]fluorotryptophan ([18F]70) and an undesired side 
product which is formed during hydrolysis of [18F]69a.  
 
In summary, the radiosynthesis of L-4-[18F]fluorotryptophan could be successfully 
accomplished in three steps with an overall RCY of about 13 % and an enantiomeric purity of 
> 99 %. Figure 15 depicts a comparison between the HPLC analysis of a standard sample of 
L-4-fluorotryptophan prepared as described by Konas et al.[160] and the radiofluorinated L-4-
[18F]fluorotryptophan which was previously purified by semi-preparative HPLC.  
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The moderate total RCY of about 13 % is mainly due to the hydrolysis which gave only 34 % 
RCY. Thus, it can probably be increased during further optimization of this reaction step or 
by using a protecting group for the amino acid function that can be hydrolyzed under milder 
conditions and thereby avoiding decomposition of the intermediate [18F]69a. 
 
Figure 15  HPLC analysis on a Supelco chirobiotic™ T coloumn (250x4.6 mm) of a 
standard sample of L-4-fluorotryptophan and the previously purified final 
product [18F]70 after hydrolysis ([18F]70 = 4FTrp). 
 
3.7.4  Specific activity 
The specific activity obtained in isotopic exchange reactions is a function of both, the amount 
of precursor and the starting 18F-activity. The amount of carrier is determined by the quantity 
of precursor employed, in this case ca. 9 µmol. Under manual experimental conditions used 
here with a low starting activity of typically 250 MBq the specific activity was always > 70 
MBq/mmol which is in the area of specific activities that can be obtained under electrophilic 
fluorination conditions. But it can be expected that the specific activity will increase 
significantly with higher starting activities and will thereby be much higher than those 
obtained with electrophilic fluorination.  
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3.8  Summary of the obtained results 
In this work, a simple three-step radiosynthesis of L-4-[18F]fluorotryptophan was developed. 
The used precursor was synthesized in an eleven-step linear synthesis in an overall yield of  
8 %. The substitution pattern of the fluorine and the formyl group for the precursor 68 was 
chosen with respect to the results that were obtained prior to its synthesis in order to 
determine the optimum substitution pattern. Furthermore, the precursor 43, which had the 
fluorine in the undesirable 6-position, confirmed the results obtained for the fluoro-1H-indole-
carbaldehydes regarding the isotopic exchange.  
However, further investigations are necessary in order to increase the yield for the 
radiosynthesis of L-4-[18F]fluorotryptophan, especially the hydrolysis. This can probably be 
achieved through a protection group on the amino acid function which can be cleaved under 
less aggressive conditions. A promising attempt for this is the protection of the carboxylic 
acid with an ester and the protection of the amine with a trityl group that can be hydrolyzed 
under slightly acidic conditions at room temperature. It is also desirable to increase the 
stability of the precursor towards elevated temperatures, since this was also an issue during 
the 18F-for-19F isotopic exchange and might also result in higher RCY during this reaction due 
to the fact that higher labeling temperatures become possible. 
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4.  Experimental  
4.1  General techniques 
All reactions sensitive to humidity were carried out under an atmosphere of argon. The 
reaction flasks were dried for 24 h at 100 °C and equipped with a septum and a balloon filled 
with argon. All liquids sensitive to humidity were transferred into the reaction flask through 
syringes. All reaction mixtures were magnetically stirred.  
4.1.1  Spectrometric devices 
1H, 13C and 19F spectra were recorded on a Varian Inova 400 MHz (ZEA-3) or a Bruker DPX 
Avance (INM-5) spectrometer using CDCl3 or d6-DMSO as solvents. All shifts are given in 
ppm using the solvent residual signals as reference. HRMS spectra were obtained on a FTICR 
‘LTQ FT Ultra (Thermo Fisher Scientific, Germany) by the ZEA-3. Elemental analyses were 
obtained on a Vario EL cube (ZEA-3). 
4.1.2  Microwave device 
Reactions under microwave heating were performed using a CEM Discover (Matthews, USA) 
single-mode microwave reactor system in the energy range from 30 to 200 W. 
4.1.3  Preparative chromatography and analytic thin layer chromatography 
Flash chromatography was performed on silica gel (Merck 60 mesh for flash chromatography, 
Germany) following the procedure proposed by Still[200] or via automated flash 
chromatography using a Reveleris Flash Chromatography system (Grace, USA) on 
commercially available Flash Grace Reveleris™ cartridges (Grace, USA). 
Thin layer chromatography (TLC) was performed on precoated plates of silica gel 60 F254 
(Merck, Germany). The compounds were detected by UV absorption at 254 nm. 
4.1.4  Radioanalytik procedures 
The analysis of the radiofluorinated products was performed by either radio thin layer 
chromatography (radio-TLC) or radio high performance liquid chromatography (radio-
HPLC). 
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Radio-thin layer chromatography 
Radio-TLC for the analysis of the 18F-labeled products and intermediates was done in order to 
determine the radiochemical yield (RCY). The measurements were performed on precoated 
silica plates of silica gel 60 F254 (Merck, Germany). The reaction mixtures were diluted with 
an appropriate solvent (Et2O or MeCN) and samples of about 2 µL were applied on the TLC 
plates. Those were developed in an appropriate solvent mixture of petroleum ether (PE) and 
ethyl acetate (EA). The identification of unreacted [18F]fluoride was simple since under the 
conditions used for the elution it remained at the origin of the TLC plate. The distribution of 
the radioactivity on the TLC plate was detected using an Instant Imager™ (Packard 
Instruments). The RCY was calculated by dividing the activity of the spot of compound of 
interest by the total activity on the TLC-plate, multiplied by 100 (Equation 1). Table 9 shows 
the corresponding Rf-values and eluent mixtures of the labeled compounds analyzed by radio-
TLC. 
𝑅𝐶𝑌 [%] =
𝐴𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑
𝐴𝑡𝑜𝑡𝑎𝑙
×  100 
 
Equation 1  Determination of the radiochemical yield by radio-TLC. 
 
Table 9  Rf-values and eluent systems for the compounds determined by radio TLC.. 
Compound Eluent system (PE/EA) Rf-value 
[18F]1d, [18F]2d, [18F]3d 3:2 0.63 
[18F]1e, [18F]2e, [18F]3e 4:1 0.65 
[18F]1f 4:1 0.63 
[18F]1g, [18F]2g 4:1 0.69 
[18F]1h 4:1 0.59 
[18F]43 3:2 0.62 
[18F]68 7:3 0.74 
[18F]69 7:3 0,24 
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Radio-high performance liquid chromatography 
Radio-HPLC separations were performed using a Knauer pump (Knauer, Germany), a Knauer 
K-2500 UV/VIS detector (Knauer, Germany) and two manual Rheodyne injectors (20 µL 
loop). The first loop was located before the HPLC-column and the second one behind it. 
Detection of radioactivity was accomplished with a NaI(Tl) well-type scintillation detector 
(EG&G Ortec; model 276 Photomultiplier Base, Ametek, USA) with an ACE Mate Amplifier 
and BIAS supply (Ortec, USA). Data acquisition and interpretation was done with Gina 
software (Raytest, Germany). 
Radioactive samples were injected into the column using the first injector. After elution of all 
compounds of interest from the column, three aliquots of the sample were injected into the 
second injector. The RCY of the product was determined using equation 2 where Aproduct is the 
activity of the desired product peak and Atotal is the activity determined by injection into the 
second injector. The term e-λt is used for decay correction during the HPLC run, where “λ” is 
the decay constant for fluorine-18 and “t” is the time difference between the retention times of 
the product and the aliquots.  
𝑅𝐶𝑌 [%] =  
𝐴𝑃𝑟𝑜𝑑𝑢𝑐𝑡   ×  100
𝐴𝑡𝑜𝑡𝑎𝑙  ×  𝑒−𝜆𝑡
 
 
Equation 2 Determination of the radiochemical yield by radio HPLC. 
 
HPLC-Systems 
System A. Analytic HPLC of the 18F-labeled indole derivatives was performed with a 
reverse-phase Kromasil 5 C18 column (250x4 mm; CS Chromatographieservice GmbH, 
Germany). Elution was performed at a constant flow rate of 1 mL.min-1 with a acetonitrile–
water mixture (65 : 35). 
System B. Preparative HPLC was carried out with a Synergi 4m Hydro-RP 80A column 
(250–10 mm; Phenomenex, Germany). The mobile phase was aqueous ethanol (10 %), and 
the flow rate was 3 mL.min-1. 
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System C. The enantiomeric purity of the radiolabeled compounds was determined by HPLC 
using a Supelco chirobiotic™ T column (250x4.6 mm; Sigma-Aldrich, Germany). Elution 
was performed at a constant flow rate of 1 mL.min-1 with a methanol-water mixture (30:70). 
System D. Analytical HPLC was carried out with a Synergi 4m Hydro-RP 80A column (250–
4 mm; Phenomenex, Germany). The mobile phase was aqueous ethanol (10 %), and the flow 
rate was 1 mL.min-1. 
 
Table 10  k' values of the probes analyzed by radio-HPLC. 
Compound System k’ 
[18F]1e A 5.18 
[18F]2e A 5.26 
[18F]3e A 5.38 
[18F]4e A 6.60 
[18F]5 A 7.49 
[18F]6 A 7.84 
[18F]7 A 8.32 
[18F]43 A 9.94/10.91 (L + D) 
[18F]68 A 14.68 
[18F]69 A 5.18 
[18F]70 B 3.44 
[18F]70 C 6.18 
[18F]70 D 2.99 
 
4.1.5  Reagents and solvents 
The dry solvents, dichloromethane, tetrahydrofurane, dioxane, methanol, N,N-
dimethylformamide, diethyl ether acetone, benzonitrile, dimethyl sulfoxide, acetonitrile, 
benzene, toluene and anisole, were purchased from Sigma-Aldrich, Germany. The solvents 
used for extraction and chromatography, diethyl ether, petroleum ether, hexanes, acetonitrile 
 93  Experimental 
(HPLC grade), ethyl acetate, ethanol, methanol, dichloromethane, were obtained from Merck, 
Germany. All solvents were used without further purification or drying. 
(S)-Boc-BMI, (S)-Z-BMI, 1,2-ethanedithiol, 1-bromo-4-fluoro-2-nitrobenzene (4a), 2-amino-
6-fluorobenzoic acid (46), 3-fluoroaniline (19), 4-bromo-2-fluorobenzaldehyde (24), 6-
fluoroindole (1a), 7-fluoroindole (3a), aluminum chloride, ammonium chloride, ammonium 
formate, benzaldehyde, benzyl bromide, boron trifluoride diethyl etherate, cesium carbonate, 
chloroethylformate, diiodoethane, diisobutylaluminium hydride, di-tert-butyl dicarbonate, 
ethyl diazoacetate, iodomethane, isopropyl magnesium bromide, isopropyl magnesium 
chloride, lithium aluminum hydride, lithium chloride, manganese dioxide (activated), 
N,N,N’,N’’,N’’-pentamethyl-diethylenetriamine, N,N-dimethylaminopyridine, n-butyllithium, 
palladium on activated charcoal, palladium(II)acetate, phosphorous tribromide, potassium 
carbonate, potassium iodide, sec-butyllithium, silver sulfate, sodium borohydride, sodium 
carbonate, sodium chloride, sodium cyanoborohydride, sodium hydride, sodium hydroxide, 
sodium sulfate, sodium thiosulfate, tert-butylcarbamate, tetrabutylammonium fluoride, tosyl 
chloride, triethylamine, trifluoroacetic acid, trimethylsilyl chloride, triphenylphosphine, 
triphosgene, triisopropylsilyl chloride, vinyl magnesium bromide, Wilkinson catalyst, Xphos 
and zinc chloride were all acquired from Sigma-Aldrich, Germany. 
4-Fluoroindole, D,L-4-fluorotryptophan, D,L-6-fluorotryptophan and phosphorous oxy-
chloride were purchased from Chempur, Germany, while acetic acid, hydrobromic acid and 
hydrochloric acid were acquired from Merck, Germany. 
IBX was prepared as described by Frigerio et al. [201]. Dess-Martin periodan was synthesized 
as described by Dess and Martin [202]. 1-Trisiopropylsilyl-4-fluoro-1H-indole (2b), 1-
trisiopropylsilyl-6-fluoro-1H-indole (1b), 1-trisiopropylsilyl-7-fluoro-1H-indole (3b)and 7-
bromo-4-fluoro-1H-indole (4b) were prepared as described by Schosser et al. [69]. 
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4.2  Synthesis of fluoro-1H-indole-carbaldehyde precursors 
1-Triisopropylsilyl-6-fluoro-1H-indole-5-carbaldehyde (1c),  
according to Schlosser et al.[69] 
A solution of 6-fluoro-1-(triisopropylsilyl)indole (4.0 g, 14 mmol) in 30 
mL tetrahydrofuran was cooled to –78 °C, and a 1.4 M solution of sec-
butyllithium in hexanes (14 mmol) was added dropwise. The resulting 
mixture was stirred for 2 h at -78 °C before 5 mL dimethylformamide were 
added slowly. The reaction was allowed to warm up to room temperature and stirred for 2 
more hours. Water was added and the aqueous phase was extracted with Et2O. The combined 
organic extracts were dried over Na2SO4, filtered and the solvents were evaporated in vacuo. 
The crude residue was purified via flash chromatography (2 % EtOAc/PE, Rf = 0,30) giving 
2.5 g (7.8 mmol, 64%) of the desired product as a colorless oil. 
1H-NMR (CDCl3) δ 10.38 (s, 1H), 8.17 (d, J = 7.0 Hz, 1H), 7.32 (d, J = 3.3 Hz, 1H), 7.24 (dd, 
J = 12.6 Hz, J = 0.7, 1H), 6.74 (dd, J = 2.4 Hz, J = 0.9 Hz, 1H), 1.72 (hept, J = Hz, 3H), 1.19 
(d, J = 7.4 Hz, 18H); 13C-NMR (CDCl3) 187.11 (J = 6.4 Hz), 161.13 (J = 246.6), 144.77 (J = 
12.1 Hz), 133.44 (J = 3.1 Hz), 128.17 (J = 1.1 Hz), 121.68 (J = 4.0 Hz), 118.37 (J = 10.9 Hz), 
106.52, 100.38 (J = 25.2 Hz), 17.99, 12.68; 19F-NMR (CDCl3) δ -130.1 
HRMS: C18H26FNOSi [M+H]
+ calcd.. 320.1840 found 320.1839 
 
1-Triisopropylsilyl-4-fluoro-1H-indol-5-carbaldehyd (2c) according to Schlosser et al.[69] 
Analogously prepared as the aldehyde 1c while starting from 4-fluoro-1-
(triisopropylsilyl)indole (2b) giving the desired product as a colorless solid 
in 66 % yield. 
1H-NMR (DMSO) δ 10.26 (s, 1H), 7.51-7.48 (m, 3H), 6.85 (d, J = 3.2 Hz), 
1.73 (hept, 3H, J = 7.6 Hz), 1.02 (d, 18H, J = 7.6 Hz); 13C-NMR (DMSO) δ 187.27 (J = 5.8 
Hz), 158.86 (J = 259.3 Hz), 147.31 (J = 11.5 Hz), 134.24, 120.94, 119.68 (J = 19 Hz), 115.77 
(J = 5.3 Hz), 111.53, 102.29, 18.13, 12.23; 19F-NMR (DMSO) δ -128,78; HRMS: 
C18H26FNOSi [M+H]
+ calcd.. 320.1840 found 320.1842; E.A. calcd. C: 67.67 H: 8.20 N: 4.38 
found C: 67.68 H: 8.25 N: 4.35  
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1-Triisopropylsilyl-7-fluoro-1H-indol-5-carbaldehyd (3c) according to Schlosser et al.[69] 
Analogously prepared as the aldehyde 1c but starting from 7-fluoro-1-
(triisopropylsilyl)indole (3b) giving the desired product as a colorless solid 
in 63 % yield. 
1H-NMR (DMSO) δ 10.32 (s, 1H), 7.71 (d, 1H, J = 2.6 Hz), 7.52 (dd, 1H, J = 8.2 Hz, J = 12.6 
Hz), 7.51 (d, 1H, J = 7.1 Hz), 6.82 (s, 1H), 1.69 (sept, 3H, J = 7.2 Hz), 1.07 (d, 18H, J = 7.5 
Hz); 13C-NMR (DMSO) δ 187.51 (J = 8.3 Hz), 153.08 (J = 257.1 Hz), 140.90 (J = 7.6 Hz), 
138.37, 126.92 (J = 9.4 Hz), 119.6, 117.36, 106.80, 18.25, 13.14 (J = 5.2 Hz); 19F-NMR 
(DMSO) δ -133.15; HRMS: C18H26FNOSi [M+H]
+ calcd. 320.1840 found 320.1840; E.A.: 
calcd. C: 67.67 H: 8.20 N: 4.38 found C: 67.42 H: 8.24 N: 4.35  
 
6-Fluoro-1H-indole-5-carbaldehyde (1d) according to Schlosser et al.[69] 
4.1 mL of a 1.0 M solution of TBAF in THF were added to a solution of 1.3 g 
(4.0 mmol) of 1-triisopropylsilyl-6-fluoro-1H-indole-5-carbaldehyde (1c) in  
5 mL THF. The reaction mixture was stirred for 5 min at room temperature, 
quenched by the addition of water and extracted repeatedly with Et2O. The 
combined organic layers were dried over Na2SO4 filtered and the solvent was removed in 
vacuo. Purification by column chromatography (PE/EA = 3:2) gave 560 mg (3.4 mmol,  
86 %) of the desired 6-fluoro-1H-indole-5-carbaldehyde (1d) as a colorless solid. 
M.p.: decomposition at 125 – 128 °C 
1H-NMR (DMSO) δ 11.60 (s, 1H), 10.16 (s, 1H), 8.06 (d, 1H, J = 6.8 Hz), 7.47 (t, 1H, J = 3 
Hz), 7.28 (d, 1H, J = 12 Hz), 6.61 (s, 1H); 13C-NMR (DMSO) δ 188.18 (J = 4.9 Hz), 160.16 (J 
= 245.7 Hz), 139.72 (J = 13.4 Hz), 128.83 (J = 2.7 Hz), 124.91, 123.22 (J = 3.8 Hz), 117.88 (J 
= 10.7 Hz), 103.728, 98.43 (J = 24.8 Hz); 19F-NMR (DMSO) δ -130.24; HRMS: C9H6FNO 
[M+H]+ calcd. 164.0506 found 164.0506; E.A.: calcd. C: 66.26 H: 3.71 N: 8.59 found C: 
65.80 H: 3.75 N: 8.55 
 
4-Fluoro-1H-indole-5-carbaldehyde (2d) according to Schlosser et al.[69] 
Analogously prepared as compound 1d while starting from 1-
triisopropylsilyl-4-fluoro-1H-indol-5-carbaldehyd (2c); colorless solid; 89% 
1H-NMR (DMSO) δ 11.89 (s, 1H), 10.27 (s, 1H), 7.49 (t, 2H, J = 6.8 Hz), 
N
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7.33 (d, 1H, J = 8.4 Hz), 6.68 (s, 1H); 13C-NMR (DMSO) δ 187.23 (J = 6.9 Hz), 159.50 (J = 
259.5 Hz), 142.84 (J = 13 Hz), 128.18, 120.45, 116.21 (J = 20.6 Hz), 115.15 (J = 5.4 Hz), 
109.38 (J = 3 Hz), 99.33; 19F-NMR (DMSO) δ -129,01; HRMS: C9H6FNO [M+H]
+ calcd. 
164.0506 found 164.0506; E.A.: calcd. C: 66.26 H: 3.71 N: 8.59 found C: 65.76 H: 3.73 N: 
8.54 
 
7-Fluoro-1H-indole-6-carbaldehyde (3d) according to Schlosser et al.[69] 
Analogously prepared as aldehyde 1d but starting from 1-triisopropylsilyl-7-
fluoro-1H-indol-5-carbaldehyd (3c) giving the desired product as a colorless 
solid in 88 % yield. 
1H-NMR (DMSO) δ 10.28 (s, 1H), 7.67-7.34 (m, 2H), 7.41-7.37 (m, 1H), 6.59 (s, 1H); 13C-
NMR (DMSO) δ 187.32 (J = 6.8 Hz), 152.7 (J = 258.9 Hz), 137.00 (J = 7.8 Hz), 131.63, 
123.24 (J = 11.24 Hz), 117.92, 116.97 (J = 2.9 Hz), 116.46 (J = 3.4 Hz), 103.66 (J = 1.2 Hz); 
19F-NMR (DMSO) δ -140.48; HRMS: C9H6FNO [M+H]
+ calcd. 164.0506 found 164.0505; 
E.A.: calcd. C: 66.26 H: 3.71 N: 8.59 found C: 65.89 H: 3.75 N: 8.62 
 
1-Benzyl-6-fluoro-1H-indole-5-carbaldehyde (1e) 
A solution of 270 mg (1.7 mmol) of 6-fluoro-1H-indole-5-carbaldehyde (1d) 
in 5 mL DMF was cooled to 0 °C, and 100 mg (2.5 mmol) of a 60% 
dispersion of NaH in mineral oil were added. The resulting solution was 
stirred for 20 min at 0 °C before 296 µL (2.5 mmol) benzyl bromide were 
added. Then, the reaction mixture was warmed to room temperature and 
stirred for 12 h. Water was added, followed by repeated extraction with Et2O. The combined 
organic layers were dried over Na2SO4, and the solvent was evaporated in vacuo. Purification 
by column chromatography gave 371 mg (1.46 mmol, 86 %) of 1-benzyl-6-fluoro-1H-indole-
5-carbaldehyde (1e) as a colorless solid. 
1H-NMR (DMSO) δ 10.17 (s, 1H), 8.08 (d, 1H, J = 6.8 Hz), 7.63 (d, 1H, J = 3.1 Hz), 7.54 (d, 
1H, J = 12.5 Hz), 7.32-7.22 (m, 5H), 5.43 (s, 2H); 13C-NMR (DMSO) δ 188.09 (J = 5.3 Hz), 
160.31 (J = 246.4 Hz), 139.58 (J = 13 Hz), 137.86, 132.67 (J = 3.1 Hz), 129.12, 128.06, 
127,65, 125.32, 123.59 (J = 3.8 Hz), 118.04 (J = 10.7 Hz), 104.07, 97.68 (J = 26 Hz), 49.77; 
19F-NMR (DMSO) δ -128.90; HRMS: C16H12FNO [M+H]
+ calcd. 254.0976 found 254.0975; 
E.A.: calcd. C: 75.88 H: 4.78 N: 5.53 found C: 75.27 H: 4.86 N: 5.27 
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1-Benzyl-4-fluoro-1H-indole-5-carbaldehyd (2e) 
Analogously prepared as the aldehyde 1e while starting from 4-fluoro-1H-
indole-6-carbaldehyde (2d) giving the desired product as a colorless solid in 
88 % yield. 
1H-NMR (DMSO) δ 10.26 (s, 1H), 7.68 (d, 1H, J = 3.2 Hz), 7.49 (dd, 1H, J = 
8.8 Hz, J = 8.4 Hz), 7.30-7.20 (m, 5H), 6.75 (d, 1H, J = 2.8 Hz), 5.47 (s, 2H); 
13C-NMR (DMSO) δ 187.24 (J = 6.1 Hz), 159.24 (J = 260.1 Hz), 142.27 (J = 13 Hz), 137.81, 
132.00, 129.01 (J = 20.6 Hz), 128.11 (J = 7.6 Hz), 127.50, 116.76 (J = 20.6 Hz), 115.40 (J = 
5.3 Hz), 108.21 (J = 3.1 Hz), 99.45, 49.94; 19F-NMR (DMSO) δ -128.90; HRMS: C16H12FNO 
[M+H]+ calcd. 254.0976 found 254.0975; E.A.: calcd. C: 75.88 H: 4.78 N: 5.53 found C: 
75.27 H: 4.86 N: 5.27 
 
1-Benzyl-7-fluoro-1H-indole-6-carbaldehyd (3e) 
Analogously prepared as the aldehyde 1e, but starting from 7-fluoro-1H-
indole-6-carbaldehyde (3d) giving the desired product as a colorless solid in 
82 % yield. 
1H-NMR (CDCl3) δ 10.36 (s, 1H), 7.52 (dd, 1H, J = 5.9 Hz, J = 2.1 Hz), 7.39 
(d, 1H, 8.3 Hz), 7.33-7.24 (m, 4H), 7.13 (d, 2H, J = 7.0 Hz), 6.58 (s, 1H), 5.51 (s, 2H); 13C-
NMR (CDCl3) δ 187.03 (J = 8.7 Hz), 153.67 (J = 258.8 Hz), 137.76 (J = 7.4 Hz), 137,36, 
133.88, 128.90, 127.98, 126.70, 122.98 (J = 8.1 Hz), 118.44, 117.61 (J = 4.5 Hz), 117.13 (J = 
3.3 Hz), 103.67 (J = 1.2 Hz), 52.65 (J = 5.6 Hz); 19F-NMR (CDCl3) δ -148.05; HRMS: 
C16H12FNO [M+H]
+ calcd. 254.0976 found 254.0976; E.A.: calcd. C: 75.88 H: 4.78 N: 5.53 
found C: 75.57 H: 4.80 N: 5.49  
 
1-Methyl-6-fluoro-1H-indole-5-carbaldehyde (1f) 
A solution of 80 mg (0.5 mmol) of 6-fluoro-1H-indole-5-carbaldehyde (1d) 
in 5 mL DMF was cooled to 0 °C, and 30 mg (0.75 mmol) of a 60% 
dispersion of NaH in mineral oil were added. The resulting solution was 
allowed to stir for 20 min at 0 °C, before 100 µL (1.6 mmol) iodomethane 
were added. The reaction mixture was allowed to reach room temperature and then stirred for 
further 12 h. Water was added followed by repeated extraction with Et2O. The combined 
organic layers were dried over Na2SO4, and the solvent was evaporated in vacuo. Purification 
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by column chromatography gave 52 mg (0.29 mmol, 58 %) of 1-methyl-6-fluoro-1H-indole-
5-carbaldehyde (1f) as an off white solid. 
M.p.: 108 – 110 °C 
1H-NMR (DMSO) δ 10.21 (s, 1H), 8.09 (d, 1H, J = 6.8 Hz), 7.52-7.46 (m, 2H), 6.67 (dd, 1H, 
J = 0.9 Hz, J = 3.2 Hz), 3.82 (s, 3H); 13C-NMR (DMSO) δ 188.18 (J = 5.3 Hz), 160.29 (J = 
245.8), 140.16 (J = 13.0 Hz), 133.14 (J = 3.1 Hz), 125.09 (J = 0.6 Hz), 123.46 (J = 4.0 Hz), 
117.79 (J = 10.8 Hz), 103.38, 97.33 (J = 25.2 Hz, 33.41; 19F-NMR (DMSO) δ -129.49; 
HRMS: C10H8FNO [M+Na]
+ calcd. 200.0482 found 200.0482; E.A.: calcd. C: 67.79 H: 4.55 
N: 7.91 found C: 66.42 H: 4.61 N: 7.61 
 
1-Boc-6-fluoro-1H-indole-5-carbaldehyde (1g), according to Koning et al.[159] 
To a solution of 100 mg (0.61 mmol) of 6-fluoro-1H-indole-5-carbaldehyde 
(1d) in 7 mL THF were added 7.3 mg (0.06 mmol) DMAP and 152 mg (0.7 
mmol) Boc2O. The resulting solution was stirred for 4 h at room 
temperature. Water was added followed by repeated extraction with Et2O. 
The combined organic layers were dried over Na2SO4 and the solvent was evaporated in 
vacuo. Purification by column chromatography gave 136 mg (0.48 mmol, 72 %) of 1-Boc-6-
fluoro-1H-indole-5-carbaldehyde (1g) as a colorless solid. 
M.p.: 91 -93 °C 
1H-NMR (DMSO) δ 10.38 (s, 1H), 8.05 (d, 1H, J = 6.7 Hz), 7.95 (d, 1H, J = 11.2 Hz), 7.62 
(d, 1H, J = 3.6 Hz), 6.63 (d, 1H, J = 3.8 Hz), 1.68 (s, 9H); 13C-NMR (DMSO) δ 187.43 (J = 
6.8 Hz), 162.63 (J = 249.8 Hz), 148.97, 139.08 (J = 13.2 Hz), 127.96 (J = 3.1 Hz), 127.01, 
121.33 (J = 3.1 Hz), 120.27 (J = 10.1 Hz), 107.81, 102.95 (J = 28.1 Hz), 85.03, 28.10; 19F-
NMR (DMSO) δ -126.44; HRMS: C16H12FNO3S [M+Na]
+ calcd. 286.0849 found 286.0849; 
E.A.: calcd. C: 63.87 H: 5.36 N: 5.32 found C: 63.71 H: 5.38 N: 5.23 
 
1-Boc-4-fluoro-1H-indole-5-carbaldehyde (2g), according to Koning et al.[159] 
Analogously prepared as the aldehyde 1e, but starting from 7-fluoro-1H-
indole-6-carbaldehyde (3d) giving the desired product as a colorless solid in 
82 % yield.  
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M.p.: 112 – 114 °C 
1H-NMR (CDCl3) δ 10.48 (s, 1H), 8.06 (d, J = 8.7 Hz, 1H), 7.82 (dd, J = 8.7 Hz, J = 6.5 Hz, 
1H), 7.67 (d, J = 3.8 Hz, 1H), 6.81 (d, J = 3.8 Hz, 1H), 1.73 (s, 9H); 13C-NMR (CDCl3) δ 
186.91 (J = 7.0 Hz), 158.72 (J = 247.38), 149.84, 141.57, 127.28, 123.65 (J = 1.62 Hz), 
119.27 (J = 20.7 Hz), 118.20 (J = 5.5 Hz), 111.94 (J = 3.8 Hz), 103.41, 85.24, 28.11; 19F-
NMR (CDCl3) δ -129.58; HRMS: C16H12FNO3S [M+Na]
+ calcd. 286.0849 found 286.0850; 
E.A.: calcd. C: 62.77 H: 5.36 N: 5.32 found C: 63.31 H: 5.22 N: 5.21 
 
1-Tosyl-6-fluoro-1H-indole-5-carbaldehyde (1h), according to Konas et al. [160] 
A solution of 150 mg (0.92 mmol) of 6-fluoro-1H-indole-5-carbaldehyde 
(1d) in 5 mL DMF was cooled to 0 °C, and 55 mg (1.38 mmol) of a 60% 
dispersion of NaH in mineral oil were added. The resulting solution was 
allowed to stir for 20 min at 0 °C, before 263 mg (1.38 mmol) tosyl 
chloride was added. The reaction mixture was allowed to reach room temperature and stirred 
for further 12 h. Water was added followed by repeated extraction with Et2O. The combined 
organic layers were dried over Na2SO4, and the solvent was evaporated in vacuo. Purification 
by column chromatography gave 239 mg (0.75 mmol, 82 %) of 1-tosyl-6-fluoro-1H-indole-5-
carbaldehyde (1h) as an off white solid. 
1H-NMR (DMSO) δ 10.15 (s, 1H), 8.06 (d, 1H, J = 6.7 Hz), 7.94 (d, 2H, J = 9.2 Hz), 7.90 (d, 
1H, J = 3.5 Hz), 7.81 (d, 1H, J = 11.4 Hz), 7.37 (d, 1H, J = 8.0 Hz), 6.93 (d, 1H, J = 3.4 Hz), 
2.27 (s, 3H); 13C-NMR (DMSO) δ 187.95 (J = 5.4 Hz), 161.43 (J = 251.0 Hz), 146.60, 137.63 
(J = 13.0 Hz), 134.06, 130.91, 129.44 (J = 3.5 Hz), 127.42 (J = 4.2 Hz), 127.39, 123.69 (J = 
3.6 Hz), 121.04 (J = 10.6 Hz), 110.24, 101.35 (J = 27.3 Hz), 21.47; 19F-NMR (DMSO) δ -
124.12; HRMS: C16H12FNO3S [M+H]
+ calcd. 318.0595 found 318.0594; E.A.: calcd. C: 
60.56 H: 3.81 N: 4.41 found C: 60.35 H: 3.95 N: 4.46 
 
1-Benzyl-7-bromo-4-fluoro-1H-indole (4d) 
A solution of 612 mg (2.9 mmol) of 7-bromo-4-fluoro-1H-indole in dry 
DMF was cooled to 0 °C, and 173 mg (4.3 mmol) of a 60% dispersion 
of NaH in mineral oil was added. After 20 min 510 µL (735 mg, 4.3 
mmol) benzyl bromide were added and the reaction mixture was 
allowed to warm up to room temperature and stirred overnight. Water 
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was added, and the aqueous phase was repeatedly extracted with Et2O. The combined organic 
layers were dried over Na2SO4, and the solvent was removed in vacuo. The crude product was 
purified by column chromatography yielding 711 mg (2.4 mmol, 81 %) of 1-benzyl-7-bromo-
4-fluoro-1H-indole (4d) as colorless oil. 
1H-NMR (DMSO) δ 7.33-7.25 (m, 4H), 7.12-7.03 (m, 3H), 6.71 (dd, 2H, J = 10.5 Hz, J = 9.4 
Hz), 5.87 (s, 2H); HRMS: C15H11BrFN [M+Na]
+ calcd. 304.0131 found; no corresponding 
peak could be detected; E.A.: calcd. C: 63.87 H: 5.36 N: 5.32 found C: 63.71 H: 5.38 N: 5.23 
 
1-Benzyl-4-fluoro-1H-indole-7-carbaldehyde (4e), according to Boymond et al.[191] 
A solution of 420 mg (1.4 mmol) of 4d in 5 mL THF was cooled to  
-78 °C, and 560 µL (1.4 mmol) of a 2.5 M solution of n-BuLi in 
hexanes were added. The mixture was stirred for 30 min, before 500 
µL DMF were added, followed by warming to room temperature and 
stirring for 3 h. Water was added, and the aqueous phase was 
repeatedly extracted with Et2O. The combined organic fractions were dried over Na2SO4, and 
the solvent was evaporated in vacuo. The crude product was purified by column 
chromatography yielding 134 mg (0.5 mmol, 39 %) of 1-benzyl-4-fluoro-1H-indole-7-
carbaldehyde (4e) as a colorless solid. 
M.p.: 75 – 77 °C 
1H-NMR (DMSO) δ 10.05 (s, 1H), 7.81 (dd, J = 8.4 Hz, J = 5.7 Hz, 1H), 7.71 (d, J = 3.2 Hz, 
1H), 7.21-7.10 (m, 6H), 6.98 (t, J = 21.0 Hz, 1H), 6.90 (d, J = 1.3 Hz), 6.82 (d, J = 3.3 Hz), 
5.97 (s, 2H); 13C-NMR (DMSO) δ 190.33, 159.89 (J = 154.01 Hz), 138.62, 136.15 (J = 12.9 
Hz), 132.14, 132.05 (J = 9.8 Hz), 129.09, 127.73, 126.50, 120.46, 105.39 (J = 19.7 Hz), 
98.85, 53.72, 28.54; 19F-NMR (DMSO) δ -111.47; HRMS: C15H11BrFN [M+Na]
+ calcd. 
304.0131 found; no corresponding peak could be detected; E.A.: calcd. C: 63.87 H: 5.36 N: 
5.32 found C: 63.71 H: 5.38 N: 5.23 
 
4.3  Synthesis of the precursor for L-6-fluorotryptophan by build-up synthesis 
3-(Trimethylsilyl)prop-2-yn-1-ol (17), as described by Ma et al.[179] 
To a solution of propargyl alcohol (1.0 mL, 17.2 mmol) in 45 mL THF 
were added 21.0 mL of a 2.5 M solution of n-BuLi in hexanes at -78 °C. 
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The solution was stirred for 30 min at –78 °C before 7.7 mL (60 mmol) TMS-Cl was added. 
The reaction mixture was warmed to room temperature and stirred for one more hour. 25 mL 
water and 25 mL 10 % hydrochloric acid were subsequently added and the mixture was 
repeatedly extracted with Et2O. The organic layers were dried over Na2SO4 and the solvents 
were removed under reduced pressure. Purification by flash chromatography gave the desired 
product 17 in 97 % yield as a colorless oil. Rf = 0.25 (PE/EA = 9:1) 
1H-NMR (CDCl3) δ 4.30 (s, 2H), 1.89 (broad s, 1H), 0.20 (s, 9H) 
 
3-(Trimethylsilyl)prop-2-yn-1-tosylate (18), according to by Ma et al.[179] 
A solution of 500 mg (3.9 mmol) of the alcohol 17 in Et2O was cooled to 
–50 °C before tosyl chloride (900 mg, 4.7 mmol) was added. The 
solution was stirred for 15 min followed by the addition of powdered KOH (700 mg, 12.4 
mmol). The reaction mixture was slowly warmed to 0 °C and stirred for about 1.5 h at this 
temperature. 30 mL ice water were added and the aqueous phase was extracted with Et2O. 
The combined organic layers were dried over Na2SO4 and the solvent was removed under 
reduced pressure. Purification via flash chromatography gave the desired tosylate 18 in 87 % 
(960 mg, 3.4 mmol) yield as a colorless oil. 
1H-NMR (CDCl3) δ7.86 (d, 2H, J = 8.3 Hz), 7.33 (d, 2H, J = 12.0 Hz), 4.75 (s, 2H), 2.49 (s, 
3H), 0.12 (s, 9H) 
 
(S,S)2-Tert-butyl-3-methyl-4-oxo-5-[3-(trimethylsilyl)prop-2-yn-1-yl]imidazolidine-1-
carboxylate (15) 
At -78 °C n-BuLi in hexane (0.73 mL, 1.8 mmol) was added to a 
solution of diisopropylamine (256 µL, 1.8 mmol) in 1.5 mL THF. 
The resulting solution was stirred for 30 min, before a solution of 
Boc-BMI (380 mg, 1.5 mmol) in 3 mL THF was added. After another 30 min of stirring at  
-78 °C a solution of 18 in 1.5 mL THF was added, and the reaction mixture was allowed to 
reach room temperature. After stirring for 3 h, the reaction was quenched with water and the 
aqueous phase was repeatedly extracted with Et2O. The combined organic layers were dried 
over Na2SO4, and the solvent was evaporated in vacuo. Purification by flash chromatography 
(PE/EA = 4:1, Rf = 0.29) gave the desired product 15 in 82 % (429 mg, 1.2 mmol) yield as a 
colorless solid. 
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M.p.: 133- 135 °C 
1H-NMR (CDCl3) δ 5.09 (s, 1H), 4.02 (s, 1H), 3.36 (d, 1H, J = 14.2 Hz) 3.10 (s, 3H), 2.88 (d, 
1H, J = 16.6 Hz), 1.55 (s, 9H), 1.00 (s, 9H), 0.12 (s, 9H) 
 
3-Fluoro-4-iodoaniline (20), according to Emmanuvel et al.[180] 
KI (1.46 g, 8.8 mmol) was added to a solution of 2-fluoroaniline (1.0 g, 8.8 mmol), 
NaIO4 (1.88 g, 8.8 mmol) and NaCl (1.0 g, 17.2 mmol) in a mixture of acetic acid 
and water and the reaction mixture was stirred for 3 h at room temperature.  
30 mL ice water was added, and the aqueous phase was extracted several times 
with DCM. The combined organic extracts were dried over Na2SO4, and the solvent was 
evaporated under reduced pressure. Purification by flash chromatography gave the desired 
aniline 20 in 82 % (1.7 g, 7.2 mmol) yield as a yellow solid.  
M.p.: 65 – 67 °C (Lit. 67 – 68.5 °C[203]) 
1H-NMR (CDCl3) δ 7.45 (dd, 1H, J = 8.5 Hz, J = 7.2 Hz), 6.46 (dd, 1H, J = 9.9 Hz, J = 2.6 
Hz), 6.31 (dd, 1H, J = 8.3 Hz, J = 2.5 Hz), 3.85 (broad s, 2H) 
 
3-Fluoro-4-bromoaniline (22), according to Majetich et al.[182] 
To a solution of 3-fluoroaniline (4.0 g, 36 mmol) in 15 mL DMSO was added  
5 mL aqueous HBr (48 %) at about 10 °C. The reaction mixture was stirred for 6 h 
at room temperature before water was added. Afterwards NaOH was added until 
the solution was basic. The aqueous phase was repeatedly extracted with Et2O and 
the combined organic extracts were dried over Na2SO4. The solvent was evaporated under 
reduced pressure. Flash chromatography (PE/EA = 4:1, Rf = 0.26) of the crude mixture 
provided 3-fluoro-4-bromoaniline (22) as a yellowish solid in 82 % (5.5 g, 29 mmol) yield. 
M.p.: 58 - 61 °C (Lit. 63  65 °C[204]) 
1H-NMR (CDCl3) δ 7.28 (dd, 1H, J = 8.3 Hz, J = 4.4 Hz), 6.49 (dd, 1H, J = 10.4 Hz, J = 2.6 
Hz), 6.39 (dd, 1H, J = 8.6 Hz, J = 2.6 Hz), 3.75 (broad s, 2H 
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1-Boc-3-fluoro-4-bromoaniline (23) according to Peterson et al.[205] 
To a solution of 3-fluoro-4-bromo-aninline (22) (743 mg, 3.9 mmol) in THF/H2O 
(18 mL, 50:50) were added K2CO3 (1.0 g, 7.8 mmol) and Boc2O (850 mg, 3.9 
mmol) subsequently. The mixture was stirred overnight at room temperature 
before it was extracted with Et2O for several times. The combined organic extracts 
were dried over Na2SO4 and the solvent was removed under reduced pressure. The crude 
mixture was purified by flash chromatography giving the desired product in 64 % (725 mg, 
2.5 mmol) yield as a yellow solid. 
M.p.: 64 – 68 °C 
1H-NMR (CDCl3) δ 7.49-7.38 (m, 2H), 6.94 (ddd, J = 8.7 Hz, J = 2.5 Hz, J = 1.0 Hz, 1H), 
6.70 (broad s, 1H), 1.55 (s, 9H); 13C-NMR (CDCl3) 161.66, 149.54 (J = 274.6 Hz), 139.35 (J 
= 10.1 Hz), 133.21 (J = 1.6 Hz), 114.92 (J = 3.3 Hz), 106.89 (J = 27.4 Hz), 101.55 (J = 21.1 
Hz), 81.34, 28.30; 19F-NMR (CDCl3) -105.68  
 
1-Boc-3-fluoro-4-formylaniline (25)   
Method A: (according to Boymond et al.[191]) 0.1 mL dioxane was added to a 
solution of i-PrMgCl.LiCl in THF (1.7 mL, 1.7 mmol) at 0 °C. The solution was 
stirred for 5 min before the bromide 23 (384 mg, 1.3 mmol) in 1 mL THF was 
added. The reaction mixture was stirred at 0 °C for 1 h. Then 200 µL DMF (2.6 
mmol) were added, the solution was warmed to room temperature and stirred for further 3 h at 
this temperature. A saturated aqueous solution of NH4Cl was added followed by extraction 
with Et2O. The combined organic extracts were dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. Flash chromatography of the crude mixture (PE/EA = 
95:5, Rf = 0.14) provided the desired product in 97 % yield as a colorless solid. 
Method B: (according to Qin et al.[183]) To a solution of 4-bromo-2-fluorobenzaldeyde (24) 
(500 mg, 2.5 mmol) in dry dioxane were added Pd(OAc)2 (17 mg, 0.075 mmol), XPhos (110 
mg, 0.225 mmol), t-butylcarbamate (350 mg, 3 mmol) and Cs2CO3 (1.1 g, 3.5 mmol). The 
reaction mixture was heated to 100 °C for 4 h, cooled to room temperature and extracted 
repeatedly with EtOAc. The combined organic extracts were dried over Na2SO4, filtered and 
the solvent was evaporated under reduced pressure. Flash chromatography of the crude 
mixture (PE/EA = 95:5, Rf = 0.14) provided the desired product 25 in 95 % (560 mg, 2.3 
mmol) yield as a colorless solid. 
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1H-NMR (CDCl3) δ 10.25 (s, 1H), 7.81 (t, 1H, J = 8.5 Hz), 7.59 (dd, 1H, J = 13.0 Hz, J = 2.0 
Hz), 7.06 (dd, 1H, J = 8.5 Hz, J = 2.0 Hz), 1.55 (s, 9H); 13C-NMR (CDCl3) δ 186.15 (J = 6.0 
Hz), 165.85 (J = 255.3 Hz), 151.79, 146.12 (J = 12.6 Hz), 129.51 (J = 3.6 Hz), 118.93 (J = 8.3 
Hz), 113.73 (J = 2.9 Hz), 105.04 (J = 26.4 Hz), 82,01, 28,20; 19F-NMR (CDCl3) δ -119.31 
 
1-Boc-4-(1,3-dithiolan-2-yl)-3-fluoroaniline (26), according to Firouzabadi et al. [186] 
 To a solution of the benzaldehyde 25 (370 mg, 1.54 mmol) and elemental iodine 
(20 mg, 0.16 mmol) in DCM 155 µL (1.84 mmol) 1,2-ethanedithiol were added. 
The mixture was stirred at room temperature for 1 h before water was added. The 
aqueous phase was repeatedly extracted with DCM. The combined organic 
extracts were dried over Na2SO4, filtered, and the solvent was evaporated under 
reduced pressure. Purification of the crude mixture by flash chromatography provided the 
desired product as a colorless solid in 90 % (437 mg, 1.38 mmol) yield as a slightly yellow 
solid. 
1H-NMR (CDCl3) δ 7.63 (t, 1H, J = 8.5 Hz), 7.34 (dd, 1H, J = 12.4 Hz, J = 2.1 Hz), 6.97 (dd, 
1H, J = 8.5 Hz, J = 2.1 Hz), 6.60 (s, 1H), 5.94 (s, 1H), 3.52-3.35 (m, 4H), 1.55 (s, 9H) 
 
4-(1,3-Dithiolan-2-yl)-3-fluoroaniline (27) 
5 mL TFA were added to a solution of the dithiolan 26 (390 mg, 1.23 mmol) in 5 
mL DCM. The reaction mixture was stirred for 1 h at room before water was 
added. Na2CO3 was added until the solution was basic followed by repeated 
extraction with DCM. The combined organic extracts were dried over Na2SO4, 
filtered, and the solvent was evaporated under reduced pressure. The crude mixture 
was purified by flash chromatography (PE/EA = 4:1, Rf = 0.23) giving the desired product in 
77 % (206 mg, 0.95 mmol) yield as a yellow solid. 
1H-NMR (CDCl3) δ 7.51 (t, 1H, J = 8.5 Hz), 6.45 (dd, 1H, J = 8.4 Hz, J = 2.3 Hz), 6.35 (dd, 
1H, J = 12.0 Hz, J = 2.3 Hz), 5.94 (s, 1H), 3.85 (s, 2H), 3.55-3.28 (m, 4H) 
 
3-Fluoro-4,6-diodoaniline (14), according to Emmanuvel et al.[180] 
KI (2.9 g, 17.6 mmol) was added to a solution of 2-fluoroaniline (1.0 g, 8.8 
mmol), NaIO4 (1.88 g, 8.8 mmol) and NaCl (1.0 g, 17.2 mmol) in a mixture of 
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acetic acid and water and the reaction mixture was stirred for 6 h at room temperature. 30 mL 
ice water were added and the aqueous phase was extracted several times with DCM. The 
combined organic extracts were dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. Purification by flash chromatography gave the desired aniline 29 in 88 % 
(2.8 g, 7.7 mmol) yield as a brown solid. 
1H-NMR (CDCl3) δ 7.93 (d, 1H, J = 6.8 Hz), 6.54 (d, 1H, J = 9.6 Hz), 4.29 (broad s, 2H); FT-
MS (ESI) C6H4FI2N m/z [M+H]
+
 calcd.: 363.849 found: 363.80 
 
4.4 Synthesis of the precursor of L-6-fluorotryptophan by linear synthesis 
5-(1,3-Dithiolan-2-yl)-6-fluoro-1-triisopropylsilyl-1H-indole (31) 
according to Firouzabadi et al. [186] 
To a solution of the indolecarbaldehyde 1c (2.5g, 7.9 mmol) and 
elemental iodine (100 mg, 0.79 mmol) in DCM were added 120 µL 
(9.5 mmol) 1,2-ethanedithiol. The reaction mixture was stirred for 1 h 
at room temperature and quenched with 40 mL 0.1 M Na2S2O3 and 40 
mL 0.1 M NaOH. The aqueous phase was extracted repeatedly with DCM, the organic layers 
were dried over Na2SO4, filtered, and the solvent was evaporated under reduced pressure. The 
crude mixture was purified by flash chromatography giving the desired product as a colorless 
solid in 40 % (1.23 g, 3.1 mmol) yield. 
1H-NMR (CDCl3) δ 7.98 (d, 1H, J = 7.8 Hz), 7.26-7.17 (m, 2H), 6.63 (dd, 1H, J = 3.3 Hz, J = 
0.9 Hz), 6.11 (s, 1H), 3.61-3.19 (m, 4H), 1.71 (hept, 3H, J = 7.7 Hz), 1.18 (d, 18H, J = 7.4 Hz) 
 
5-(1,3-Dithiolan-2-yl)-6-fluoro-1H-indole (32), according to Schlosser et al.[69] 
1 mL of a 1.0 M solution of TBAF in THF was added to a solution of the 
dithiolan 31 (1.2 g, 3 mmol) in THF. The mixture was stirred at room 
temperature for about 10 min before the solvent was evaporated. The 
crude product was purified by flash chromatography giving the desired 
indole 32 as a colorless solid in 92 % (655 mg, 2.74 mmol) yield. 
1H-NMR (CDCl3) δ 8.11 (broad s, 1H), 7.98 (d, 1H, J = 7.4 Hz), 7.16 (t, 1H, J = 3.0 Hz), 7.03 
(d, 1H, J = 10.9 Hz), 6.53-6.50 (m, 1H), 6.07 (s, 1H), 3.57-3.30 (m, 4H) 
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6-Fluoro-5-iodo-1H-indole (35), as described by Schlosser et al.[69] 
sec-BuLi in hexane (20 ml, 28 mmol, 1.4 M) was added to solution of 8.0 g 
(27.5 mmol) 6-fluoro-1-triisopropyl-1H-indole (1b) and 5.8 ml  
N,N,N’,N’’,N’’-pentamethyldiethylenetriamine (4.9 g, 27.5 mmol) in 40 mL 
THF at –78 °C. The solution was stirred at this temperature for 6 h before 7.8 g (27.5 mmol) 
of 1,2-diiodoethane were added. The reaction mixture was slowly warmed up to room 
temperature and stirred overnight. Water was added, and the aqueous phase was repeatedly 
extracted with Et2O. The combined organic layers were dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude product 34, a brownish oil, was dissolved in 30 ml THF and 
7.1 g (27.1 mmol) TBAFxH2O were added. The mixture was stirred for 30 min at RT before 
water was added. The aqueous phase was extracted several times with Et2O. The organic 
layers were dried over Na2SO4, filtered, and the solvent was evaporated in vacuo. The crude 
residue was purified by flash chromatography (PE/EA = 4:1; Rf = 0.45) giving 4.7 g (17.9 
mmol, 65 %) of the desired product as a light green solid.  
M.p.: 32 – 36 °C (Lit. 37 – 39 °C[69]) 
1H-NMR (200 MHz, CDCl3) δ 8.21 (br s, 1H), 8.02 (d, 1H, J = 6.1 Hz), 7.30-7.16 (m, 2H), 
6.53-6.50 (m, 1H) 
 
6-Fluoro-5-iodo-1H-indole-3-carbaldehyde (36), according to Konas et al.[160] 
At 0 °C 5.7 mL POCl3 (35.5 mmol) were added to 16.0 mL DMF. The 
mixture was stirred at this temperature for 15 min before 4.1 g (15.6 mmol) 
of 6-fluoro-5-iodo-1H-indole (35) in 37 mL DMF were added. The solution 
was warmed up to RT and stirred until it became an opaque paste 
(approximately 1 h). 10 % NaOHaq was added until the pH of the solution was greater than 
10. The suspension was heated to reflux for 10 min before it was cooled to 0 °C. The 
precipitate was filtered and washed with water and Et2O. After drying under reduced pressure 
at 50 °C, the desired product was obtained as an off white solid (64 %, 2.9 g, 10.0 mmol). 
M.p.: decomposition at 289 – 291 °C 
1H-NMR (400 MHz, DMSO) δ 12.28 (s, 1H), 9.90 (s, 1H), 8.47 (d, 1H, J = 6.3 Hz), 8.32 (s, 
1H), 7.44 (d, 1H, J = 8.7 Hz); 13C-NMR (400 MHz, DMSO) δ 185.44, 157.77 (J = 234.5 Hz), 
139.89 (J = 1.9 Hz), 137.40 (J = 11.4 Hz), 130.46 (J = 3.2 Hz), 123.31 (J = 1.0 Hz), 117.22, 
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99.88 (J = 28.9 Hz), 75.72 (J = 28.0 Hz); 19F-NMR (400 MHz, DMSO) δ -100.44; HRMS: 
C8H7FINO2 [M+H]
+ calcd. 289.9473 found 381.2975; E.A.: calcd. C: 37.40 H: 1.74 N: 4.85 
found C: 37.54 H: 1.88 N: 4.86  
 
6-Fluoro-5-iodo-1-tosyl-1H-indole-3-carbaldehyde (37a), according to Konas et al.[160] 
A solution of 3.8 g (13.3 mmol) of 4-fluoro-5-iodo-1H-indole-3-
carbaldehyde (36) in 40 mL THF was cooled to 0 °C and 480 mg (20 mmol) 
of a 60 % dispersion of NaH in mineral oil was added. The resulting 
solution was stirred for 20 min at 0 °C before 3.8 g (20 mmol) Tos-Cl were 
added. The reaction mixture was warmed to RT and stirred for another 2 h. Water was added 
and the aqueous phase was repeatedly extracted with DCM. The combined organic extracts 
were dried over Na2SO4 and the solvent was removed in vacuo. Purification by flash 
chromatography (PE/EA = 4:1 Rf = 0.38) gave the desired product as a colorless solid (88 %, 
5.2 g, 11.7 mmol).  
M.p.: 191-192 °C 
1H-NMR (400 MHz, CDCl3) δ 10.02 (s, 1H), 8.65 (d, 1H, J = 6.2 Hz), 8.19 (s, 1H), 7.83 (d, 
2H, J = 8.1 Hz), 7.69 (d, 1H, J = 8.3 Hz), 7.32 (d, 2H, J = 8.1 Hz), 2.39 (s, 3H); 13C-NMR 
(400 MHz, CDCl3) δ 184.70, 159.51 (J = 242.0 Hz), 146.63, 136.51 (J = 3.2), 135.25 (J = 
11.2 Hz), 133.71, 132.60 (J = 2.8 Hz), 130.47, 127.13, 124.16 (J = 2.0 Hz), 120.86 (J = 0.9 
Hz), 100.71 (J = 31.3 Hz), 78.44 (J = 27.3 Hz), 21.63 ; 19F-NMR (400 MHz, CDCl3) δ -93.31; 
HRMS: C16H11FINO3S [M+H]
+ calcd. 443.9561 found 443.9561; E.A.: calcd. C: 43.36 H: 
2.50 N: 3.16 found C: 43.05 H: 2.59 N: 3,11 
 
[6-Fluoro-5-iodo-1-tosyl-1H-indol-3-yl]methanol (38a), according to Konas et al.[160] 
541 mg (14.3 mmol) NaBH4 were added to a solution of 4.2 g of 37 (9.5 
mmol) in 150 mL THF/EtOH (2:1) at 0 °C. The resulting solution was 
warmed to RT and stirred for 30 min. Saturated NH4Claq was added and 
the mixture was extracted with DCM. The combined organic extracts were 
washed with brine, dried over Na2SO4 and filtered. Evaporation of the solvent gave the 
desired product as a colorless solid (97 %, 4.1 g, 9.2 mmol).  
M.p.: 171-172 °C 
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1H-NMR (200 MHz, CDCl3) δ 8.13 (d, 1H, J = 6.3 Hz), 7.92 (d, 2H, J = 8.3 Hz), 7.81 (d ( 1H, 
J = 8.9 Hz), 7.70 (s, 1H), 7.41 (d, 2H, J = 8.5 Hz), 5.23 (t, 1H, J = 5.6 Hz), 4.58 (d, 2H, J = 5.4 
Hz), 2.34 (s, 3H); 13C-NMR (200 MHz, CDCl3) δ 158.77 (J = 136.7 Hz), 146.32, 135.29, 
135.06. 134.26, 130.80, 128.61, 127.33, 125.00 (J = 3.8 Hz), 123.53 (J = 1.3 Hz), 101.82 (J = 
31.3 Hz), 77.54 (J = 28.1 Hz), 55.23, 21.53; 19F-NMR (200 MHz, CDCl3) δ -97.75; HRMS: 
C16H13FINO3S [M+H]
+ calcd. 445.9718 found 427.9612 (ohne OH); E.A.: calcd. C: 43.16 H: 
2.94 N: 3.15 found C: 43.32 H: 3.01 N: 3.13 
 
[3-(Bromomethyl)-6-fluoro-5-iodo-1-tosyl]-1H-indole (39a), according to Appel et al.[189] 
A solution of the alcohol 38 (2.0 g, 4.5 mmol) was cooled to 0 °C before 
PPh3 (1.3 g, 5.0 mmol) and CBr4 (1.7 g, 5.0 mmol) were added 
subsequently. The mixture was stirred at 0 °C and monitored by TLC 
(PE/EA = 4:1, Rf = 0.72). After approximately 30 min the reaction was 
finished and the solvent was partially removed in vacuo at room temperature. The oily residue 
was applied to a silica column and eluted with a mixture of PE/EA (4:1). Removal of the 
solvents under reduced pressure gave the desired product as a colorless solid (64 %, 1.4 g, 
2.8mmol).  
M.p.: decomposition at 184 – 186 °C 
1H-NMR (200 MHz, CDCl3) δ 8.03 (d, 1H, J = 5.9 Hz), 7.82-7.74 (m, 2H), 7.64 (s, 1H), 7.32 
(d, 2H, J = 7.3 Hz), 4.53 (s, 2H), 2.42 (s, 3H); 13C-NMR (200 MHz, CDCl3) δ 519.30 (J = 
240.5 Hz), 145.87, 135.53 (J = 11.4 Hz), 134.55, 130.28, 129.95, 129.89, 127.33, 127.29, 
126.95, 125.81 (J = 3.9 Hz), 117.80 (J = 1.4 Hz), 101.34 (J = 31.2 Hz), 22.77 (J = 8.7 Hz); 
19F-NMR (200 MHz, CDCl3) δ -95.54; HRMS: C16H12BrFINO2S [M+Na]
+ calcd. 529,8693 
found 529.8696, 531.8676 (C16H12
81BrFINO2S); E.A.: calcd. C: 37.82 H: 2.38 N: 2.76 found 
C: 37.79 H: 2.49 N: 2.51 
 
Benzyl (2S,5S)-2-tert-butyl-5-[(6-fluoro-5-iodo-1-tosyl-1H-indol-3-yl)methyl]-3-methyl-4-
oxoimidazolidine-1-carboxylate (40) 
n-BuLi in hexane (1.24 mL, 3.1 mmol) was added to a solution of 
diisopropylamine (435 µL, 3.1 mmol) in 3 mL THF at -78 °C. The 
resulting solution was stirred for 30 min before a solution of Z-BMI 
(772 mg, 2.7 mmol) in 3 ml THF was added. After another 30 min 
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of stirring at -78 °C a solution of the bromide 39 in 4.5 mL THF was added. The reaction was 
slowly warmed to RT and stirred overnight before it was quenched with saturated NH4Claq. 
Water was added and the aqueous phase repeatedly extracted with Et2O. The combined 
organic extracts were dried over Na2SO4, and the solvent was removed under reduced 
pressure. Purification of the crude product by flash chromatography (PE/EA = 7:3; Rf = 0.4) 
gave the desired product as a colorless solid (74 %, 1.4 g, 2.0 mmol).  
M.p.: 75 – 78 °C 
1H-NMR (200 MHz, CDCl3) δ 9.43 (s, 1H),  
13C-NMR (200 MHz, CDCl3) δ 171.52, 145.28, 134.90, 134,86, 134,68, 130.04, 129.42, 
129.39, 126.91, 115.65, 100.96, 100.33, 81.61, 81.19, 31.83, 28.21, 26.57, 21.59; 19F-NMR 
(200 MHz, CDCl3) δ -95.54; HRMS: C16H12BrFINO2S [M+Na]
+ calcd. 529.8693 found 
529.8696, 531.8676 (C16H12
81BrFINO2S); E.A.: calcd. C: 37.82 H: 2.38 N: 2.76 found C: 
37.79 H: 2.49 N: 2.51 
 
Benzyl (2S,5S)-2-tert-butyl-5-[(6-fluoro-5-formyl-1-tosyl-1H-indol-3-yl)methyl]-3-
methyl-4-oxoimidazolidine-1-carboxylate (41), according to Boymond et al.[191] 
1.7 mL of a 2.9 M solution of i-PrMgBr in THF were added to a 
solution of the iodide 40 (1.8 g, 2.5 mmol) in 5 mL THF at 0 °C. 
The resulting solution was stirred for 1 h at 0 °C before 770 µL 
DMF (10 mmol) were added. The reaction was warmed up to room 
temperature and stirred for another 3 h. Saturated NH4Claq was 
added, and the aqueous phase was extracted several times with 
Et2O. The combined organic extracts were dried over Na2SO4, and the solvent was removed 
under reduced pressure. Flash chromatography (PE/EA = 7:3, Rf = 0.27) of the crude mixture 
gave the desired product as a colorless solid (85 %, 1.3 g, 2.1 mmol).  
1H-NMR (200 MHz, CDCl3) δ 10.31 (s, 1H), 7.76-7.67 (m, 3H), 7.41-7.20 (m, 8H), 6.95 
(ddd, 1H, J = 9.0 Hz, J = 9.0 Hz, J = 2.5 Hz), 5.11 (q, 2H, J = 11.8 Hz), 4.60 (s, 1H), 4.38 (s, 
1H), 3.94 (s, 1H), 3.29 (d, 1H, J = 14.3 Hz), 3.08 (s, 1H), 2.64 (s, 3H), 2.36 (s, 3H), 0.91 (s, 
9H); 19F-NMR (200 MHz, CDCl3) δ -124.90; HRMS: C33H34FN3O6S [M+H]
+
 calculated 
620.2225 found 620.2227; E.A.: calculated C: 63.96 H: 5.53 N: 6.78 found C: 64.42 H: 4.96 
N: 7.42 
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Benzyl (2S,5S)-2-tert-butyl-5-[(6-fluoro-5-formyl-1H-indol-3-yl)methyl]-3-methyl-4-oxo-
imidazol-idine-1-carboxylate (42), according to Yasuhara et al.[170] 
3.5 mL of 1.0 M solution of TBAF in THF were added to a solution 
of 432 mg (0.7 mmol) 41 in 10 mL THF. The resulting mixture was 
heated to reflux for 3 h, cooled to room temperature, and the solvent 
was evaporated in vacuo. Flash chromatography of the crude 
mixture gave the desired product as a colorless solid in 91 % (297 
mg, 0.64 mmol) yield.  
1H-NMR (CDCl3) δ 8.04-7.65 (m, 3H), 7.44-7.15 (m, 9H), 5.10 (d, J = 3.6 Hz, 2H), 4.62 (s, 
1H), 4.38 (s, 1H), 3.88 (s, 1H), 3.24 (d, J = 14.7 Hz, 1H), 2.77 (s, 3H), 2.38 (s, 3H), 0.92 (s, 
9H); 19F-NMR (CDCl3) δ -95.67; HRMS C26H28FN3O4 [M+H]
+ calculated 466.2137 found 
466.2141 
 
Benzyl (2S,5S)-2-tert-butyl-5-[(1-benzyl-4-fluoro-5-formyl-1H-indol-3-yl)methyl]-3-
methyl-4-oxoimidazolidine-1-carboxylate (43) 
A dispersion of NaH in mineral oil (16 mg, 0.4 mmol) was added to 
a solution of 42 (200 mg, 0.38 mmol) in 5 mL DMF at 0 °C. The 
reaction mixture was stirred at 0 °C before 70 µL benzyl bromide 
were added, and the mixture was warmed to room temperature and 
stirred for 3 h. Water was added, and the aqueous phase was 
repeatedly extracted with Et2O. The combined organic extracts were 
dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. The crude 
mixture was purified via flash chromatography giving the desired precursor 43 as a colorless 
solid in 62 % yield (146 mg, 0.24 mmol) 
M.p.: 152 – 154 °C 
1H-NMR (CDCl3) δ 10.30 (s, 1H), 8.09 (d, J = 6.2 Hz), 7.37-7.12 (m, 10H), 6.98-6.70 (m, 
3H), 5.18 (s, 2H), 4.62 (s, 2H), 4.48 (s, 1H), 4.41 (s, 1H), 3.92 (broad s, 1H), 3.32 (d, J = 18.8 
Hz), 2.65 (s, 3H), 0.90 (s, 9H); 19F-NMR (200 MHz, CDCl3) δ -122.88; HRMS C33H34FN3O4 
[M+H]+ calculated 556.2606 found 556.2608; E.A.: calculated: C: 71.33 H: 6.17 N: 7.56 
found: C: 71.86 H: 5.88 N: 7.08 
 
N
H
N
N
O
O
O
O
F
N
N
N
O
O
O
O
Bn
F
 111  Experimental 
4.5   Synthesis of the precursor of L-4-fluorotryptophan by build-up synthesis 
5-Fluoro-2H-3,1-benzoxazine-2,4(1H)-dione (47), according to Tedesco et al.[194] 
10.0 g (64.5 mmol) 2-amino-6-fluorobenzoic acid (46) were dissolved in 
140 mL THF and 9.5 g (32.6 mmol) triphosgen were added. The mixture 
was stirred at 50 °C overnight, allowed to cool to room temperature and 
filtered. The resulting solid was washed with Et2O for several times and 
dried in vacuo at 40 °C to yield 10.47 g (58 mmol, 90%) 5-fluoro-2H-3,1-benzooxazine-
2,4(1H)-dione (47) as an off white solid. 
M.p.: decomposition at 251 – 259 °C 
1H-NMR (200 MHz, DMSO) δ 11.89 (s, 1H), 7.74 (td, 1H, J = 8.3 Hz,J = 8.3 Hz, J = 5.7 Hz), 
7.10-6.95 (m, 2H); 13C-NMR (200 MHz, DMSO) δ 164.69, 159.49, 155.95 (J = 4.8 Hz), 
147.33, 143.53 (J = 2.6 Hz), 138.46 (J = 11.1 Hz), 111.73 (J = 3.9 Hz), 110. 60 ( J = 20.0 Hz); 
19F-NMR (200 MHz, DMSO) δ -110.25; Ms (+c ESI): C8H4FNO3 [M + H
+]+calculated 181.12 
found 181.97, 213.90 [M + Na+]+ 
 
Methyl 6-amino-2-fluoro-benzoate (48), according to Levesque et al. [193] 
580 mg (4.8 mmol) DMAP were added to a solution of 8.7 g (48 mmol) 47 in 
300 ml dry MeOH. The resulting mixture was heated to reflux for 24 h, 
allowed to cool to room temperature, and the solvent was removed in vacuo. 
The residue was taken up in Et2O, the organic phase washed with water, dried over Na2SO4, 
and the solvent was evaporated in vacuo. The residue was purified by column 
chromatography (PE/EA = 4:1, Rf = 0.74) giving 7.8 g (46.1 mmol, 97 %) of the desired 
product as a colorless solid. 
M.p.: decomposition at 161 – 166 °C 
1H-NMR (200 MHz, DMSO) δ 7.20 (td, 1H, J = 8.2 Hz, J = 8.2 Hz, J = 6.2 Hz), 6,63-6,58 (m, 
3H), 6.32 (ddd, 1H, J = 11.7 Hz, J = 8.0 Hz, J = 1.1 Hz), 3.82 (s, 3H); 13C-NMR (200 MHz, 
DMSO) δ 166.74 (J = 3.3 Hz), 165.37, 160.35, 152.67 (J = 4.8 Hz), 134.11 (J = 12.1 Hz), 
112.55 (J = 2.9 Hz), 102.16 (J = 23.3 Hz), 52.17 (J = 0.6 Hz); 19F-NMR (200 MHz, DMSO) δ 
-108.21; Ms (+c ESI): m/z = 169.99 [M + H+]+ 
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Methyl 6-amino-2-fluoro-3-iodobenzoate (49), according to DeVita et al. [195] 
12.7 g (41 mmol) Ag2SO4 and 5.2 g (41 mmol) I2 were consecutively added 
to a solution of 6.9 g (41 mmol) of the methyl ester 48 in 100 ml EtOH. The 
reaction mixture was stirred for 3 h at room temperature, the solid was 
filtered off and the filtrate concentrated in vacuo. The residue was taken up in EtOAc, and the 
organic phase was washed with saturated NaHCO3, brine and water, dried over Na2SO4, and 
the solvent was removed in vacuo. The crude product was purified by column 
chromatography to yield 9.8 g (32.9 mmol, 80 %) of the desired iodo benzoate 49 as a 
colorless solid. 
M.p: 133 – 134 °C 
1H-NMR (200 MHz, DMSO) δ 7.53 (dd, 1H, J = 8.9 Hz, J = 7.0 Hz), 6.73 (s, 2H), 6.38 (dd, 
1H, J = 8.2 Hz, J = 1.0 Hz), 3.83 (s, 3H); 13C-NMR (200 MHz, DMSO) δ 165.90 (J = 4.0 Hz), 
160.95 (J = 248.1 Hz), 152.35 (J = 4.6 Hz), 141.73 (J = 5.1 Hz), 114.79 (J = 3.2 Hz), 101.56 
(J = 17.0 Hz), 63.24 (J = 28.4 Hz), 52.33; 19F-NMR (200 MHz, DMSO) δ -87.93; HRMS: 
C8H7FINO2 [M+H]
+ calculated 295,9578 found 295,9579; E.A.: calculated C: 32,57 H: 2,39 
N: 4,75 found C: 32,68 H: 2,44 N: 4,68 
 
Methyl 6-(benzylamino)-2-fluor-3-iodbenzoate (50), according to Levesque et al.[193] 
3.0 g (22 mmol) ZnCl2 and 2.8 g (26.2mmol) benzaldehyde were added 
to a solution of 3.86 g (13.1 mmol) 49 in 30 ml MeOH. The reaction 
mixture was stirred for 20 min at room temperature before 1.4 g (22 
mmol) NaBH3CN were added. After stirring overnight at room 
temperature and refluxing for 2 h, the reaction was quenched with  
1 M HCl and extracted with DCM. The combined organic extracts were dried over Na2SO4, 
filtered, and concentrated in vacuo. Purification by flash chromatography gave the desired 
product as an off white solid (3.9 g, 10.2 mmol, 78 %). 
M.p: 106-107 °C 
1H-NMR (200 MHz, CDCl3) δ 7.54 (dd, J = 9.0 Hz, J = 6.7 Hz, 1H), 7.40-7.31 (m, 5H), 6.32 
(dd, J = 9.1 Hz, J = 1.0 Hz), 4.46 (s, 2H), 3.95 (s, 3H) ); 13C-NMR (200 MHz, CDCl3) δ 
167.35, 165.79 (J = 146.2 Hz), 151.76 (J = 4.1 Hz), 142.68 (J = 5.1 Hz), 137.85, 128.84, 
127.49, 127.03, 109.75 (J = 3.2 Hz), 101.85 (J = 16.0 Hz), 63.88 (J = 29.1 Hz), 52.16, 47.63; 
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19F-NMR (200 MHz, CDCl3) δ -83.19; HRMS: C15H13FINO2 [M+H]
+ calculated 386.0048 
found 386.0049; E.A. calculated C: 46.77 H: 3.40 N: 3.64 found C: 45.94 H: 3.35 N: 4.08 
 
[6-(Benzylamino)-2-fluoro-3-iodophenyl]methanol (51a) 
DIBAL (10.4 mL, 10.4 mmol) was added to a solution of the 
aminobenzoate 50 (2.0 g, 5.2 mmol) in 20 mL THF at 0 °C. The reaction 
mixture was stirred overnight and quenched with water. Et2O was added, 
the precipitate was filtered off and washed with DCM. The organic 
phase was separated, dried over Na2SO4 and the solvent was removed 
under reduced pressure. Flash chromatography (PE/EA = 9:1; Rf = 0.28) of the crude mixture 
provided the benzyl alcohol 51a as a colorless solid in 60 % (1.1 g, 3.1 mmol) yield. 
M.p. 83-84 °C 
1H-NMR (200 MHz, DMSO) δ 7.41-7.20 (m, 5H), 6.29 (t, J = 5.7 Hz, 1H), 6.20 (d, J = 8.7 
Hz, 1H), 5.24 (t, J = 5.5 Hz, 1H), 4.60 (q, J = 1.9 Hz, 2H), 4.40 (d, J = 6.0 Hz, 2H); 13C-NMR 
(200 MHz, DMSO) δ 159.20 (J = 236.7 Hz), 149.57 (J = 6.4 Hz), 139.95, 137.91 (J = 4.4 Hz), 
128.86, 127.44 (J = 5.1 Hz), 127.24, 113.68 (J = 19.3 Hz), 109.55 (J = 2.5 Hz), 64.10 (J = 
28.2 Hz), 53.80 (J = 6.2 Hz), 46.77; 19F-NMR (200 MHz, DMSO) δ -101.27; HRMS: 
C14H13FINO [M+H]
+ calculated 358.0099 found 358.0099; E.A. calculated: C: 47.08 H: 3.67 
N: 3.92 found C: 47.25 H: 3.71 N: 3.78 
 
6-(Benzylamino)-2-fluoro-3-iodobenzaldehyde (52a) 
Activated MnO2 (1.7 g, 20 mmol) was added to a solution of the benzyl 
alcohol 51a (700 mg, 1.96 mmol) in 15 mL DCM. The reaction mixture was 
stirred overnight, filtered, and the solvent was evaporated under reduced 
pressure. Flash chromatography (PE/EA = 95:5) provided the desired benzaldehyde as a 
colorless solid 52a in 61 % (420 mg, 1.18 mmol) yield. 
M.p. 113-115 °C 
1H-NMR (200 MHz, CDCl3) δ 10.31 (s, 1H), 9.23 (s, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.53-7.30 
(m, 5H), 6.31 (d, J = 9.1 Hz, 1H), 4.74 (d, J = 5.7 Hz, 2H); 13C-NMR (200 MHz, CDCl3) δ 
189.03 (J = 11.8 Hz), 165.03 (J = 252.5 Hz), 151.82 (J = 3.4 Hz), 145.13 (J = 5.4 Hz), 137.35, 
128.89, 127.61, 126.91, 110.12 (J = 3.6 Hz), 108.72 (J = 11.0 Hz), 60.88 (J = 26.1 Hz), 46.88; 
19F-NMR (200 MHz, CDCl3) δ -102.27; HRMS C14H11FINO [M+H]
+ calculated 355.9942 
found 355.9943; E.A. calculated C: 47.08 H: 3.67 N: 3.92 found C: 47.25 H: 3.71 N: 3.78 
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Ethyl 1-benzyl-4-fluoro-5-iodo-1H-indole-3-carboxylate (53), according to Levesque et 
al.[193] 
BF3OEt2 (0.67 ml, 2.5 mmol) was added dropwise to a solution of the 
benzaldehyde 52a (865 mg, 2.44 mmol) and ethyl diazoacetate (1.4 g, 
12.2 mmol) in 15 mL DCM at 0 °C. The reaction mixture was stirred 
for 3 h at 0 °C before a saturated aqueous solution of NaHCO3 was 
added. The aqueous phase was repeatedly extracted with DCM, the 
combined organic extracts were dried over Na2SO4, and the solvent was removed under 
reduced pressure. Flash chromatography of the crude mixture (PE/EA = 4:1, Rf = 0.33) 
provided the desired indole 53 as a colorless solid in 92 % (954 mg, 2.25 mmol) yield. 
1H-NMR (200 MHz, CDCl3) δ 7.80 (s, 1H), 7.49 (dd, J = 8.4 Hz, J = 5.4 Hz, 1H), 7.34-7.31 
(m, 3H), 7.11 (d, J = 7.1 Hz, 2H), 6.87 (d, J = 8.6 Hz, 1H), 5.30 (s, 1H), 4.36 (q, J = 7.1 Hz, 
2H), 1.40 (t, J = 7.1 Hz, 3H); 13C-NMR (200 MHz, CDCl3) δ 163.54, 154.94 (J = 251.2 Hz), 
139.53 (J = 9.9 Hz), 135.75, 135.18, 132.67, 129.13, 128.42, 126.90, 115.12 (J = 22.0 Hz), 
108.30 (J = 4.1 Hz), 107.09 (J = 4.3 Hz), 73.02 (J = 26.0 Hz), 60.35, 51.13, 14.44; 19F-NMR 
(200 MHz, CDCl3) δ -89.73, HRMS: C18H15FINO2 [M+H]
+ calculated 424.0204 found 
424.0204; E.A. calculated C:51.08 H: 3.57 N: 3.31 found C: 50.78 H: 3.59 N: 3.22 
 
Ethyl 4-fluoro-1H-indole-3-carboxylate (56b), according to Murakami et al.[176] 
AlCl3 (96 mg, 0.72 mmol) was added to a solution of 53 (100 mg, 0.24 
mmol) in 5 mL benzene. The reaction mixture was stirred for 2 h at room 
temperature before water was added. The aqueous phase was repeatedly 
extracted with DCM, the combined organic layers were dried over 
Na2SO4, filtered, and the solvent was removed under reduced pressure. Flash chromatography 
of the crude mixture provided the debenzylated and deiodinated indole as a yellowish solid 
56b in 78 % (40 mg, 0.19 mmol) yield. 
1H-NMR (200 MHz, CDCl3) δ 9.56 (s, 1H), 7.94 (s, 1H), 7.23 (d, J = 8.1 Hz, 1H), 7.17 (dd, J 
= 12.5 Hz, J = 7.7 Hz, 1H), 6.92 (t, J = 9.2 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 
Hz); 13C-NMR (200 MHz, CDCl3) δ 164.57, 156.32 (J = 249.8 Hz), 139.35 (J = 10.6 Hz), 
132.37, 123.86 (J = 7.8 Hz), 114.02 (J = 20.2 Hz), 108.03 (J = 3.6 Hz), 107.90, 107.76, 60.30, 
14.42 (J = 4.2 Hz); 19F-NMR (200 MHz, CDCl3) δ -112.76; HRMS: C11H10FNO2 [M+H]
+ 
calculated 208.0787 found 208.0786 [M+Na]+ calculated 230.0588 found 230.0588 ; E.A. 
calculated C: 63.76 H: 4.86 N: 6.76 found C: 63.35 H: 4.79 N: 6.59 
N
F
I
O
O
N
H
F O
O
 115  Experimental 
6-Amino-2-fluoro-3-iodobenzaldehyde (52b), according to Satam et al.[197] 
IBX (873 mg, 3.12 mmol) was added to a solution of 51a (934 mg, 2.6 mmol) 
in 15 mL DMSO at room temperature. The reaction mixture was stirred for 30 
min before water was added. The aqueous phase was extracted several times 
with Et2O, the combined organic extracts were dried over Na2SO4, filtered, and the solvent 
was removed under reduced pressure. Flash chromatography of the crude mixture provided 
the aniline 52b as a yellow solid in 67 % (450 mg, 1.7 mmol) yield. 
1H-NMR (200 MHz, DMSO) δ 10.12 (s, 1H), 7.62 (broad s, 2H), 7.56 (t, J = 8.3 Hz, 1H), 
6.49 (d, J = 9.0 Hz, 1H); 13C-NMR (200 MHz, DMSO) δ 188.64 (J = 10.6 Hz), 164.75 (J = 
248.6 Hz), 152.71 (J = 4.1 Hz), 144.33 (J = 5.5 Hz), 115.41 (J = 3.3 Hz), 107.99 (J = 5.9 Hz), 
60.97 (J = 26.0 Hz); 19F-NMR (200 MHz, DMSO) δ -104.24; HRMS: C7H5FINO [M-H]
+ 
calculated 263.9316 found 263.9317; E.A. calculated: C: 31.72 H: 1.90 N: 5.29 found C: 
31.80 H: 2.04 N: 5.21 
 
4.6  Synthesis of the precursor of L-4-fluorotryptophan by linear synthesis 
4-Fluoro-5-iodo-1H-indole (60), according to Schlosser et al.[69] 
Analogously prepared as iodoindole 35 while starting from 4-fluoro-1-
(triisopropylsilyl)indole (2b) giving the desired product as a colorless solid in 
65 % yield. 
M.p. 58 – 60 °C;  
1H-NMR (CDCl3) δ 8.30 (broad s, 1H), 7.42 (dd, J = 8.4 Hz, J = 6.0 Hz, 1H), 7.14 (t, J = 2.7 
Hz, 1H), 6.99 (d, J = 8.5 Hz, 1H), 6.61 (t, J = 2.0 Hz, 1H); 13C-NMR (CDCl3) δ 155.18 (J = 
244.7 Hz), 138.32 (J = 10.8 Hz), 131.13, 124.68, 117.78 (J = 24.2), 109.17 (J = 3.7 Hz), 98.81 
(J = 5.9 Hz), 68.30 (J = 23.4 Hz); 19F-NMR (CDCl3) δ -101.74; E.A. calculated: C: 36.81 H: 
1.93 N: 5.37 found C: 37.64 H : 2.17 N: 5.14 
 
4-Fluoro-5-iodo-1H-indole-3-carbaldehyde (61), according to Konas et al.[160] 
Analogously prepared as indolecarbaldehyde 36 but starting from 4-fluoro-
5-iodo-1H-indole (60) giving the desired product as an off white solid in 89 
% yield. 
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M.p. decompostition at 246-249 °C 
1H-NMR (DMSO) δ 12.60 (s, 1H), 10.02 (d, J = 3.3 Hz, 1H), 8.30 (d, J = 2.9 Hz, 1H), 7.60 
(dd, J = 8.6 Hz, J = 5.8 Hz, 1H), 7.23 (d, J = 8.5 Hz, 1H); 13C-NMR (DMSO) δ 184.07 (J = 
1.7 Hz), 155.09 (J = 245.1 Hz), 140.10 (J = 11.3 Hz), 136.79, 132,81, 116.84 (J = 6.5 Hz), 
113.81 (J = 24.6 Hz), 111.70 (J = 3.7 Hz), 73.23 (J = 24.4 Hz); 19F-NMR (DMSO) δ -92.94; 
HRMS: C9H5FINO [M-H]
+ calculated 289.9473 found 289.9477; E.A.: calculated: C: 37.40 
H: 1.74 N: 4.85 found: C: 37.86 H:1.84 N: 5.22  
 
4-Fluoro-5-iodo-1-tosyl-1H-indole-3-carbaldehyde (62), according to Konas et al.[160] 
Analogously prepared as indolecarbaldehyde 37 while starting from 4-
fluoro-5-iodo-1H-indole-3-carbaldehyde (61) giving the desired product as a 
colorless solid in 74 % yield. 
M.p. decomposition at 148-153 °C.  
1H-NMR (CDCl3) δ 10.02 (s, 1H), 8.65 (d, 1H, J = 6.2 Hz), 8.19 (s, 1H), 7.83 (d, 2H, J = 8.1 
Hz), 7.69 (d, 1H, J = 8.3 Hz), 7.32 (d, 2H, J = 8.1 Hz), 2.39 (s, 3H); 13C-NMR (CDCl3) δ 
184.70, 159.51 (J = 242.0 Hz), 146.63, 136.51 (J = 3.2), 135.25 (J = 11.2 Hz), 133.71, 132.60 
(J = 2.8 Hz), 130.47, 127.13, 124.16 (J = 2.0 Hz), 120.86 (J = 0.9 Hz), 100.71 (J = 31.3 Hz), 
78.44 (J = 27.3 Hz), 21.63 ; 19F-NMR (CDCl3) δ -89.70;HRMS: C16H11FINO3S [M+H]
+ 
calcd. 443,9561 found 443,9561; E.A.: calcd. C: 43,36 H: 2,50 N: 3,16 found C: 43,05 H: 
2,59 N: 3,11 
 
[4-Fluoro-5-iodo-1-tosyl-1H-indol-3-yl]methanol (63), according to Konas et al.[160] 
 Analogously prepared as tosylate 38 by starting from 4-fluoro-5-iodo-1-
tosyl-1H-indole-3-carbaldehyde (62) giving the desired product as a 
colorless solid in 97 % yield.  
 
M.p. 131-132 °C 
1H-NMR (DMSO) δ 7.87 (d, J = 8.4 Hz, 2H), 7.70 (dd, J = 8.6 Hz, J = 6.0 Hz, 1H), 7.63 (s, 
1H), 7.61 (d, J = 8.7 Hz, 1H), 7.40 (d, J = 8.2 Hz, 2H), 5.26 (t, J = 5.4 Hz, 1H), 4.63 (d, J = 
5.3 Hz), 2.33 (s, 3H); 13C-NMR (DMSO) δ 154.63 (J = 244.7 Hz), 145.94, 136.70 (J = 9.8 
Hz), 134.33, 133.73, 130.41, 126.79, 124.42, 121.74 (J = 4.8 Hz), 118.01 (J = 23.3 Hz), 
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111.63 (J = 3.8 Hz), 74.86 (J = 23.9 Hz), 55.53 (J = 1.8 Hz), 21.04; 19F-NMR (DMSO) δ -
100.88; HRMS: C16H13FINO3S [M+Na]
+ calculated 467.9537 found 467.9539; E.A. 
calculated C: 43.16 H: 2.94 N: 3.15 found C: 43.40 H: 3.03 N: 3.15 
 
[3-(Bromomethyl)-4-fluoro-5-iodo-1-tosyl]-1H-indole (64), according to Appel et al.[189] 
Analogously prepared as bromide 39 while starting from the alcohol 63 
giving the desired product as a colorless solid 63 % yield. 
M.p. decomposition at 166-168 °C 
1H-NMR (DMSO) δ 8.08 (s, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.75 (dd, J = 8.7 Hz, J = 6.0 Hz, 
1H), 7.62 (d. J = 8.8 Hz, 1H), 7.42 (d, J = 8.2 Hz, 2H), 4.82 (s, 2H), 2.33 (s, 3H); 13C-NMR 
(DMSO) δ 154.27 (J = 246.8 Hz), 146.16, 136.29 (J = 9.1 Hz), 134.91, 133.28, 130.41, 
126.74, 124.28, 117.37 (J = 22.8 Hz), 117.00 (J = 3.7 Hz), 111.57 (J = 3.9 Hz), 75.62 (J = 
24.1 Hz), 55.39 (J = 1.8 Hz), 20.94; 19F-NMR (DMSO) δ -102.l3; HRMS: C16H12BrFINO2S 
[M-Br]- calculated 427.9617 found 427.9636; E.A. calculated C: 37.82, H: 2.38 N: 2.73 found 
C: 38.12 H: 2.38 N: 2.64 
 
Benzyl (2S,5S)-2-tert-butyl-5-[(4-fluoro-5-iodo-1-tosyl-1H-indol-3-yl)methyl]-3-methyl-4-
oxoimidazolidine-1-carboxylate (65) 
 Analogously prepared as 40 but starting from the bromide 64 giving 
the desired product as a colorless solid in 73 % yield. 
M.p. 83 – 86 °C 
1H-NMR (CDCl3) δ 7.73 (broad s, 2H),  7.52 (dd, J = 8.7 Hz, J = 5.7 
Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.25 (broad s, 2H), 7.15-6.60 
(broad m, 6H), 5.18 (broad s, 1H), 4.84 (d, J = 6.1 Hz, 2H), 4.38 (s, 
1H), 3.76 (broad s, 1H), 3.40 (d, J = 14.4 Hz, 1H), 3.06 (s, 3H), 2.32 (s, 3H), 1.02 (s, 9H); 
13C-NMR (CDCl3) δ 171.12, 155.39 (J = 248.9 Hz), 145.47, 136.54 (J = 9.1 Hz), 134.86, 
134.68, 134.23, 130.06, 128.48, 128.33, 128.27, 127.07, 122.15, 120.23 (J = 21.2 Hz), 115.04 
(J = 3.0 Hz), 111.15 (J = 3.8 Hz), 81.21, 73.83 (J = 24.4 Hz), 67.61, 60.41, 58.28, 40.85, 
32.13, 26.30, 21.08, 21.60;  19F-NMR (CDCl3) δ -100.94; HRMS: C33H32FIN3O5S [M+Na]
+ 
calculated 740.1061 found 740.1053; E.A. calculated C: 53.56 H: 4.64 N: 5.86 found C: 53.13 
H: 4.58 N: 5.39 
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 Benzyl (2S,5S)-2-tert-butyl-5-[(4-fluoro-5-formyl-1-tosyl-1H-indol-3-yl)methyl]-3-
methyl-4-oxoimidazolidine-1-carboxylate (66), according to Boymond et al.[191] 
 Analogously prepared as 41 by starting from 65 giving the desired 
product as a colorless solid in73 % yield. 
M.p. 73-75 °C 
1H-NMR (CDCl3) δ 10.34 (s, 1H), 7.81-7.71 (m, 4H), 7.31 (d, J = 
7.7 Hz, 2H), 7.02-6.87 (m, 6H), 5.16 (s, 1H), 4.93 (s, 2H), 4.45 (s, 
1H), 4.16 (d, J = 7.1 Hz, 1H), 3.53 (d, J = 17.2 Hz, 1H), 3.05 (s, 
3H), 2.37 (s, 3H), 1.06 (s, 9H); 13C-NMR (CDCl3) δ 186.55 (J = 7.9 Hz), 171.02, 160.01 (J = 
263.5 Hz), 145.83, 140.02 (J = 11.0 Hz), 134.90, 134.60, 130.19, 128.41, 128.29, 127.15, 
123.93, 119.48 (J = 16.8 Hz), 118.81 (J = 5.2 Hz), 116.01, 109.89 (J = 3.5 Hz), 81.25, 67.62, 
40.83, 32.08, 26.31, 21.63; 19F-NMR (CDCl3) δ -129.12, HRMS: C33H34FN3O6S [M+Na]
+ 
calculated 642.2044 found 642.2030, E.A: calculated: C: 63.96 H: 5.53, N: 6.78 found C: 
63.91 H: 5.63 N: 6.48 
 
Benzyl (2S,5S)-2-tert-butyl-5-[(4-fluoro-5-formyl-1H-indol-3-yl)methyl]-3-methyl-4-oxo-
imidazol-idine-1-carboxylate (67), according to Yasuhara et al.[170] 
3.5 mL of 1.0 M solution of TBAF in THF were added to a solution 
of 432 mg (0.7 mmol) 66 in 10 mL THF. The resulting mixture was 
stirred at room temperature for 3 h before the solvent was 
evaporated in vacuo. Flash chromatography of the crude mixture 
gave the desired product as a colorless solid in 42 % (140 mg, 0.3 
mmol)  
1H-NMR (DMSO) δ 11.53 (s, 1H), 10.27 (s, 1H), 7.48 (dd, J = 8.4 Hz, J = 6.2 Hz, 1H), 7.27 
(d, J = 8.5 Hz, 1H), 7.19-7.14 (m, 3H), 7.08 (d, J = 7.2 Hz, 2H), 6.72 (s, 1H), 5.19 (s, 1H), 
5.00 (d, J = 12.3 Hz, 1H), 4.79 (d, J = 12.3 Hz, 1H), 4.50 (d, J = 4.4 Hz, 1H), 3.97-3.94 (broad 
s, 1H), 3.38 (d, J = 15.4 Hz, 1H), 2.93 (s, 3H), 0.93 (s, 9H); 13C-NMR (DMSO) δ 187.15 (J = 
7.5 Hz), 171.02, 160.84 (J = 262.5 Hz), 142.62 (J = 13.9 Hz), 136.29, 128.58, 128.30, 123.64, 
120.46, 115.80 (J = 16.0 Hz), 115.21 (J = 5.3 Hz), 109.95, 109.23, 80.41, 66.90, 58.69, 31.84, 
26.47; 19F-NMR (DMSO) δ -130.47; HRMS: C26H28FN3O4 [M+Na]
+ calculated 488.1956 
found 488.1992; E.A. calculated: C: 67.08 H: 6.06 N: 9.03 found C: 65.20 H: 5.92 N: 8.60 
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Benzyl (2S,5S)-2-tert-butyl-5-[(1-Boc-4-fluoro-5-formyl-1H-indol-3-yl)methyl]-3-methyl-
4-oxoimidazolidine-1-carboxylate (68), according to de Koning et al.[159] 
60 mg (0.27 mmol) Boc2O were added to a solution of 67 (110 mg, 
0.23 mmol) and DMAP (3 mg, 24 µmol) in 5 ml THF. The resulting 
mixture was stirred for 1 h at room temperature. The solvent was 
evaporated under reduced pressure. Purification of the crude 
mixture by flash chromatography (PE/EA = 7:3, Rf = 0.5) yielded 
the desired product as a colorless solid (86 %, 112 mg, 0.20 mmol).  
M.p.: 133 – 136 °C 
1H-NMR (CDCl3) δ 10.37 (s, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 12.7 Hz, J = 6.5 Hz, 
1H), 7.39-7.03 (m, 5H), 6.98 (s, 1H), 5.14-4.89 (m, 3H), 4.49 (d, J = 1.2 Hz, 1H), 4.03 (d, J = 
16.8 Hz, 1H), 3.59 (d, J = 17.2 Hz), 3.11 (s, 3H), 1.58 (s, 9H), 0.99 (s, 9H); 13C-NMR 
(CDCl3) δ 187.45 (J = 6.7 Hz), 170.92, 160.64 (J = 261.3 Hz), 148.45, 140.51 (J = 11.5 Hz), 
136.25, 128.33 (J = 5.3 Hz), 124.61, 123.23, 118.78, 118.53, 118.41, 114.50 (J = 3.0 Hz), 
111.96, 85.51, 80.79, 66.83, 58.09, 31.99, 27.99, 26.38; 19F-NMR (CDCl3) δ -130.61; HRMS 
C31H36FN3O4 [M+Na]
+ calculated  588.2480 found 588.2461; E.A. calculated C: 65.83 H: 
6.42 N: 7.43 found C: 64.58 H: 6.39 N: 7.32 
 
 
4.7  Radiochemistry 
4.7.1  Preparation of tetrabutylammonium [18F]fluoride (TBA18F) 
N.c.a. [18F]fluoride was produced by the 18O(p,n)18F nuclear reaction via bombardment of an 
isotopically enriched [18O]water target with 17 MeV protons at the JSW cyclotron BC 1710 
(FZ Jülich).[206] An aliquot of the [18F]fluoride solution was added to 150 µL (18 µmol) of a 
0.12 M tetrabutylammonium bicarbonate solution (TBAHCO3).
[31] After adding 1.0 mL of dry 
MeCN by a syringe, azeotropic distillation under a steam of argon at 75 °C and 600 mbar was 
performed. The azeotropic evaporation was repeated twice. Afterwards the vial was evacuated 
for about 5 min at 10 – 20 mbar and flushed again with argon. 
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4.7.2  General procedure for the radiosynthesis of 1-benzyl-[18F]fluoro-1H-indoles 
 ([18F]1-4b) by conventional heating 
A solution of 20 µmol of the corresponding precursor (1e, 2e, 3e or 4e) in 1.0 mL DMF was 
added to the vial containing the dry TBA18F with a typical activity of 15 to 30 MBq. The 
reaction mixture was heated to the desired temperature (usually between 60 and 160 °C) for 
typically 15 min. After labeling the reaction solution was diluted with 10.0 mL water and 
passed through a previously conditioned LiChrolut RP-18e cartridge (Merck, Germany). 
Afterwards, the fixed labeled compound was eluted with 2.0 ml acetonitrile into a second vial 
followed by the evaporation of the solvent. A solution containing Wilkinson’s catalyst (2 – 4 
eq.) in 1.0 mL of the desired solvent (benzonitrile or dioxane) was added and the mixture was 
heated to 150 °C for 20 min.  
 
4.7.3  General procedure for the radiosynthesis of 1-benzyl-[18F]fluoro-1H-indoles 
 ([18F]1-4b) by microwave heating 
A solution of 20 µmol of the corresponding precursor in 1.0 mL DMF was added to the vial 
containing the dried TBA18F with a typical activity of 15 to 30 MBq. The reaction mixture 
was heated with microwaves of the desired energy (usually between 30 and 140W) during  
1 min. After labeling the solution was diluted with 10.0 mL water and passed through a 
previously conditioned LiChrolut RP-18e cartridge (Merck, Germany). Afterwards the fixed 
labeled compound was eluted with 2.0 ml acetonitrile into a second vial followed by the 
evaporation of the solvent. A solution containing Wilkinson’s catalyst (2 – 4 eq.) in 1.0 mL of 
the desired solvent (benzonitrile or dioxane) was added and the mixture was heated with  
100 W microwaves for 2 min.  
 
4.7.4  General procedure for the radiosynthesis of L-4-[18F]fluorotryptophan ([18F]70) 
by conventional heating 
A solution of 8-9 µmol of the precursor 68 in 1.0 mL DMF was added to the vial containing 
the dry TBA18F with a typical activity of 200 – 300 MBq. The reaction mixture was heated to 
the desired temperature for typically 10 min. After labeling the reaction mixture was diluted 
with 1.0 mL acetonitrile and 9.0 mL water and passed through a previously conditioned 
LiChrolut RP-18e cartridge (Merck, Germany). Afterwards the cartridge was eluted with 2.0 
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mL acetonitrile, and the solvent was evaporated. A solution containing Wilkinson’s catalyst 
(generally 2 – 4 eq.) in 1.0 mL benzonitrile was added and the reaction mixture was heated to 
the desired temperature for typically 20 min. The mixture was diluted with 1.0 mL of a 
solution of ethyl acetate in petroleum ether (5% EA/PE), and filtered through a silica cartridge 
(600-700 mg silica gel in a 3 mL polyethylene filtration tube) followed by elution with 9 mL 
of the same solvent mixture. Subsequently the desired compound was eluted with a solution 
of ethyl acetate in petroleum ether (60% EA/PE). The solvents were evaporated followed by 
the addition of 0.5 ml of concentrated hydrochloric acid and heating of the reaction mixture to 
the temperature of choice (110 – 160 °C) for usually 30 min. 
 
4.7.5  General procedure for the radiosynthesis of L-4-[18F]fluorotryptophan ([18F]70) 
 under microwave  heating 
A solution of 8-9 µmol of the precursor 68 in 1.0 mL DMF was added to a vial containing the 
dry TBA18F with activities of usually 200 – 300 MBq. The reaction mixture was treated with 
microwaves of the desired energy (usually 30 - 80 W) for 1 min. After labeling the reaction 
mixture was diluted with 1.0 mL acetonitrile and 9.0 mL water and passed through a 
previously conditioned LiChrolut RP-18e cartridge (Merck, Germany). Afterwards the 
cartridge was eluted with 2.0 mL acetonitrile and the solvent was evaporated. A solution 
containing Wilkinson’s catalyst (2 – 4 eq.) in 1.0 mL benzonitrile was added and the reaction 
mixture was heated with 100 W microwaves for 2 min. The mixture was diluted with 1.0 mL 
of a solution of ethyl acetate in petroleum ether (5% EA/PE), and filtered through a silica 
cartridge (600-700 mg silica gel in a 3 mL polyethylene filtration tube) followed by elution 
with 9 mL of the same solvent mixture. Subsequently the desired compound was eluted with a 
solution of ethyl acetate in petroleum ether (60% EA/PE). The solvents were evaporated 
followed by the addition of 0.5 ml of concentrated hydrochloric acid, and the reaction mixture 
was heated to temperatures between 110 and 160 °C for typically 30 min. 
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5. Summary and outlook 
Aromatic α-[18F]fluoroamino acids have been developed as potential tracers for different 
purposes in nuclear medicine. The most established of those amino acids for PET are  
6-[18F]fluoro-L-DOPA and O-[18F]fluoroethyl-L-tyrosine ([18F]FET) which are widely used 
for the diagnosis of cerebral and peripheral endocrine tumors. Furthermore, 6-[18F]fluoro-L-
DOPA is also used for the diagnosis of several central motor disorders that are due to striatal  
(mal-)functions.  
Another interesting aromatic amino acid is tryptophan which has earlier been radiofluorinated 
by electrophilic approaches or secondary groups. On one hand, radiolabeled derivatives of 
tryptophan have been prepared in the past aiming at the measurement of serotonin synthesis, 
and they might be useful for the diagnosis of diseases that are connected with the serotonergic 
receptor system. On the other hand, radiofluorinated tryptophan might also be useful in tumor 
diagnosis, since recent studies have revealed that some types of tumors have highly elevated 
tryptophan consumption due to overexpression of the enzyme indoleamine dioxygenase. 
Recently a nucleophilic approach made the radiosynthesis of 2-[18F]fluoro-L-phenylalanine 
and 2-[18F]fluoro-L-tyrosine available in three steps. In these studies the corresponding 
precursor was radiofluorinated by an isotopic 18F-for-19F exchange, followed by the removal 
of an activating aldehyde group by reductive decarbonylation, and a final step where 
hydrolysis of the protecting groups was performed. Based on this three-step procedure the 
radiosynthesis of L-4-[18F]fluorotryptophan was realized in the present work.  
Prior to the preparation of a suitable precursor for the radiosynthesis of L-4-[18F]fluoro-
tryptophan, the influence of the substitution pattern of several ortho- and para-substituted 
fluoro-1H-indolecarbaldehydes on an isotopic 18F-exchange was investigated in order to find 
the optimal position of the fluorine that provides the highest RCY. Additionally, a reductive 
decarbonylation with Wilkinson’s catalyst was examined on the fluoro-1H-indole-
carbaldehydes in order to determine if the removal of the carbonyl function is easily possible 
for the selected precursor. 
The precursors for the isotopic exchange on the fluoro-1H-indolecarbaldehydes 1-3 with an 
ortho-substitution pattern were prepared in a 4-step linear synthesis starting from 
corresponding fluoroindoles. The only precursor with a para-substitution pattern, 4-fluoro-
1H-indole-7-carbaldehyde (4), was prepared by a Bartoli reaction. 
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The indole nitrogen of 4-, 6- and 7-fluoroindole was protected with a TIPS group followed by 
a formylation with n-BuLi and DMF. Subsequently, the TIPS group was removed with TBAF 
and the resulting unprotected fluoro-1H-indolecarbaldehydes (1d, 2d, 3d) were protected with 
different protecting groups (benzyl, methyl, Boc and tosyl) resulting in the corresponding 
precursors. For the preparation of the para-substituted indole, 1-bromo-4-fluoro-2-
nitrobenzene was used in a Bartoli reaction for the synthesis of 7-bromo-4-fluoro-1H-indole 
(4b) which was then protected with a benzyl group and formylated with n-BuLi and DMF 
giving 1-benzyl-4-fluoro-1H-indole-7-carbaldehyde (4e) as precursor. 
With respect to the isotopic exchange, the best RCY was obtained when the indole nitrogen of 
the precursors was protected with a benzyl group. A RCY of above 90 % was obtained for all  
1-benzyl-fluoro-1H-indolecarbaldehydes (2e, 3e, 4e); except for 1-benzyl-6-fluoro-1H-indole-
5-carbaldehyde (1e). It could only be labeled in ca. 60 %, RCY, but showed the best results 
regarding chemical stability. The radiofluorination reaction itself was carried out in DMF with 
TBAHCO3 as anion activator. Protection with a methyl group provided a slightly lower RCY 
than the benzyl group while the Boc-protected compounds (1g, 2g) gave a RCY of 6 % and  
28 %, respectively. Labeling was not possible when the indole nitrogen was not protected or 
tosylated. The best results regarding RCY and chemical stability were obtained with 1-benzyl-
4-fluoro-1H-indole-5-carbaldehyde (2e). Additionally, a microwave assisted procedure was 
developed for the isotopic exchange giving similar RCY as under conventional heating, but, 
however, in a much shorter reaction time of 1 min. 
Furthermore, the decarbonylation reaction was performed on the 1-benzyl-fluoro-1H-
indolecarbaldehydes [18F]1e, [18F]2e, [18F]3e and [18F]4e with Wilkinson’s catalyst 
(Rh(PPh3)3Cl). When this reaction was done in dioxane, only a low RCY of about 6 % was 
obtained regardless the equivalents of catalyst, reaction temperature and time. With 
benzonitrile as solvent, 3 equivalents of Rh(PPh3)3Cl and conventional heating of the reaction 
mixture to 150 °C for 20 min provided all 1-benzyl-fluoro-1H-indoles [18F]5, [18F]6 and 
[18F]7 with a RCY of > 95 %. This reaction was also carried out with microwave assisted 
heating. Hereby 3 equivalents of Rh(PPh3)3Cl and heating with microwaves of 100 W for  
120 s gave a similar RCY compared to the reaction with conventional heating, whereas a 
shorter reaction time led to incomplete conversion of the starting material.  
The synthesis of the precursor 43 for L-6-[18F]fluorotryptophan was attempted following two 
principally different synthetic pathways: Via a build-up synthesis by a palladium mediated 
heteroannulation and alternatively by a linear synthesis. 
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For the build-up synthesis, the preparation of alkyne 15 and a functionalized 2-iodoaniline 
were necessary. The alkyne was prepared in three steps starting from propargyl alcohol by the 
introduction of a TMS group followed by tosylation and coupling with Z-BMI. The second 
molecule for the coupling should be one of the iodoanilines 11, 12 or 13, however, the 
preparation of none of those carbonyl activated iodoanilines was successful. Therefore, the 
coupling of 3-fluoro-4,6-diiodoaniline (14) with the alkyne 15 was examined in order to get a 
precursor for L-6-[18F]fluorotryptophan. This resulted in a variety of products, but the 
tryptophan analogue 30 could not be isolated. For this reason the approach via this synthetic 
pathway was not further investigated. 
The alternative preparation of the precursor 43 in a linear synthetic route started from 6-
fluoroindole which was protected with a TIPS group followed by iodination in the 5- position 
with sec-BuLi and 1,2-diiodoethane. The TIPS group was removed with TBAF and a formyl 
group was introduced in the 3-position by a Vilsmeier-Haack reaction, resulting in the indole-
carbaldehyde 36 which was protected and reduced to the corresponding alcohol 38a with 
NaBH4 and converted into the bromine 39a by an Appel reaction. Subsequent coupling with 
Z-BMI and formylation gave the tosyl protected precursor 41. The exchange of the tosyl to 
the benzyl protecting group was further performed by deprotection with TBAF and 
benzylation with BnBr which resulted in the final precursor 43 for L-6-[18F]fluorotryptophan. 
The overall yield of the synthesis of this precursor was about 8 %. 
As mentioned above, the radiosynthesis of L-6-[18F]fluorotryptophan was performed in three 
steps: isotopic exchange, reductive decarbonylation and the removal of the protecting groups. 
For the isotopic exchange of 43 the optimum conditions were found with TBAHCO3 as anion 
activator, DMF as solvent and at 150 °C. Hereby a RCY of about 9 % was obtained, while the 
formation of a diastereomer was observed. The ratio between the L- and D- diastereomer was 
about 70:30. The decarbonylation reaction gave a RCY of ca. 11 % with 3 equivalents 
Rh(PPh3)3Cl, benzonitrile as solvent and microwave heating with 100 W microwaves for 2 
min. The removal of the protecting groups, however, could not be accomplished since the 
removal of the benzyl group on the indole nitrogen proved impossible. Any tested attempt for 
that resulted in decomposition of the decarbonylated precursor [18F]44. 
The synthesis of the precursor of the positional isomer L-4-[18F]fluorotryptophan (68) was 
also carried out in two generally different ways. It was attempted by a build-up synthesis 
based on an [1,2]-aryl shift condensation as well as by a linear synthetic pathway similar to 
the one described above for the synthesis of the precursor 43. 
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For the [1,2]-aryl shift condensation ethyl diazoacetate was necessary, which is commercially 
available, and 6-(benzylamino)-2-fluoro-3-iodobenzaldehyde (52) which was prepared in a 
linear six step synthesis starting from 2-amino-6-fluoro-benzoic acid (46). The first step 
thereby was a cyclisation with triphosgene followed by an esterification which was 
accomplished in MeOH with DMAP giving the aniline 48. In the next step an iodination was 
performed with Ag2SO4 and elemental iodine, followed by a reductive amination with 
NaBH3CN and benzaldehyde. The reduction to the benzyl alcohol 51a was carried out with 
DIBAL in THF, followed by an oxidation with MnO2 giving the desired aminobenzaldehyde 
52a. An aryl shift condensation of ethyl diazoacetate and the aminobenzaldehyde 52a, 
performed with BF3
.OEt2 in DCM, gave the N-benzylindole 53. The reduction of the ethyl 
ester to the alcohol followed by a bromination through an Appel reaction, however, was not 
successful due to decomposition of the N-benzylindole 53. Also, debenzylation of 53 with 
AlCl3 led to deiodinated 56b which made a formylation at a later stage impossible. 
Alternatively, formylation and protection of 53 prior to debenzylation resulted again in 
decomposition of the starting material which made a synthesis of a suitable precursor (68) for 
L-4-[18F]fluorotryptophan impossible via this approach. 
The synthesis of precursor 68 was therefore performed according to the linear synthesis 
described for the preparation of 43. Only the protecting group on 68 was changed from benzyl 
to Boc, since the 1-Boc-4-fluoro-1H-indole-5-carbaldehyde (2g) provided a RCY of 28 % for 
the isotopic exchange and the Boc group can be removed under milder conditions than the 
benzyl group. In summary, the synthesis of precursor 68 was successfully realized with 8 % 
overall yield following an 11 step linear synthetic procedure. 
The first attempt of the isotopic exchange on 68 was done under the optimum conditions 
obtained for 2g leading to a RCY of ca. 19 %. After optimization, however, a RCY of about 
51 % was obtained by heating the reaction mixture to 80 °C for 10 min while TBAHCO3 was 
used as anion activator. Also here, the microwave assisted reaction was investigated, but 
leading to a somewhat lower RCY of about 41 % under optimum conditions.  
The decarbonylation reaction was carried out under the optimum conditions obtained for that 
of 1-benzyl-fluoro-1H-indolecarbaldehydes and optimized regarding the molar ratio of 
Rh(PPh3)3Cl, solvent and reaction time. The optimum conditions with conventional heating 
were found to be 3 equivalents of Rh(PPh3)3Cl and keeping the reaction mixture at 150 °C for 
20 min. Those conditions provided a RCY of about 45 %. When this reaction was performed 
with microwave heating, this time, an excellent RCY of ca. 75 % was obtained under the 
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optimum conditions of 3 equivalents of Rh(PPh3)3Cl and heating with 100 W microwaves for 
2 min. 
The final step in the radiosynthetic pathway was the hydrolysis which was done with conc. 
HCl by heating the reaction mixture to 150 °C for 30 min giving a RCY of about 34 %. In this 
case, a side product was formed that was not subject to incomplete hydrolysis but not further 
characterized.  
After optimization of all three reaction steps the desired L-4-[18F]fluorotryptophan could be 
isolated in a total RCY of about 13 % and an enantiomeric purity of > 99 % in about  
115 min. All reactions were carried out under developmental conditions with low starting 
activities of around 250 MBq. The obtained specific activity under those conditions was 
always > 70 MBq/mmol which is in the area of specific activities for standard electrophilic 
fluorinations, but is expected to increase considerably when higher starting activities are 
applied that are commonly used for routine production.  
 
On the basis of the obtained results with the radiosynthesis of L-4-[18F]fluorotryptophan 
several suggestions for optimizations can be made. The step with the lowest RCY was the 
hydrolysis step. This was probably due to the harsh reaction conditions that are necessary for 
the cleavage of the BMI group. During the synthesis of the precursor and the radiosynthesis it 
proved that the precursor 68 is highly sensitive towards elevated temperatures. Hence, the 
introduction of a chiral protecting group for the amino acid function is desirable that can be 
hydrolyzed under less aggressive conditions. A suggestion for the preparation of such a 
precursor would be the introduction of the chiral center with Schöllkopf’s bislactimether 
which can be cleaved under much milder conditions. The amine function could then be 
protected with a trityl group that can also be hydrolyzed under very mild conditions within a 
short time. 
Furthermore, it would be interesting to test if a Baeyer-Villiger Oxidation is possible on the 
labeled compound [18F]68 under reaction conditions where L-4-[18F]fluoro-5-hydroxy-
tryptophan is expected to be the major product after hydrolysis of the protecting groups. This 
would provide another potentially very interesting new radiotracer, since L-5-
hydroxytryptophan is an important intermediate in the serotonergic pathway. 
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 Abbreviations 
5-FPTRP 5-(-3-fluoropropyl)-DL-tryptophan 
5-HT 5-hydroxytyramine 
AADC aromatic amino acid decarboxylase 
AcOH acetic acid 
Ag2SO4 silver sulfate 
AlCl3 aluminum chloride 
ATP adenosine triphosphate 
BF3OEt2 trifluoroboroetherate 
BGO bismut-germanate  
BnBr benzyl bromide 
Boc2O di-tert-butyl dicarbonate 
Boc-BMI (S)-(−)-1-Boc-2-tert-butyl-3-methyl-4-
imidazolidinone 
Bq Becquerel 
BuLi butyllithium 
c.a. carrier added 
cAMP cyclic adenosine monophosphate 
CBr4 tetrabromomethane 
CH conventional heating 
CNS central nervous system 
COCl2 phosgene 
CT computed tomography 
DCM dichloromethane 
DIBAL diisobutylaluminium hydride 
 DMAP N,N-dimethylaminopyridine 
DMF N,N-dimethylformamide 
DMP  Dess-Martin periodane 
DMSO dimethylsulfoxide 
DOPA dihydroxy phenylalanine 
e.e. enantiomeric excess 
EA ethyl acetate 
EDA ethyl diazoacetate 
EOB end of bombardment 
Et2O diethyl ether 
Et3N triethylamine 
EtOH ethanol 
FDG 2-fluorodeoxyglucose 
FEHTP 5-(2-fluoroethoxy)-L-tryptophan  
H2O water 
HCl hydrochloric acid 
HPLC high performance liquid chromatography 
I2 iodine 
IBX 2-iodoxybenzoic acid 
IDO indoleamin dioxygenase 
IP3 inositol triphosphate 
i-PrMgBr isopropyl magnesium bromide 
i-PrMgCl isopropyl magnesium chloride 
KI potassium iodide 
KOH potassium hydroxide 
LDA lithium diisopropylamine 
 LSO lutetium-yttrium-oxide-ortho-oxosilicate  
M.p. melting point 
MeCN acetonitrile 
MeI iodomethane 
MeOH methanol 
MH microwave heating 
MnO2 manganese dioxide 
MRI magnetic resonance tomography 
n.c.a. no carrier added 
Na2SO4 sodium sulfate 
NABH3CN sodium cyanoborohydride 
NaBH4 sodium borohydride 
NaH sodium hydride 
NaHCO3 sodium bicarbonate 
NaIO4 sodium periodate 
NH4HCO2 ammonium formate 
NMR nuclear magnetic resonance 
PE petroleum ether 
PET  positron-emission-tomography 
POCl3 phosphorous oxychloride 
PPh3 triphenylphosphine 
PPi pyrophosphate 
PRPP phosphor-ribosylpyrophosphate 
PSR protein synthesis rate 
PTC phase transfer catalyst 
RCY radiochemical yield 
 Rh(PPh3)3Cl Wilkinson's catalyst 
RT room temperature 
SPECT single-photon-emission-tomography 
t1/2 half life 
TBA tetrabutylammonium 
TBAF tetrabutylammonium fluoride 
TDO tryptophan dioxygenase 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TLC thin layer chromatography 
TMS trimethylsilyl 
Tos-Cl tosyl chloride 
TPH tryptophan hydroxylase 
Z-BMI (S)-1-Z-2-tert-Butyl-3-methyl-4-imidazolidinone 
ZnCl2 zinc chloride 
α-MTrp alpha-methyltryptophan 
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